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ABSTRACT 
A schistosome vaccine would be of great value in controlling schistosomiasis. Exposure of 
experimental animals to live gamma-irradiated cercariae (GI) is highly effective and 
although not logistically feasible for human vaccination has provided insight into the 
immune mechanisms which may facilitate development of defined antigen vaccines. 
In mice the radiation attenuated vaccines induce IFN-y dependent immunity 
following a single exposure and antibody mediated immunity following repeated exposure. 
In order to induce high levels of immunity the irradiated larvae need to survive for 2-3 
weeks and to reach the lung stage in order to "arm" the lungs with sensitized cells, but it 
has been shown that larval infections with 500 larvae treated with the drug Rol 1-3128 at 
just 2 days post-infection also results in high levels of immunity but with an apparently 
more focal and truncated exposure to living larvae in the skin. The focus of this thesis is to 
compare the immune mechanism underlying this Rol 1-3128-induced vaccination (RoNI) 
(which induced >90% protection) with the GI (which induced 60-70% protection) and with 
infections which are both irradiated and drug treated which induce poor levels of immunity 
(RoGI) (induced only 30% protection). 
RoNI, GI, RoGI and a normal unattenuated infection (NI) all resulted in a Th 1 
biased response (IFN-y>IL-4) in the skin-draining lymph nodes (SLN), but RoNI and RoGI 
induced enhanced and more prolonged responses. RoNI was unique in causing highly 
elevated antigen specific IFN-y responses in the spleen suggesting local but protracted 
stimulation of a strong systemic response. Studies in B6RAG 1-/- mice (no B or T cells), 
IFN-y -/-, k-MT mice (no B cells) and by in vivo depletion of IFN--y with neutralizing 
monoclonal antibody during challenge showed that RoNI is mediated almost entirely by 
IFN-y mediated mechanisms and antibody is not involved. 
Adding Roll-3128 to cultures containing RoNI-sensitized SLN cells and living 
schistosomula enhanced the IFN-y production in the presence of in vitro bone marrow 
(bm)-derived DCs suggesting that altered antigen presentation is induced by drug treatment. 
However, the superiority of Rol 1-3128 in inducing immunity compared with other drugs 
could not be attributed simply to its ability to induce membraneous blebs as these were also 
produced by Roll-3128-treated irradiated schistosomula. Furthermore, there was no 
evidence of the drug having a general adjuvant effect. 
To try to establish how the larval exposure induces the Th 1 biased response, living 
schistosomula were cultured with bone marrow-derived dendritic cells. This had no effect 
(up- or down- regulate) on surface activation maker expression (MHCII, CD86, CD40) 
even if the bm-DCs, were partially activated with LPS or TNF-a. There was also no 
cytokine production (IL-12p70, TNF-a, IL-10 or IL-6). However, schistosomula induced a 
differential dose-dependent reduction in cytokine production by LPS-activated bm-DCs 
(IL-12p70 >IL-6 and TNF-a) but IL-10 was relatively unaffected. Again this was 
unaffected by addition of Rol 1-3128. 
This work indicates that it is possible to induce highly effective Th 1 mediated 
systemic immunity in mice by protracted but local stimulation of the skin/SLN suggesting 
that delivery of defined schistosome antigens by Th 1 promoting strategies such as prime- 
boosting with heterologous recombinant viruses delivered in the skin would be worth 
investigating. There was no evidence that the Th l response to larval infection is caused by 
direct action of larvae or larval products on dendritic cells and in fact there was evidence of 
an anti-inflammatory effect, which should be investigated further at the mRNA level. It is 
suggested that schistosomula may interact differently with other cells encountered in the 
skin e. g. keratinocytes in initiating the Th 1 bias. 
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DMSO - dimethyl sulphoxide. 
DOC-SCAP - sodium deoxycholate extract of the aqueous insoluble fraction of cercariae 
ELISA - enzyme linked immunosorbent assay. 
EU - Endotoxin unit 
FACS - Fluorescence-activated cell sorter. 
F/T - Freeze-Thawed. 
GI - (Gamma irradiated infection) i. e. percutaneous exposure to 
500 cercariae irradiated 
with 20krad. 
GM-CSF - Granulocyte-macrophage colony stimulating 
factor. 
i. d. - intradermal. 
IL- interleukin. 
i. p. - intraperitoneal. 
KO - knockout (applied to gene knockout mice, otherwise 
designated -/-). 
krad - kilorad. 
LC - Langerhans cells. 
Lex -Lewis x trissacharide. 
LN - lymph node. 
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CHAPTER 1 
INTRODUCTION 
1.1 Schistosomiasis - History and Health: 
Among human parasitic diseases, schistosomiasis is one of the great endemic diseases 
of the tropics and subtropics. It is ranked only second behind malaria in terms of socio- 
economic and public health importance. It has been a disease since ancient times, as 
reviewed by Grove (1990) and Ouma and Fenwick (1991), who reported that from 
hieroglyphic records and from parasitological examination of mummified remains that 
human schistosomiasis was endemic in Dynastic Egypt. It was not until 1852, however, 
that the adult worms were first discovered from a human body in Cairos's Kasr ElAini 
hospital in Egypt by Theodor Bilharz, a young German pathologist, from whom the 
disease took its original name, Bilharziasis, a name which is still occasionally used. A 
further 65 years elapsed before the three main human schistosome species and their 
complete life cycles were clearly described (reviewed by Taylor, 1994). 
According to recent current WHO assessment (WHO website, 2003), the disease is 
endemic in 74 developing countries, with an estimated 600 million people worldwide 
exposed to the risk of infection, while more than 200 million people are currently 
infected. Of these, 20 million individuals suffer severe consequences of the disease, and 
an estimated 120 million are symptomatic. The disease causes a great deal of morbidity 
(1932 thousand disability-adjusted life years, DALYs) and an estimated 20,000 deaths 
each year. This mortality is mostly due to bladder cancer or renal failure associated with 
urinary schistosomiasis and to liver fibrosis and portal hypertension associated with 
intestinal schistosomiasis. 
1.2 Causative Agents: 
The major forms of schistosomiasis in humans are caused by several different species of 
blood flukes which are water borne flatworms (Trematodes) of the genus Schistosoma. 
Three species are the principle causes of disease in man. Schistosoma haematobium is 
responsible for urinary symptoms and disease, Schistosoma mansoni and Schistosoma 
japonicum cause intestinal symptoms and hepatosplenic disease. 
1.3 Geographical Distribution: 
Schistosomiasis is a waterborne, snail-transmitted infection. The geographical distribution 
of the schistosomes roughly corresponds to the distribution of susceptible fresh water 
intermediate snail hosts, which are present in many tropical and subtropical regions. 
Snails are found in many different habitats including permanent or semi-permanent 
small ponds, marshes, swamps, rivers and streams and large permanent water bodies 
such as lakes, dams, irrigation channels and rice fields. Those snail hosts are specific for 
each species of schistosome. S. mansoni and S. haematobium are transmitted by aquatic 
snail hosts of the genus Biomphalaria and Bulinus, respectively, whilst amphibious 
snails of the genus Oncomelania transmit S. japonicum (Jordan, Webbe and Sturrock, 
1993). 
S. mansoni is the most widespread species, being prevalent in 53 countries in Africa, the 
Middle East, the Caribbean and South America. S. haematobium has a similar 
distribution to S. mansoni in the Old World, where it is endemic in 54 countries in 
Africa and the Eastern Mediterranean (WHO, 1993). In Africa, S. mansoni and 
S. haematobium often coexist, and mixed infections are common. Apart from a possible 
small focus of S. haematobium in India, neither S. mansoni nor S. haematobium occurs in 
central or east Asia. Oriental or Asian intestinal schistosomiasis mostly caused by S. 
japonicum is endemic in seven countries in South-East Asia and in the Western Pacific 
Region (WHO, 1993). 
1.4 The Life Cycle of Schistosomes: 
The complex life cycle of schistosomes (see Figure 1) involves the mammalian definitive 
host and the snail intermediate host. The cycle is initiated when the free living larvae 
(cercariae), shed from the intermediate snail host, locate a mammalian host in the water, 
and burrow into the skin epidermis. On entering the mammalian host, the cercariae shed 
their tails and form the schistosomula stage of the parasite. The schistosomula then enter 
the peripheral lymphatic vessels or the blood venules and are carried via the lungs to the 
liver. Based largely on studies in mice, the larvae spend on average 2 to 5 days in the skin 
(Miller & Wilson, 1978), after which they penetrate the nearest blood vessel and gain entry 
to the blood. Once within the capillary they are rapidly transported by the blood flow to the 
1) 
lungs. Those few (about 10-20%) that penetrated the lymphatics (Wheater & Wilson, 
1979) enter the circulation from the thoracic duct. On reaching the lungs, schistosomula 
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Figure 1. Life cycle of S. mansoni (taken from Mckerrow and Salter, 2002) 
spend 3-4 days (Wilson et al., 1978) crossing the capillary bed of the lungs and are then 
carried around the body by the systemic circulation, a proportion reaching the liver as they 
circulate with the majority of the parasites reaching the liver by 10-15 days after infection 
(Wilson et al., 1986). Here the worms mature and by 6 weeks post infection nearly all 
worms have paired before migrating, via the hepatic portal vessels, to either the mesenteric 
veins in the case of S mansoni and S. japonicum or to the vesical plexus around the 
bladder and ureters in the case of S. haematobium, where the female begins to produce 
eggs. The worms which may live for an estimated 3-7 years in man (Fulford et al., 1995), 
remain in copulo with the female laying hundreds (S. mansoni and S. haematobium) to 
thousands (S. japonicum) of eggs every day. Many of these eggs are released by the female 
parasites within the vasculature; they cross the endothelium and basement membrane of 
the vein, and traverse the intervening tissue, basement membrane and epithelium of the 
l` 
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intestine or bladder tissues from where they exit the body via the faeces (S. mansoni and S. 
japonicum) or urine (S. haematobium). The eggs contain a developing embryo, the 
miracidium, which when mature hatches in a suitable fresh water environment and locates 
its intermediate snail host. Four to five weeks following miracidial penetration and asexual 
reproduction of intramolluscan schistosome parasite life stages, snails will begin shedding 
the infective larval stages, the cercariae, which will infect humans and other mammalian 
definitive hosts, notably in the case of S. japonicum, which is a true zoonosis. Around 50% 
of the eggs fail to reach the lumen of the gut or bladder becoming trapped in the wall of the 
bladder or ureter or being carried by the blood to other organs notably the liver in the case 
of S. mansoni and S. japonicum. These eggs contain live developing miracidia that 
produce potent antigens. These are secreted through microscopic pores within the rigid 
egg shell and induce the formation of an `Egg Granuloma'. This granuloma formation 
together with subsequent fibrosis is the major cause of schistosome related pathology 
(Cheever & Yap, 1997). 
1.5 Schistosomiasis - "An Immunopathological Disease": 
The development of the disease is thought to be, to a large extent, due to the nature of 
the immune response and its effects on granuloma formation around the trapped eggs 
and associated pathologies in target organs (Cheever et al., 2000). Two main clinical 
conditions are recognized in S. mansoni-infected individuals- Acute schistosomiasis and 
Chronic schistosomiasis. 
1.5.1 Acute/Chronic disease: 
9 Acute Schistosomiais: 
In humans, Katayama fever, which is the acute form of schistosomiasis is a debilitating 
febrile illness that can occur before the appearance of eggs in the stool. It is thought 
generally to peak between 6 and 8 weeks after the host is infected by cercariae (Rabello, 
1995). This febrile illness seems to be uncommon in individuals who live in areas that 
are endemic for schistosomiasis, and only occurs in individuals who have no previous 
history of exposure who become infected after travelling into an endemic area. During 
this acute illness, there is a measurable level of tumour-necrosis factor (TNF-(x) in the 
plasma, and peripheral blood mononuclear cells (PBMCs) produced large quantities of 
4 
TNF-a, interleukin-1 (IL-1) and IL-6 (de Jesus et al., 2002). The PBMCs from patients 
with acute schistosomiasis were stimulated by parasite antigen to produce elevated 
levels of IFN-y and low levels of IL-5 as compared to PBMCs from patients with 
chronic disease, thus reflecting a dominant Thl, rather than Th2 response in the acute 
form of the disease (de Jesus et al., 2002). 
In mice, the acute prepatent phase of infection is also associated with the antigen- 
specific production of Th 1 cytokines (IFN-7, IL-2 and TNF-a) (Grzych et al., 1991) but 
as soon as eggs are produced this switches to a Th2 dominated response, but one in 
which there is an underlying Thl response (Rutitzky et al., 2001). The inability to 
develop a Th2 response to regulate the initial pro-inflammatory response that is 
associated with acute schistosomiasis is lethal. This was first observed when C57BL/6 
IL-4 deficient mice were infected with S. mansoni. These mice suffered from cachexia 
and significant mortality on the onset of parasite egg production (Brunet et al., 1997) 
eventhough they developed relatively normal hepatic granulomas (although they lacked 
an eosinophil component). Their intestines, on the other hand, showed pathological 
changes which included non-haemorrhagic lesions on the mucosal surface (Brunet et al., 
1997) that were associated with the inefficient passage of eggs into the lumen (Fallon et 
al., 2000b). Analysis of the immune responses of infected IL-4 deficient mice showed 
that there was a correlation between elevated levels of nitric oxide (NO) and disease 
severity (Brunet et al., 1997). 
0 Chronic Schistosomiasis: 
Chronic disease is graded according to severity. The liver granulomas themselves do not 
generally affect the liver function, but pathology occurs by blockage of portal blood flow 
(the granuloma is around 100 times the size of the egg itself). In some respects, the 
pathology in mice is comparable with that observed in humans (Fallon, 2000). Impairment 
of the hepatic blood flow leads to the development of portal hypertension and 
hepatosplenomegaly. This may be further complicated by fibrosis, which may progress to 
irreversible Symmers' clay pipe-stem fibrosis caused by calcification around branches of 
the portal veins (Lambertucci, 1993). In severe cases portal hypertension leads to the 
formation of the collateral circulation, which enables blood to by-pass the liver and carry 
eggs to organs such as the lungs, kidneys or central nervous system (CNS) where 
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granulomas may also form. The collateral circulation can carry blood to thin walled 
oesophageal varices which can bleed or rupture causing haematemesis. In the case of 
S. haematobium infections calcification of the bladder and ureters can take place leading to 
loss of bladder, ureter and kidney function. The immunological basis of this pathology is 
considered below. 
1.5.2 The Egg Granuloma: 
The cell-mediated delayed-type host granulomatous inflammatory reactions (Boros and 
Warren, 1970) that develops around the schistosome egg is composed of eosinophils, T 
cells, mast cells, B cells, epitheloid cells, fibroblasts, macrophages, basophils, giant 
cells and some neutrophils. Research in mice has shown that the granuloma structure is 
influenced by antibodies (Jankovic et al., 1998), chemokines (Park et al., 2001), 
cytokines (Cheever et al., 1998), adhesion molecules (Ritter and McKerrow, 1996) and 
apoptosis (Lundy et al., 2001; Rumbley et al., 2001). Because of the constant turnover 
of cell populations, granulomas change in size during their development and resolution. 
Their circumoval localisation and dense cellularity of the granulomas isolates the egg 
from the healthy liver parenchyma thus rendering protection of the host. This concept 
was shown from infection studies in T cell-depleted mice (Mathew and Boros, 1986), 
thymectomised mice (Domingo and Warren, 1967; Dunne & Doenhoff, 1983; Cheever 
et al., 1985), SCID mice (Cheever et al., 1999) and nude mice (Cheever at al., 1989), 
where the host is unable to form a well-organised, circumoval granuloma, there is 
circumoval parenchymal necrosis and the mice die. It has been demonstrated by 
Doenhoff et al., (1981) and Dunne and Doenhoff, (1983) that certain S. mansoni egg 
molecules are highly toxic to liver parenchyma cells, thus confirming that if a mature 
circumoval granuloma is not formed during S. mansoni infections then these 
`hepatotoxic' egg antigens can cause extensive liver damage. 
1.5.3 What type of immune response do schistosome eggs induce? 
The formation of granulomas during murine infection has been shown to be dependent 
upon T cell, and specifically CD4+ T-cell, responses (Cheever et al., 1985, Mathew and 
Boros, 1986). Infection of mice deficient for CD4+ T cells (Fallon et al., 2000a) led to a 
similar pathological outcome as infected thymectomised, SCID, nude or T cell-depleted 
mice, where the granuloma inflammation was abrogated, liver damage took place and 
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mortality rates increased. In humans, a study of CD4+ T cell-deficient humans (HIV co- 
infected) also suggested that CD4+ve T cells are involved in granuloma formation 
(Karanja et al., 1997). It had previously been shown that T-cell deprived mice showed 
reduced faecal egg output and it was reasoned that the granuloma formation was 
necessary for this excretion (Doenhoff et al., 1981; Cheever et al., 1999). Similarly the 
HIV and schistosome co-infected individuals had a significant defect in egg excretion in 
comparison to HIV negative-schistosome positive individuals suggesting that they also 
had impaired granuloma formation (Karanja et al., 1997). 
In mice the involvement of CD4+ T cells in pathology has been further defined as a 
requirement for the production of Th2 cytokines. A number of studies in mice have 
demonstrated that down-regulation in the production of Thl type cytokines e. g. IFNy and 
IL-2 and an up-regulation in Th2 cytokines such as IL-4, IL-5 and IL-10 (although not 
exclusively a Th2 cytokine), occurs at the onset of egg production (Pearce et al., 1991; 
Sher et al., 1991; Grzych et al., 1991). This also appears to be the same in human 
infections (Parra et al., 1992; Williams et al., 1994; El Ridi et al., 1997), although 
Montenegro et al., (1999) reported that in chronically infected individuals a mixed type- 
1/type-2 anti-egg cytokine response can be observed. 
Production of IL-4 is crucial for the development of Th2 responses and for the counter- 
regulation of Thl responses. IL-4 depletion in shistosome-infected mice or 
intravenously egg-injected mice (a commonly used model of granulomatous response 
and which synchronous pulmonary granulomas are produced) demonstrated a dramatic 
effect in reducing egg-induced granuloma inflammation and the production of the type- 
2 cytokines IL-5 and IL-13 (Yamashita and Boros, 1992; Wynn et al., 1993; Cheever et 
al., 1994). On the otherhand, administration of recombinant IL-4 to chronically infected 
animals reversed the down-regulated granulomatous response typically observed in later 
stages of infection (Yamashita and Boros, 1992). It is clear from the above studies that 
IL-4 is, in part, responsible for the generation and maintenance of the type-2 immune 
responses. 
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1.5.4 How do eggs induce the Th2 response? 
It was established a long time ago that the egg, rather than the adult worm, could sensitize 
cells to induce granuloma formation (Warren and Domingo, 1970). There has been much 
recent interest in trying to define the molecular basis of the interaction of egg products 
with cells of the innate immune response resulting in Th2 polarization of the immune 
response. 
i- Eosinophils and Mast cells: 
The ability of eggs themselves to initiate production of Th2-associated cytokines was 
demonstrated by Sabin et al. (1996a). Thus, intraperitoneal injection of isolated eggs into 
mice rapidly stimulated production by peritoneal exudate cells of IL-4 and IL-5, early 
peritoneal recruitment of eosinophils and a loss of mast cells. The data suggested that egg 
derived molecules induce IL-5 release from degranulated mast cells and this IL-5 then 
recruits and activates eosinophils which provide the early burst of IL-4 required for 
subsequent Th2 cell development. Rumbley et al., (1999) have shown that eosinophils are 
the major source of IL-4 in the granulomas themselves. 
ii- Basophils: 
Basophils have also been shown to produce IL-4 in direct response to SEA (Falcone et al., 
1996). Recently, Schramm et al. (2003) have characterized a factor in S. mansoni eggs 
that could be responsible for the switch to a Th2 response. A protein, which the authors 
named IPSE (IL-4-inducing principle from S. mansoni eggs) was isolated and 
characterized. In response to exposure to S. mansoni egg antigen extract (SEA), 
basophils degranulate rapidly and release IL-4 and other inflammatory mediators. The 
results of functional in vitro assays in which human basophils were incubated with 
whole SEA, SEA fractions and recombinant IPSE, and the fact that antibodies raised 
against recombinant IPSE inhibited the activation of basophils by SEA, indicated that 
IPSE is the sole factor responsible for the basophil-activating effects of SEA. Further 
analysis confirmed that IPSE can bind IgE, indicating that it is the crosslinking of 
receptor-bound IgE that accounts for IPSE-mediated basophil activation. 
iii- Dendritic cells (DC): 
9 In Mice 
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Much attention has been focussed in recent times on the initial interaction between 
microbial products and receptors on dendritic cells which are specialised for sampling 
foreign material and initiating appropriate responses. In an elegant series of experiments, 
Macdonald and Pearce (2002a; 2002b) showed that mouse derived DCs cultured with 
soluble S. mansoni egg antigen (SEA) could be primed such that they can transfer Th2 
responsiveness to recipient mice i. e. splenocytes from such mice given SEA-pulsed DCs 
were stimulated in vitro by SEA to produce IL-4, IL-5, IL-13 but not IFN-y. Carbohydrate 
components of the SEA have been implicated in this process because LN cells of mice that 
received periodate-treated SEA-pulsed DCs produced 6- to 10-fold less Th2 cytokines (IL- 
4, IL-5 and IL-10) upon in vitro stimulation with SEA (Faveeuw et al., 2002). 
" In Humans 
Studies with Human myeloid DCs have shown the upregulation of OX40L expression (a 
factor known to be expressed by the peripheral blood DC and involved in Th2 cell 
development [Flynn et al., 1998]), and production of poor levels of IL-12p70, TNF-a and 
IL-6 following interaction with SEA upon CD40 ligation (de Jong et al., 2002). 
Interestingly, glycan moieties present on egg glycoproteins or glycolipids have also been 
implicated in this DC priming for Th2 response. 
iv- Suppressor macrophages: 
Relatively recently, populations of natural suppressor cells originating from the 
granulocyte -macrophage lineage and expressing Gr 1, CD 11 b and/or F4/80 have been 
described (Angulo et al., 1995; Maruyama et al., 1999; Salvadori et al., 2000). These fall 
into two categories: `classically activated' macrophages which are IFN-, y dependent and 
associated with cancers and viral infections (e. g. Cauley et al., 2000) and `alternatively 
activated' macrophages which are IL-4 dependent and have been demonstrated in mice in 
response to implanting the filarial worm Brugia malayi (Allen et al, 1996; MacDonald et 
al., 1998). 
Two schistosome oligosaccharides, lacto-N-fucopentaose III (LNFPIII) and lacto-N- 
neotetraose (LNnT), which are components of SEA molecules were identified as Th2- 
biasing and capable of suppressing Thl responses in vivo (Vellupillai et al., 1997: 
Okano, et al., 2001). Atochina et al. (2001) showed that a single injection of mice with 
a glycoconjugate composed of LNFPIII conjugated to dextran (LNFPIII-dex) rapidly 
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expanded the peritoneal CD11b+/Grl+/F4/80 population in aT cell-independent 
manner suggesting a direct interaction of the CHO moieties with macrophages. These 
cells suppressed the in vitro proliferation of naive CD4+ T cells to primary stimulation 
with anti-CD3 and anti-CD28 antibodies and the process of inhibition was found to be 
NO- and IFN-y-dependent showing that, in contrast to the filariae (Loke et al, 2000), 
schistosome eggs stimulate a `classically activated' suppressor population. Injection of 
the structurally related glycoconjugate lacto-N-neotetraose-dextran (LNnT-dex) has also 
been shown to expand such suppressor cells and these were able to imprint a Th2 
phenotype on naive CD4+ T cells, characterized by lower IFN-y, but increased IL-13 
production (Terrazas et al., 2001). 
The ability of these helminth-expressed oligosaccharides to induce suppressor 
macrophages may also be responsible for the modulation of the host response and 
induction of immune anergy as the infection progresses (Atochina et al., 2001). In terms 
of the mechanism of action Terrazas et al. (2001) showed that the Grl+ population that 
suppressed the proliferative in vitro response of naive CD4+T cells required cell-to-cell 
contact (suggesting a receptor-mediated mechanism). Furthermore, the suppressor cells 
produced low levels of pro-inflammatory cytokines together with raised IL-10 and 
TGF-ß but did not lead to CD4+ T cell apoptosis. 
1.5.5 Immunopathology following a skewed Thl-immune response: 
The host response to schistosome eggs is, most of the time, one that recognises the 
destructive nature of these agents and responds in a controlled manner to limit severe 
pathology. These responses can lead to fibrotic tissue lesions, but generally do not result 
in mortality. Deviation away from this tightly regulated, egg-associated, Th2-dominated 
immune response leads to pathologies that are severe and often life-threatening. 
In a study undertaken by Mwatha et al. (1998), the immunological responses in S. 
mansoni infected-children and adolescents were described. There was no apparent 
periportal or hepatic fibrosis in either study group in which individuals were carefully 
matched for age, prevalence, intensity of infection and tribal origin. It was found that 
children/adolescents who suffered severe enlargement of liver and spleen had 
significantly more type-1 associated IFN-a and TNF-a production from antigen- 
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stimulated PBMCs in comparison to those who did not develop organ enlargement. 
Additionally, high plasma levels of sTNFR-I (TNF-a receptor I), sTNFR-II and ICAM- 
1 (Intercellular Adhesion Molecule-1) were all significantly associated with 
hepatosplenomegaly, whereas individuals who had less severe disease but similar 
intensity infections (as assessed by counting the number of eggs in faecal samples) had 
more of a Th2 response and low plasma levels of soluble TNFR. These observations 
indicated that hepatosplenomegaly, in the absence of severe fibrosis, can be associated 
with elevated Thl associated immune responses. 
Skewed Thl responses have also been studied in mice. Brunet et al., (1997) showed that 
IL-4 deficient mice responded to schistosome infection by generating strongly polarised 
type-1, as opposed to type-2 inflammatory reactions. This type-1 inflammatory response 
was observed shortly after the onset of egg deposition and was characterised by egg- 
specific IFN-y, TNF-a and inducible nitric oxide (iNO) production as well as a rapid 
rate of weight loss and ultimately mortality. The granulomas formed around tissue- 
deposited eggs in those IL-4 deficient mice were of similar size to control, infected 
wild-type mice but hepatic fibrosis was diminished. It was suggested that lesions seen in 
the gut of the IL4-/- mice led to bacterial invasion and it was concluded that the 
pronounced type-l-mediated inflammatory reactions that developed in the absence of 
IL-4 in combination with increased systemic endotoxin levels induced a state of 
cachexia that led to a rapid mortality. In another study of infected IL4-1" mice, the 
immune response was also biased to a Thl response but the mortality in this study was 
less which was attributed to less gut associated pathology (Hoffmann et al, 2000). 
Additional studies showed that infected IL-4 deficient mice suffering from increased 
mortality rates, had significantly less ex-vivo antigen-specific IL-10 production in 
comparison to control infected animals (Brunet et al., 1997). Sher at al., (1991) had 
earlier demonstrated that IL-10 was rapidly produced at a time concomitant with egg 
deposition and that this cytokine remained elevated into the chronic stages of disease. 
Further studies have implicated IL-10 in regulating inflammatory responses in both 
mice and humans. Administration of exogenous IL-10 to infected mice was found to 
dramatically decrease the size of granulomas during the acute stages of disease (Flores- 
Villaneuva et al., 1996). Later Wynn et al., (1998) demonstrated that infected IL-10- 
deficient mice displayed significantly larger circumoval granulomas than control- 
infected WT animals. A detailed examination of the immunological characteristics in 
these infected IL-10-deficient mice demonstrated that they develop increases in both 
type-1 and type-2 immune responses and suffer enhanced mortality (Wynn et al., 1998). 
Immune hyporesponsiveness characterizes the chronic stages of many helminth 
infections including schistosomiais, and T regulatory (Treg) cells have been implicated 
in this process. The factors controlling Treg as opposed to Thl or Th2 development are 
comparatively poorly understood. However, recent studies have implicated TLR2 
ligation in this process, as schistosome lyso-phosphatidylserine isolated from 
schistosome eggs or adult worms was found to condition human DCs via TLR2 to 
induce Treg responses (van der Kleij et al., 2002). This might account for the skewing 
to IL-10 production and T-cell hyporesponsiveness that is seen during chronic 
schistosomiasis. 
Studies in humans confirmed the role of IL-10 in urinary tract morbidity during S. 
haematobium infection (King et al., 2001). IL-10 (and TNF-(X) release from egg- 
stimulated PBMC cultures was compared in age and sex matched infected children and 
adolescents suffering from moderate to severe bladder wall pathology. A significantly 
lower ratio of egg-specific IL-10: TNF-a production from PBMC cultures obtained from 
the patients with severe bladder wall pathology, suggesting that low IL-10 and high 
TNF-a can correlate with an increased risk of developing severe disease during 
schistosomiasis. A recent study examining the correlates of developing severe fibrosis 
in adult male populations living in Uganda who were chronically infected with S. 
mansoni, also demonstrated that a deficiency in IL-10 was partly responsible (M. Booth 
and D. W. Dunne, cited as a personal communication in Hoffmann et al., (2002)). 
In an elegant series of experiments Hoffmann et al (2000) compared the responses of 
knock-out mice for either IL-4, IL-10 or both cytokines. Infected, IL-4-deficient mice 
displayed type-1 immune responses but made similar levels of IL-10 and lived just as 
long as infected WT animals, whereas animals deficient in both IL-10 and IL-4 suffered 
100% mortality by week 8 post-infection and showed a strongly polarized Th 1 
response. Rapid cachexia, abundantly produced IFN-y and TNF-a, elevated 
12 
hepatotoxicity, minimal fibrosis and increased splenic NO production were all 
detectable in the IL-10/IL-4 doubly deficient mice. 
Despite the more severe pathology induced by a marked shift towards Thl responses, it 
has been demonstrated in mice that promoting a Thl response to the egg by immunizing 
with egg antigens plus IL-12 can result in lower Th2/Thl cytokine response to eggs 
following infection with a resultant reduction in fibrosis and mortality (Wynn, 1995). It has 
been suggested that this might form the basis of a defined anti-pathology vaccine but 
clearly this is a risky strategy in a genetically diverse human population. 
1.5.6 Immunopathology following a skewed Th2-immune response: 
The above series of experiments (Hoffmann et al, 2000) also included mice strongly 
polarised to Th2 responses. Infected animals deficient in both IL-10 and IL-12, 
compared to WT mice, produced 10 times the amount of antigen-specific type-2- 
associated IL-4, IL-5 and IL-13 during the acute stages of schistosomiasis. All of the 
type-2 polarised, IL-10/IL-12 doubly deficient animals also lost weight at the onset of 
schistosome oviposition (- 5 weeks post-infection) and over 50% succumbed to death at 
12 weeks post-infection. The increased mortality was directly related to overproduction 
of the pro-fibrotic cytokines IL-4 (Kovacs, 1991) and IL-13 (Chiaramonte et al., 1999) 
as well as to diminished levels of the anti-fibrotic cytokine, IFN-y (Czaja et al., 1989). 
This increased ratio of pro-/anti-fibrotic mediators was confirmed by cDNA microarray 
analysis and resulted in the deposition of significantly more hepatic collagen in the 
livers of infected IL-10/IL-12 doubly deficient mice and ultimately death, in a high 
proportion of animals (Hoffmann et al., 2000; Hoffmann et al., 2001). From these 
investigations a link was made between the development of unregulated type-2 immune 
responses and severe, fibrosis-related immunopathology contributing to enhanced 
mortality rates during schistosomiasis. 
In humans, the vast majority of all schistosome-infected humans do not develop severe 
hepatic morbidity, but a minority (2.5-5%) of individuals will develop quite severe 
hepatosplenomegaly and immunopathology related to fibrosis. These severely ill 
individuals are not necessarily the most heavily infected, but have usually harboured the 
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disease for the longest period of time. Ultrasound measurements have confirmed that 
the progression of hepatic and periportal fibrosis develops with age. This has been 
observed in S. japonicum-infected patients where more severe fibrosis was observed in 
older individuals as compared to young individuals (Olds et al., 1996). This age/fibrosis 
relationship was also confirmed in cross-sectional studies in Uganda and other 
investigators' studies in S. mansoni endemic areas (Hoffmann et al., 2002). These 
findings suggest that individuals who go on to develop severe fibrotic-related 
hepatosplenomegaly later in life are a subgroup of the infected population that fail to 
resolve their initial low-grade hepatic lesions. 
In an analysis of pedigrees in the Sudan, in an area where S. mansoni is endemic, 
Dessein and colleagues found that severe hepatic fibrosis (as identified by ultrasound) 
was more likely to occur in certain families (Dessein et al., 1999). A codominant major 
gene, known as SM2, was shown by segregation analysis to be responsible for the 
observed familial distribution of hepatic fibrosis and portal hypertension. `Informative' 
families, which had multiple cases of severe fibrosis, were used to map SM2 to 6q22- 
q23 -a region that contains the gene that encodes IFN-y receptor 1 (IFN-yRI) (Dessein 
et al., 1999). One interpretation of these data is that mutations in IFN-yR1 that lead to 
loss of function of the receptor are associated with a lack of effectiveness of IFN-y in 
suppressing fibrogenesis. As IFN-y is a potent anti-fibrotic cytokine (Czaja et al., 1989), 
segregation of 6q22-q23 among severely fibrotic individuals suggests that these infected 
people cannot counter-regulate the pro-fibrotic activities of IL-4 and IL- 13. 
A more recent study carried out in Uganda is reported to provide firm evidence linking 
high IL-4 and IL-13 levels with chronically infected adult male and female individuals, 
respectively, suffering from severe fibrosis (M. Booth and D. W. Dunne, cited as a 
personal communication in Hoffmann et al., (2002)). The combination of defective 
IFN-y signalling with improperly balanced type-2 cytokine regulation leads to an 
environment suitable for collagen synthesis, hepatic and periportal fibrosis, and elevated 
morbidity and mortality. From existing evidence, this type of immunopathology 
becomes manifested fully only after years of exposure to schistosome parasites and/or 
abnormal host responses, which may be more often observed during the chronic stages 
of disease. 
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In summary this balanced Th2 granulomatous response to the egg is host protective despite 
inducing immunopathology, but a shift in the balance in either the Thl or Th2 direction 
can cause even more severe disease. 
1.6 The Control of Schistosomiasis: 
Major factors associated with the spread and intensification of schistosomiasis are its 
links with water development projects, particularly construction of dams, man-made 
lakes and irrigation schemes, since these are often sites of population immigrations for 
farming and fishing. Control of schistosomiasis has been attempted for many years, and 
has usually been based on a mixture of measures directed against the snail hosts and 
chemotherapeutic treatment of man, together with environmental management and 
public health measures. However, in many developing countries the use of these methods 
and their integration within suitable control programmes is limited by economic 
constraints, and chemotherapy remains the mainstay of schistosomiasis control (Savioli et 
al., 2004). 
Although Oxamniquine is still used in some areas for the treatment of S. mansoni and 
Metrifonate for the treatment of S. haematobium, Praziquantel, the major drug of choice, is 
able to eliminate all species of schistosome infections. Thus, the main problem with 
control programmes which rely upon chemotherapy is the cost. Although Praziquantel is a 
comparatively cheap drug, in areas of high transmission a high rate of reinfection after 
chemotherapeutic cure among young children means that re-treatment is often required at 
frequent intervals, thus, long-term funding needed for such control programmes can be 
difficult to sustain (Dunne et al., 1995). Added to this is the growing concern regarding the 
possible development of drug resistance which has been shown for Oxamniquine in South 
America (Coles et al., 1986) and experimentally in mice with praziquantel (Fallon and 
Doenhoff, 1994). 
While highly effective drugs are available for treatment, schistosome parasites continue 
to cause significant morbidity and mortality in the human population. This is due in part 
to the failure of previously infected individuals to develop resistance against the parasite 
until the mid teenage years. A major focus of schistosomiasis research is to develop an 
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effective anti-schistosome vaccine that will be effective in children and so significantly 
reduce the incidence of severe disease. With this aim in view there have been extensive 
studies into the nature of the immune response to schistosomes in both humans and 
experimental animals. In addition numerous parasite antigens have been identified as 
potential vaccine candidates (Bergquist and Colley, 1998). In the following sections the 
evidence for naturally occurring immunity in man and for immunity in experimental 
animals is considered along with the current understanding of the status of vaccine 
development. 
1.7 Immunity in Humans: 
Two groups of individuals have been identified as manifesting immunity to 
schistosomiasis infection in the field. Those that are demonstrably resistant to 
reinfection after chemotherapeutic treatment of existing infections, and those that 
appear to have developed natural resistance to infection named `Endemic Normals' 
(EN). The former differ from the EN in that they harbour infections of some level of 
intensity but their level of resistance to reinfection with schistosomes prior to treatment 
cannot be determined. Most work has been done on resistance after chemotherapy but 
reference will be made where relevant to the studies of ENs. 
1.7.1 Age-intensity patterns: 
In infected populations resident in schistosomiasis endemic areas, children carry the 
heaviest parasite burdens (Fisher, 1934). As measured by the increase in egg output 
(which indicates a build up in the number of established adult worms) infection 
intensities rise in early childhood, peak around the age of 12 years, and then rapidly 
decline (Mutapi, 2001). It was originally thought that this was entirely due to the fact 
that children, on average, tend to have more water contact than either adults or the very 
young (Warren, 1973). However, alternative possibilities were that adults may have 
lower innate susceptibility, or enhanced protective immunity either due to long-term 
exposure to infection or to an age-dependent ability to develop appropriate immune 
responses to infection (Butterworth, 1990). More recent studies of populations in which 
the infection had been recently introduced (reviewed by Gryseels, 1994) demonstrate 
that similar age-intensity profiles develop relatively soon after the start of exposure 
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indicating that it is age per se more than duration of exposure that is responsible for the 
lower infection intensities in the adults (Polman et al., 1995; van Dam et al., 1996). 
1.7.2 Resistance after chemotherapy: 
In order to investigate the relative importance of water contact and immunity several 
important studies have been conducted in which infected people of different ages were 
chemotherapeutically cured and their reinfection rates monitored along with their level 
of water contact. In this way water contact could be controlled for. 
Such studies on S. mansoni in Kenya (Butterworth et al., 1984; Butterworth et al., 1985) 
identified a group of children classed as resistant because they had high water contact but 
low rates of reinfection and a group of susceptible children which become heavily 
reinfected following treatment. Comparison of the data for these two cohorts demonstrated 
that the average age of the resistant group was 13 and that of the susceptible 11 which 
indicated the operation of age dependent factors that prevent reinfection. Demeure et al. 
(1993) took a similar approach and concluded that although water contact was a major 
factor in intensity of infection it could not explain the patterns adequately. 
Fulford et al., (1996) looked at data from a number of studies and showed that the peak 
in intensity of re-infection occurred at a very consistent age followed by a sharp decline. 
The data on water contact for several areas showed generally higher contact for the 
younger age groups but the distribution was much more spread and clearly did not 
mirror the age intensity pattern. Furthermore, in a study of a fishing community in 
Uganda, the pattern of observed contact with water known to contain infected snails was 
greater in adults than in children (Fulford et al., 1996). Despite this, six months after 
treatment, the Ugandan community showed a peak of reinfection intensity at about ten 
years of age, which fell away to a much lower level by the age of twenty (Kabateriene et 
al., 1999). In a recent study by Scott et al., (2003), of 5 recently infected villages in 
northern Senegal there was evidence that a person's age, sex and place of residence 
determines water contact behaviour, but none to suggest that exposure has an influence 
on the relationship between these factors and intensity of infection. 
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So overall water contact is obviously a major influence on infection intensity especially 
in the young but other factors also play a major role among which immunity has been 
proposed to play a role (Butterworth et al., 1992). 
1.7.3 Immune Mechanisms involved in immunity in vivo: 
1.7.3.1 Humoral responses: 
A study of S. haematobium infection in Gambia first demonstrated that the level of IgE 
antibodies, mainly against adult worms, increased progressively with the age of the 
patient and so was related to resistance to reinfection after chemotherapy in that specific 
IgE was high in the adults and low in the children (Hagan et al., 1991). The levels of 
IgE alone however could not explain the pattern of reinfection intensity but when IgG4 
and IgE were considered together a better correlation was seen. IgG4 also increased 
with age up to late childhood but then declined in the teenage children. The lowered 
reinfection intensity correlated with high IgE but lowered IgG4 and it has been 
suggested that the IgG4 might act to block a protective action of IgE (perhaps involving 
ADCC/blocking antibodies against the larval stages - see section 1.7.6. ). So it is when 
the IgG4 production declines that the protective effect of IgE appears. The influence of 
IgE and the reciprocal effect of IgG4 in immunity to S. mansoni reinfection has also 
been reported in several independent investigations carried out in Africa and Brazil 
(Dunne et al., 1992a and 1992b; Demeure et al., 1993; Rihet et al., 1991; Caldas et al., 
2000). 
The influence of age itself rather than duration of infection on specific IgE levels was 
studied in a population of very recent immigrants to an endemic area in Kenya (Naus et 
al.. 1999) and it was concluded that the development of such IgE was dependent on age 
but also influenced by the intensity of infection. The way in which antibody isotypes are 
affected by age and exposure was also investigated by Naus et al., (2003). They 
analysed the specific antibody isotype responses (IgA, IgGI, IgG2, IgG3, IgG4. IgE, 
IgM) against S. mansoni worm and egg antigens in relation to age, sex and faecal egg- 
count, in a Ugandan community where adults are heavily exposed to 
infection through 
the fishing economy, but where infection intensity, as measured by egg counts, is higher 
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in males across all ages. Even though the duration of water contact on a daily basis is 
similar in the 2 sexes, they are involved in different activities that may carry different 
risks of infection (Kabateriene et al., 1999). Using statistical analysis, Naus et al. (2003) 
showed that in both sexes within this fishing Ugandan community most anti-S. mansoni 
worm antigen responses (anti-SWA) increased with age, whereas anti-SEA (anti-S. 
mansoni egg antigens) decreased with age, especially after puberty. IgG 1, IgG4, IgE 
anti-S. mansoni worm antigen and IgG4 anti- S. mansoni egg antigen responses were 
independently higher in males, whereas IgG2-SEA responses were independently 
higher in females. The significant effects of sex on isotype responses to adult worm 
antigens may be partly because of different levels of cumulative exposure. The fishing 
activities of males may expose them to more cercariae than females over a period of 
years, and thus the cumulative exposure to schistosome antigens may vary substantially 
between the sexes (Naus et al., 2003). 
1.7.3.2 Which antigens are recognised by "protective" antibodies? 
There has been interest in trying to identify which antigens may be preferentially 
recognised by putatively protective antibody isotypes. IgE responses to a 22.6kDa adult 
worm antigen has been identified as correlating with immune status (Dunne et al., 1997, 
Webster et al., 1996). Although there is a focus on IgE as a potentially important 
effector isotype in immunity in humans there is data implicating other antibody types. 
Investigations in Kenya and Senegal have shown an association between IgA anti- 
Sm28GST and the age-dependent decrease in egg excretion in infected individuals 
(Grzych et al., 1993). Also, resistance to reinfection with S. mansoni has been 
associated with higher levels of IgG reactivity to a 37 kDa larval surface antigen 
(Dessein et al., 1988). These observations suggest that expression of immunity is not 
simply determined by the balance of IgE and IgG4, but might include the participation 
of other mechanisms. 
Antibody class switching to IgE is controlled by IL-4, a key cytokine and marker of Th2 
responses (Janeway et al., 2001) and so the identification of IgE as a possible mediator 
of resistance after chemotherapy in humans focuses attention on the 
Th2 component of 
the immune response. 
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1.7.4 Other evidence for Th2-mediated effector functions in resistance after 
chemotherapy: 
1.7.4.1 IL-5 correlates with resistance to reinfection: 
A longitudinal study of cellular responses of infected individuals in Kenya before and 
after treatment showed a clear negative association between the proliferative responses 
to adult worm- and schistosomulum-stage antigens and subsequent reinfection intensity 
in older individuals (the resistant group), who also had significantly higher levels of IL- 
5 in tissue culture supernatants of in vitro-stimulated cells than did younger individuals 
(the susceptible group) (Roberts et al., 1993). IL-5 is produced by Th2 cells and as it is 
responsible for eosinophil production/action this suggested a role for eosinophils in 
human immunity in vivo. In fact earlier studies had suggested that resistance to S. 
haematobium in humans was related to high eosinophil counts (Hagan et al., 1985). 
1.7.4.2 Genetically "resistant" individuals make high Th2 responses: 
The acquired immune responses that have been associated with resistance to reinfection 
after chemotherapy are all of the Th2 type, characterized by high secretion of IL-4, IL-5 
and IgE and high numbers of eosinophils (Roberts et al, 1993; Medhat et al., 1998; 
Hagan et al., 1991; Dunne et al., 1992a; Rihet et al., 1991; Hagan et al., 1985). This 
conclusion is supported by genetic studies that demonstrated, by segregation analysis, 
that a major gene (SMI ), which regulates the `intensity of infection' phenotype, can be 
linked to a gene region located on chromosome 5 (5g31-q33), which encodes IL-4, IL- 
5, IL-9 and IL-13 cytokines involved inTh2 responses (Abel et al., 1991; Marquet et al., 
1996). Most strikingly schistosome antigen-specific T cell clones derived from 
homozygous resistant individuals produced 10-1000 fold higher levels of IL-4 and IL-5 
compared with clones from homozygous susceptible individuals 
but comparable levels 
of IFN-y (Rodrigues et al., 1999). This clearly implicates Th2 responsiveness controlled 
by the SMI gene in natural resistance to schistosomes even in the absence of am, 
treatment induced responses. 
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Apart from this clear polymorphism in relation to Th2 responsiveness there have been 
other studies implicating genetic diversity in relation to recognition of specific 
schistosome antigens. Studies in Brazilians and Kenyans infected with S. mansoni have 
suggested that there is some genetic restriction with regards to the ability of the host to 
recognize different epitopes, to mount a specific immune response and to produce an 
isotype profile against the same antigen. Thus, Bethony et al., (1999) studying S. 
mansoni egg positive siblings from different families demonstrated that there was 
significant familial resemblance for all IgG subclasses and IgE levels directed against 
adult-stage antigens (Smp20.8 and Smp50). Amongst both egg positive and egg 
negative siblings only IgE and IgG4 isotypes showed familial resemblance to an egg- 
stage antigen (Smp40). In Kenya, anti-schistosome IgE responses were restricted to 
only a few people whose immune system recognized a limited repertoire of antigens 
(Dunne et al., 1992b). Although no genetic basis has been established for the Kenyan 
results, they are still consistent with at least some genetic restriction of host immuno- 
competence and antigen recognition. 
1.7.5 Immune Mechanisms demonstrated in vitro: 
1.7.5.1 Eosinophil / IgE-mediated ADCC: 
Studies performed in vitro have demonstrated that human effector cells: eosinophils, 
macrophages and platelets are able to kill freshly transformed schistosomula in the 
presence of complement and / or antibody (Butterworth et al., 1975; Joseph et al., 1983; 
Joseph et al., 1985). Regarding antibody-mediated cellular cytoxicity both the IgG (Anwar 
et al., 1979) and IgE (Capron et al., 1984) fractions of human infection sera have been 
shown to be capable of opsonising the schistosomula for killing but IgE/eosinophils is a 
particularly potent combination (Dunne et al., 1993). 
1.7.6 Blocking antibodies: 
Using blood samples taken from children deemed either resistant or susceptible to 
reinfection, Butterworth et al., (1985) examined the antibody response to the 
schistosomula, adult and egg stages of the parasite as well as measuring eosinophilia. No 
positive correlation between resistance and the levels of antibody or number of eosinophils 
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was detected but negative correlations were observed between the levels of antibody raised 
against the egg stages and resistance to reinfection (Butterworth et al., 1987) and it is now 
suggested that the development of human immunity requires the down regulation of 
antibodies which are capable of preventing the cytotoxic action of others i. e. blocking 
antibodies. 
The existence of antibodies able to block in vitro ADCC were initially described by 
Grzych et al., (1982,1984) using monoclonal rat IgG2a, which had Fc receptors on 
eosinophils and IgG2c which did not. Monoclonal antibodies of the IgM isotype which are 
able to block in vitro killing of schistosomula by immune human serum and eosinophils 
have also been described (Dunne et al., 1987). Evidence that blocking antibodies are raised 
during a natural infection of humans was provided by Khalife et al. (1986) who 
demonstrated that the in vitro killing of schistosomula by the IgG fraction of sera taken 
from infected individuals was abolished by prior incubation of the larvae with the IgM 
fraction. The levels of IgG2 in human sera have also been shown to correlate negatively 
with resistance to reinfection (Dunne et al., 1987; Demeure et al., 1993). As IgG2 like 
IgM, is raised in response to carbohydrate epitopes it has been suggested that antibodies 
raised against carbohydrate epitopes on the egg prevent the binding of effector antibodies 
directed at cross reactive epitopes upon the surface of the schistosomula and may in part 
account for the lack of immunity seen in younger children (Khalife et al., 1986; Dunne et 
al., 1987). 
The killing of schistosomula with eosinophils and IgE is not affected by prior incubation 
with IgM (Khalife et al., 1986) and suggests that IgE recognises different epitopes to these 
blocking antibodies. However, as discussed above there is an in vivo correlation between 
resistance and a high IgE response coupled with a low IgG4. It has therefore been 
suggested that the onset of immunity may represent an immunoglobulin class switch which 
is caused by the involvement of different T cell cytokines (Hagan et al., 1991). Like the 
IgM and IgG2 isotypes which block the IgG cytotoxic killing of the schistosomula, IgG4 
may block IgE mediated larval killing. Although the target antigens for any such ADCC 
operating in vivo are not known, IgG4 levels in serum of infected Kenyan 
schoolchildren against the recombinant glutathione-S-transferase (GST) of S. mansoni 
were found to be significantly greater in the susceptible group than in the resistant 
group (Auriault et al., 1990). 
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1.7.7 Why does intensity of infection/intensity of reinfection after treatment peak 
in early teens and then rapidly decline? 
1.7.7.1 The influence of puberty: 
In the studies of resistance to reinfection following treatment reviewed by Fulford et al. 
(1998), marked declines in reinfection rate occurred at a very consistent and narrow age 
range corresponding to the age of puberty. It is suggested (Fulford et al., 1998) that a 
number of physiological non-immunological responses could account for the 
differences in susceptibility between children and adults such as changes in skin- 
thickness, body fat, size of the animal, and circulating schistosomicidal factors. In 
addition steroid hormones such as dehydroepiandrosterone (DHEA) which rise during 
puberty and have been implicated in immune responsiveness, might be involved in 
development of the protective anti-schistosome immune response. In mice, the age- 
associated hormonal factors, such as testosterone and DHEA have also been implicated 
as putative schistosomicidal compounds (Nakazawa et al., 1997; Fallon et al., 1998). It 
has been recently reported that testosterone is directly toxic to larval schistosomes in 
vitro (Fantappie et al., 1999). It was shown in earlier studies that even juvenile mice, as 
well as hamsters, are more susceptible than adult animals to schistosome infection 
(Purnell et al., 1966). 
1.7.7.2 History of infection: 
It has also been proposed that acquired immunity develops as a function of cumulative 
exposure (duration and frequency) to parasite antigens (Woolhouse & Hagan, 1999). 
There have been several studies on the influence of infection history on immune 
responses before treatment (Butterworth et al., 1988; Mutapi et al., 1997). It was 
reported that acquired immunity develops quicker in exposed individuals in areas of 
high-transmission than in those areas of lower transmission because the population is 
exposed to a higher level and a greater diversity of antigens in a high transmission area 
(Mutapi et al., 1997). From studies performed in Zimbabwe, Mutapi et al., (1997) 
showed that the humoral responses also develop quicker and reaches higher levels in 
areas of intense transmission compared with those in areas of low transmission. 
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Inspite of this evidence of a relationship between exposure and development of 
resistance, the fact that the age of peak intensity does not vary much (Fulford et al, 
1996) and the fact that similar age-intensity profiles become established in newly 
established foci (Gryseels, 1994) emphasise the overriding importance of age per se in 
relation to development of resistance. 
1.7.8 Does treatment induce/enhance immunity in humans? 
In recent years it has been suggested that, in the treatment/reinfection studies, rather 
than simply removing the worms to allow assessment of pre-existing resistant 
(putatively immune) status, the drug-induced killing of the worms in vivo resulted in 
antigen release and so served to boost and/or alter the immune response in a way that 
might enhance immunity. 
1.7.8.1 Antibody responses: 
A recent study of anti-schistosome Ab responses in Zimbabwean children treated with 
either Praziquantel (PZQ) or Oxamniquine (OXAM) by Mutapi et al., (2003) 
demonstrated a significant increase in the proportion producing anti-S. mansoni SEA 
IgA, IgE and IgG3 post treatment while the proportion producing IgG 1 and IgG4 
decreased. 
There are also significant differences in the type of immune responses in children and 
adults following chemotherapy (Grogan et al., 1996). Two studies that compared 
children with adult immune responses showed that the immune response profile in 
treated children was similar to that in untreated adults (Grogan et al., 1996; Mutapi et 
al., 1998). For example, in Gabonese children (5-10 years old) infected with S. 
haematobium, the levels of IgE and IgG4 antibodies against (adult worm antigen and 
soluble egg antigen) schistosomes increased significantly following treatment - in 
contrast to the adult immune responses, which remained unchanged (Grogan et al., 
1996). In Zimbabweans infected with S. haematobium, children produced a 
predominant IgA response before chemotherapy. Following treatment, all children 
switched from IgA to IgGI (production against egg and worm antigens (Mutapi et al., 
1998). Hence, their post-treatment Ab profile became similar to that of untreated adults. 
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Earlier studies on the interaction of PZQ with schistosomes reported modifications in 
the cell proliferative responses (Ottesen et al., 1978). These modifications have been 
reported to remain for >1 year (Naus et al., 1998; Satti et al., 1996) and confer some 
resistance to re-infection (Dunne et al., 1992a; Roberts et al., 1993). 
1.7.8.2 Cellular responses: 
In a re-infection study by Mduluza et al. (2003), an attempt was made to show the 
cytokine profiles that appear before treatment and the change in the period following 
treatment with PZQ. Cytokine profiles were compared, in this study, of individuals from 
two areas with different transmission patterns for Schistosoma haematobium in 
Zimbabwe. Before treatment, both infected and uninfected groups showed low and 
similar ratios, respectively, of IL-4: IFN-y, IL-5: IFN-y and IL-10: IFN-y, while IFN-y 
was high in the infected individuals. After treatment the non re-infected individuals had 
higher levels of IL-4, IL-5 and IL-10, while the infected had high levels of IFN-y. The 
results indicated that the cytokine balance determines, in part, susceptibility or 
resistance to S. haematobium infection with Th-1 responses dominating during infection 
and the Th2 responses dominating post treatment and in uninfected individuals. 
Suggestions about how the treatment might affect the immune response include 
increased antigen release and reduction in immunosuppression by loss of antigen 
stimulation. Praziquantel (PZQ) treatment has been shown to damage the adult 
schistosome tegument (Andrews, 1985). This treatment also exposes the antigens on the 
worm surface (Fallon & Doenhoff, 1995) to the host immune system, which induces 
specific cellular and humoral immune responses (Woolhouse & Hagan, 1999), thus 
resulting in the death of the parasite. Such effects may underlie the proposed 
enhancement of development of humoral responses to tegumental and internal antigens 
(Mutapi et al., 2003). Cellular studies have stressed the differences in proliferation 
between individuals with acute and chronic forms of schistosome infection (Colley et 
al., 1986; Ottesen et al., 1978). During chronic infections, the host is exposed to large 
quantities of antigenic material from worms and eggs of the parasite and the usual 
response of the host immune system to such repeated or continuous antigen exposure is 
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down regulating or modulating the immune response to prevent continued over- 
reactivity which might be harmful to the host (Barsoum et al., 1982; Ellner et al., 1985), 
but following treatment the antigenic stimulation of the immunosuppressive response 
will stop allowing other responses to increase. 
Whilst it is clear that chemotherapeutic cure causes qualitative and quantitative changes 
in the immune response to schistosome antigens and that this seems to promote the 
putative immunoprotective responses e. g., specific IgE, the extent to which this is 
necessary for promoting the resistance to reinfection is difficult to establish. It should be 
pointed out that in the original observation of a correlation between resistance to 
reinfection and high IgE/lowered IgG4 (Hagan et al., 1991) the sera showing this 
correlation was taken prior to treatment. 
1.7.9 Endemic Normals: 
The EN individuals manifest immune responses to S. mansoni antigens that differ 
significantly from those of post-treatment-resistant and patent-infected individuals. A 
number of immunological studies of naturally acquired resistance in EN individuals 
showed the involvement of both Thl (cellular) and Th2-type (humoral) responses in the 
development of protection against S. mansoni infection (Viana et al., 1994; Viana et al., 
1995; Correa-Oliveira et al., 1989; Bahia-Oliveira et al., 1992), whereas as seen above, 
resistance seen following chemotherapeutic cure appears to be mediated mainly by Th2- 
type responses (Roberts et al., 1993). 
1.7.9.1 Antibody responses: 
Several studies have compared antibody responses in EN and infected/treated 
individuals. In the endemic area of Siqueira, longitudinal analysis of antibody responses 
of EN individuals demonstrated that the anti-adult worm IgE level in EN individuals 
was similar to that of individuals infected or resistant to reinfection after chemotherapy 
(identified 21 months after treatment) (Viana et al., 1995; Caldas et al., 2000). The IgE 
antibody response to schistosomula tegument antigens was significantly higher in EN 
individuals than in infected patients. After chemotherapy, the IgE response to 
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schistosomula tegument antigens increased only in those patients who became resistant 
to reinfection. This suggests that the IgE antibody response might play an important role 
in eliminating the parasite in EN. Regarding the response to specific antigens, Correa- 
Oliveira et al., (1989) reported that EN individuals had higher IgG anti-paramyosin 
antibody responses than did infected patients. This elevated response was associated 
with the lack of eggs in the stool. A significant increase in IgG anti-paramyosin 
antibodies was also observed in patients resistant to reinfection. 
1.7.9.2 Cellular responses: 
The cellular proliferative response of patients resistant to reinfection after treatment has 
also been compared with patients who became reinfected after chemotherapy. An 
increased response to soluble egg and cercarial antigen preparations has been observed 
in the resistant group (Colley et al., 1986). Similarly a study carried out in Brazil 
showed that individuals resistant to reinfection had higher cellular lymphoproliferative 
responses to schistosomula and adult worm antigens (Ribeiro et al., 1993). In contrast to 
infected individuals, peripheral blood mononuclear cells (PBMCs) from EN individuals 
proliferate vigorously in vitro after antigenic stimulation with parasite antigens. High 
levels of IFN-y are secreted by PBMCs from EN individuals independent of the 
schistosome antigen preparation used (Viana et al., 1994; Bahia-Oliveira et al., 
1992). The main cell source of IFN-y secretion among PBMCs was found to be CD4+ T 
cells (Brito et al., 2000). 
In EN individuals, a clear Th2 cytokine profile was not observed, as compared to 
resistant to reinfection individuals (Roberts et al., 1993; Medhat et al., 1998; Hagan et 
al., 1991). It has been suggested that EN individuals may differ genetically from those 
who are able to develop effective Th2 immune responses after treatment or, 
alternatively, that chemotherapy leads to the presentation of novel antigens that are 
stage specific and not recognized by cells or antibodies from EN individuals. However, 
the data on SMI resistance status and Th2 bias clearly indicates the importance of Th2 
responses in resistance independent of chemotherapy (Abel et al., 1991; 
Marquet et al., 
1996). How the Thl responses implicated in the EN response relates to distribution of 
the SMI alleles remains to be resolved. 
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1.8 Co-infection with other parasites: 
Many people who live in schistosome-endemic areas are also exposed to many other 
infectious diseases and other immunological challenges. Some of these other pathogens 
induce a Th 1 biased immune response when present as a single infection. Given the 
counter-regulatory effects that are exerted by Thl and Th2 cells on each other's 
development and the presence of regulatory pathways e. g. IL-10 and T-regulatory cells, 
studies on co-infections between schistosomes and other pathogens and effects of 
schistosomiasis on vaccine efficacy, allergic and autoimmune responses have been the 
subject of growing interest. 
1.8.1 Thl vs Th2 co-infections: 
i- Experimental infections in mice 
Data from experimental studies of vaccinia infections in mice, showed that mice 
infected with schistosomiasis are less able to mount a specific anti-viral CD8+ Thl 
immune response, and are therefore less able to clear viruses (Actor et al., 1993). 
Infected mice also had greater susceptibility to malaria (Helmby et al., 1998), and are 
extremely susceptible to infection with Toxoplasma gondii (Marshall et al., 1999), a 
parasite that induces marked Thl responses and that is lethal in mice that have defects 
in IFN-y production. 
ii- Human studies 
Tetanus Toxoid: In vitro re-stimulation of PBMCs with Tetanus Toxoid antigens (TT) 
from TT immunized individuals, who were either not infected or had light, medium or 
heavy S. mansoni infections, showed progressively lower levels of IFN-'y and increases 
in Th2 cytokine mRNA. It was concluded that the schistosome-induced Th2 
environment into which the TT vaccine was introduced either promoted development of 
TT-specific Th2 cells at the expense of Thl cells or specifically down-regulated 
development of TT-specific Thl cells, by for example stimulating the production of IL- 
10 (Sabin et al., 1996b). 
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BCG: Malhotra et al., (1999) demonstrated that children vaccinated with 
Mycobacterium bacillus Calmette-Guerin (BCG) at birth make significantly lower IFN- 
y responses to purified protein derivative of Mycobacterium bacillus (PPD) at 10-14 
months after birth if they are born of worm-infected (S. haematobium or Wuchereria 
bancrofti) mothers. These important observations suggest that prenatal sensitization to 
worm antigens results in a persistent Th2 biased immune response (producing IL-4 and 
IL-5). People vaccinated with BCG, on the otherhand, (before being exposed to any 
worms in their life) were reported to be less susceptible to intestinal nematodes 
(Elliott et al., 1999). This same phenomena of pre-natal exposure to worm antigens, 
priming the individuals immune response to a reduced Thl response may have 
important implications for responses to other infections acquired early in life e. g. 
malaria. 
AIDS/HIV-1: With regard to the possible interaction of concurrent schistosome and 
HIV-1 infections, Th2 cells which would be promoted by schistosome infections have, 
in some cases, been found to support HIV replication in vitro more strongly than Th 1 
cells (Maggi et al., 1994), which led to the hypothesis that schistosomiasis and other 
helminth infections contribute to the high prevalence of AIDS and HIV infection in 
Africa (Bentwich et al., 1999). Conversely, it was recently also found from in vitro 
studies that when comparing T cells in the peripheral blood of S. mansoni-infected 
individuals, those in schistosome and HIV co-infected individuals responded to egg 
antigen by making less IL-4 and IL-10, but similar (low) amounts of IFN-y, indicating 
that there is a shift in the overall balance of the response from Th2 to Thl (Mwinzi et 
al., 2001). On the basis of the various roles that have been established for CD4+ T cells 
during schistosomiasis in the mouse model, it would be anticipated that individuals with 
AIDS would have altered patterns of hepatic fibrosis and, perhaps, an increased risk of 
liver damage owing to the insufficient sequestration of egg hepatotoxins and/or the 
relatively increased production of pro-inflammatory cytokines. 
Malaria: The possible interaction of malaria and schistosomiasis was investigated in 
school children from 2 areas in Kenya with contrasting prevalences of 
hepatosplenomegaly but similar prevalences and intensities of Schistosoma mansoni 
infection. When plasma was assayed for anti-Plasmodium falciparum and anti-S. 
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mansoni antibodies to test whether greater exposure to Plasmodium was a cofactor for 
hepatosplenomegaly, it was found that hepatosplenic children had significantly higher 
levels of anti-P. falciparum antibodies, compared with non-hepatosplenic children, a 
finding that strongly suggests that some experience of P. falciparum influenced the 
development of hepatosplenomegaly in these S. mansoni-infected children (Mwatha et 
al., 2003). 
1.8.2 Th2 vs Th2 co-infections: 
Ongoing Th2 responses in chronic shistosomaiasis might be beneficial (a) during co- 
infection with other pathogens against which Th2 responses may be host-protective (for 
example, the intestinal nematodes), (b) in preventing the onset of Th 1-mediated 
autoimmunity (e. g., diabetes mellitus in genetically predisposed non-obese diabetic 
mice (Cooke et al., 1999) and (c) in modulating allergy. 
Other Helminths: 
In experimental studies of Trichuris muris in the mouse, in which Th2 responses are 
protective resulting in rapid worm expulsion in some strains of mice (Curry et al., 
1995), coinfection with schistosomes was able to promote protective Th2 responses in 
another strain of mice which otherwise would have developed Thl responses and 
persistent infection. 
Allergies: In situations where helminth infections and allergy co-exist, both are 
associated with Th2-dominated immune responses. Allergic disease seems to be less 
frequent in developing countries that still have widespread helminth infection 
(Yazdanbakhsh et al., 2002). Several recent studies in human populations that are 
infected with S. mansoni (Araujo et al., 2000) and S. haematobium (van den Biggelaar, 
2000b) have shown a clear inverse relationship between allergen responsiveness and 
schistosome infection. It has been proposed that the regulatory mechanisms that are 
induced as a component of the immune response to chronic helminth infection, such as 
the production of IL-10 and, possibly, TGF-ß, may result in non-specific prevention of 
inflammatory sequelae during allergic responses (Yazdanbakhsh et al., 2002). For 
example, van den Biggelaar et al., (2000b) reported a correlation between S. 
haematobium infection and reduced levels of immediate skin test responsiveness to 
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house dust mite allergen. There was no correlation between this reduced level of skin 
test responsiveness and polyclonal IgE levels indicating that the effect was unlikely to 
be due to non-specific blockage of mast cell receptors by excess non-allergen IgE, 
which has been suggested as a mechanism of interference. However, there was an 
inverse correlation of skin test response with levels of IL-10 produced in vitro to 
schistosome antigen. 
1.9 Immunity in Experimental Animals: 
Much of the research using experimental animals has focused on S. mansoni, simply 
because it is the easiest of the three major schistosome species (S. mansoni, S. 
haematobium & S. japonicum) to maintain in the laboratory. Likewise, the ability of the 
mouse to manifest many pathological features of human schistosomiasis, and to develop 
immunity, coupled with its relatively low cost and ease of production, makes it a suitable 
model of study. 
1.9.1 Concomitant Immunity: 
Owing to the difficulties inherent in identifying and defining immune mechanisms in the 
human host it has proved necessary to use animal models of schistosomiasis. Progress in 
this area has been greatly enhanced by the fact that several laboratory animals are 
susceptible to the parasite, although to varying degrees depending on the host and 
schistosome species. Rodents, such as mice and rats and, to a lesser extent, primates such 
as the rhesus monkey and the baboon have all been used in experimental infections with 
S. mansoni. The baboon and the mouse are, like humans, permissive hosts, which tolerate 
the development of the adult worm and the onset of egg production 4-5 weeks post 
infection (Smithers and Doenhoff, 1982). Also the pathological consequences are similar 
to that in humans. In contrast, the rat is a non-permissive host in which a small proportion 
of stunted worms survive but do not produce viable eggs (Cioli et al., 1978) and the rhesus 
monkey a semi-permissive. 
Studies of S. mansoni infections in rhesus monkeys (Smithers and Terry, 1969) showed 
that primary light infections could be established giving rise to egg production in the 
faeces, but that following a challenge infection with large numbers of cercariae, egg 
output was not altered although in challenge control monkeys faecal output rose 
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dramatically and the animals got sick. This was termed "concomitant immunity" as the 
primary worm burden was apparently unaffected by the response which eliminated the 
challenge infection. It has been suggested that a similar phenomenon may operate in 
naturally acquired immunity in humans. Unfortunately nothing is known of the 
mechanism of this resistance. 
In mice, resistance to challenge arises within 8 weeks of a single unattenuated infection 
(Dean, 1983) and resembles concomitant immunity in that the primary infection persists 
but the incoming larvae appear to succumb. However, it has become apparent that the 
resistance seen in this model is associated with the pathological response of the host to 
parasite eggs deposited within the tissues (Wilson et al., 1983; McHugh et al., 1987) or 
with factors related to egg-associated pathology, such as the degree of portal hypertension 
(Harrison et al., 1982) or formation of portal shunts which allow the migrating larvae to 
bypass the liver and die in other organs (Wilson et al, 1983). The lack of evidence for 
specific anti-larval immune-mediated protection in infected mice means that this model 
has contributed little to our understanding of immunity to infection. This resistance, is 
therefore, more anatomical than immunological, and it is related to pathological changes 
that are more prevalent in infected mice than in infected humans. In contrast there is 
considerable evidence that attenuated larval vaccines do induce immunologically specific 
immunity. 
1.9.2 Attenuated Vaccine-induced Immunity: 
Most attention has been focused on resistance to reinfection which is brought about by 
exposure to parasites that are attenuated and die within the host during migration. In the 
vast majority of the studies attenuation is brought about by exposure of the larvae before 
infection to radiation (Irradiated Vaccine Model), but attenuation by treating with the 
schistosomicide Rol 1-3128 1-2 days post infection has also been studied (Rol 1-3128 
Vaccine Model). Such attenuated vaccines are not feasible for human use but particular 
attention has focussed on them because crude dead antigen preparations induce poor or 
irreproducible levels of protection. Studying such models is aimed at understanding (i) the 
nature of the protective response, (ii) the characteristics of antigen presentation, and (iii) 
the protective antigens, so that progress can be made to develop defined antigen vaccines. 
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Much of this thesis is concerned with the Rol 1-3128 terminated infections but the 
following sections describe what has been learnt about immunity from the much more 
extensively studied irradiated vaccine model. This is followed by a consideration of the 
drug terminated model, how this differs from the irradiated model and how studying it 
further may contribute to our understanding of the mechanisms of immunity and vaccine 
development. 
1.9.2.1 The Irradiated Vaccine Model: 
In the 1960s, protection experiments were first carried out using irradiated schistosome 
larvae which died out during migration and so did not reach the adult, egg producing 
stage (reviewed by Taylor, 1994). Later work focussed on natural schistosome species 
of domestic animals and Taylor et al., (1976) demonstrated that sheep could be 
protected against infection with S. mattheei by immunisation with homologous 
irradiated schistosomula and that both sheep and cattle could be protected against S. 
bovis under laboratory conditions (Taylor et al., 1979). The latter studies were extended 
into the field and it was demonstrated that immunisation with irradiated S. bovis 
schistosomula reduces worm and egg burdens and egg associated pathology (Majid et 
al., 1980) under conditions of natural exposure. The effectiveness of this procedure in 
inducing high levels of immunity (>90%) against the human schistosome species S. 
haematobium in the baboon (Harrison et al., 1990) demonstrated the potential efficacy 
of schistosome vaccines and the relevance of this procedure as a model for development 
of a human vaccine. 
(A) The Effect of radiation on the parasite: 
Understanding of the parasite stages responsible for, and the mechanisms of immunity 
have largely come from studies in rats and mice. Both species develop schistosome 
species-specific and long lasting immunity (>24 weeks in mice) (Bickle et al., 1985). 
Early studies in both mice and rats showed that the level of protection was markedly 
influenced by the irradiation dose used. The optimum dose of 20krad results in the 
majority of the attenuated parasites migrating to the lungs where they persist in significant 
numbers for longer than unirradiated larvae, eventually dying in that site (Ford et al., 
1984a, b; Bickle et al., 1979a, b; Mastin et al., 1983). An assessment of the ultrastructure of 
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the attenuated schistosomula fixed in situ in the lungs (Mastin et al., 1985b) showed that 
these persistent schistosomula were normal in appearance but abnormal in location, 
lying in alveoli where they elicited a marked inflammatory reaction. 
Wales and Kusel (1992) proposed that radiation may directly alter antigen expression so 
that vaccinating parasites are more immunogenic than their normal counterparts. Using 
electron microscopy, Harrop and Wilson (1993) revealed marked distinctions in surface 
morphology between normal versus irradiated larvae at the lung stage of development, 
artificially transformed and cultured in vitro for several days. The latter parasites 
exhibited random constrictions at intervals along the length of the body, probably 
resulting from overcontraction of circular muscle fibres; they were also less motile than 
normal larvae. The authors postulated that the disruption in neuromuscular co- 
ordination accounts for the limited migratory capacity of attenuated schistosomula in 
vivo. 
(B) Persistence of attenuated schistosomula: 
An apparent conclusion to be drawn from the above studies is that an optimum dose of 
radiation does not cause rapid death of schistosomula, since many are able to persist in 
various sites for up to 3 weeks. The persistence of attenuated schistosomula was also 
the subject of a subsequent autoradiographic study (Mountford et al., 1988) by paying 
particular attention to the lymph nodes draining organs on the parasite migration route. 
It was discovered that a proportion of normal (i. e. non-attenuated) schistosomula 
entered and rapidly migrated through lymph nodes draining the skin exposure site 
(SLN, skin-draining Lympn nodes), since numbers peaked at 16% of applied parasites 
on day 5 and declined to less than 3% on day 7. Fewer attenuated parasites were 
detected in SLNs (peak of 11.5% on day 5), but they persisted throughout the second 
week after exposure (Mountford et al., 1988). Furthermore, proportionally greater 
amounts of parasite-released material were detected in the nodes of vaccinated mice 
compared to those infected with normal cercariae (Mountford et al., 
1988), which was 
suggested to be due to increased turnover of parasite proteins caused 
by irradiation. It 
was concluded that optimally attenuated (20krad) schistosomula are sequestered 
in this 
location and that this is vital for their optimal induction of immunity. 
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Earlier studies had shown that schistosomula exposed to very high doses of radiation 
e. g. 80krad were poorly protective and it was found that few of such irradiated larvae 
migrated from the skin exposure site to the SLNs and none reached the lungs (Constant 
et al., 1990). The importance of the sensitisation of the SLNs was investigated by 
surgical excision of the nodes, 5 days before vaccination and up to 10 days after. This 
caused a significant reduction (up to 75%) in the level of immunity compared to that in 
sham-operated controls (Mountford and Wilson, 1990). It was concluded that 
sensitisation of, and perhaps persistence of radiation-attenuated parasites in, the skin 
draining lymph nodes, together with the prolonged release of antigen in the latter site, 
are major factors in the induction of resistance. 
The incomplete ablation of resistance by removal of SLN shows that a component of 
the response is elicited elsewhere. It was postulated by Mastin et al., (1983) that the 
persistence and subsequent death of irradiated schistosomula in the lungs could provide 
the appropriate antigenic stimulus for the induction of an immune response against 
challenge parasites. When optimally attenuated cercariae are applied percutaneously 
(Mountford at al., 1988) or attenuated schistosomula are administered intradermally 
(Coulson and Mountford, 1989), many migrate as far as the lungs and both can induce a 
high level of protection results. However, if attenuated schistosomula are introduced 
directly to the lungs (i. e. bypassing the lymph nodes) they induce only moderate levels 
(intratracheal route) or virtually no protection (intravenous route), despite the larvae 
remaining in this location for at least nine days (Coulson and Mountford, 1989). It 
therefore appears that the irradiated larvae must persist in both lymphatic tissue and 
lungs in order to generate an optimum immune response. 
(C) The nature of the immune response: 
Studies using athymic and µ-MT (T- and B-cell deficient animals, respectively) depleted 
rats and mice (Ford et al., 1987a; Sher et al., 1982) first suggested the involvement of both 
T and B cells in the resistance generated. In rats the immunity induced following a single 
or multiple exposure to irradiated cercariae is antibody (IgG2a) mediated (Ford et al., 
1987b), whereas in mice a single exposure results in a mixed CMI/antibody dependent 
protection but with repeated vaccination antibody becomes more important. 
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(D) Immune Mechanisms following Single Vaccination : 
Mouse strains differ widely in the extent of immunity developing after exposure to 
attenuated cercariae (Murrell et al., 1979). C57B1/6 strain are consistently high 
responders for S. mansoni (Richter et al., 1995) and a single exposure to 500 optimally 
irradiated cercariae routinely induces 60-70% protection against a challenge with 
normal cercariae administered 5 weeks after vaccination. This strain has been used for 
the majority of studies on the irradiated vaccine and was used in the present studies 
also. 
(i) Events in the Skin (ear Pinnae): Radiation-attenuated larvae exhibit severely 
retarded migration from the skin (Mastin et al., 1983; Mountford et al., 1988) and 
therefore would be expected to produce enhanced stimulation of accessory cells of the 
innate immune response, including antigen-presenting cells (APCs) (Riengrojpitak et 
al., 1998). Hogg et al. (2003) have recently reported significant production of IL-12p40 
in the skin (pinna) after exposure to 20krd irradiated larvae, and that majority of the IL- 
12p40+ cells were myeloid dendritic cells (DCs) although a proportion were identified 
as macrophages. The attenuated larvae also induced the production of IL-10, which 
regulates inflammation and the production of IL- 12. 
(ii) Events in the Lymph Nodes: Constant et al., (1990) demonstrated that following 
percutaneous infection with 20 krad-irradiated parasites, there was a large fold-increase in 
T-cell numbers in the skin-draining (axillary) and lung-draining (mediastinal) lymph 
nodes. Anti-CD4 monoclonal antibody treatment largely inhibited this, implicating a major 
presence of T helper cells. Around day 5 post vaccination, antigen-stimulated SLN cells 
produced IL-2, IL-3, IL-4 and IFN-y revealing a ThO or mixed Thl/Th2 response 
(Pemberton et al., 1991). However, by days 18 and 23, IL-3 and IFN-y were predominant 
and no IL-4 was seen, demonstrating a polarized Thl response. Such a polarised cytokine 
response was also reported by Caulada-Benedetti et al. (1991). From 14 days after 
vaccination, a large and sustained expansion of the circulating leucocyte pool could be 
detected, mainly due to changes in lymphocyte numbers (Menson et al., 1989). This is 
believed to represent cells entering the circulation from the SLNs. Additionally, 
splenocytes (Pemberton et al., 1991) and in particular splenic CD4+ T cells (Caulada- 
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Benedetti et al., 1991) recovered from mice up to 4 weeks after vaccination produced 
substantial amounts of IFN-y in response to schistosome antigen. 
(iii) Events in the Lung: Attention has been focussed on events in the lung as this was 
known to be where the irradiated cercariae mainly died, because the failure of SLN 
removal to remove immunity suggested that stimulation of additional sites was important 
for induction of optimal immunity and also because the lung is the site of attrition of the 
challenge infection. Studies by Aitken et al. (1988) demonstrated a sustained and 
significant increase in the number of leucocytes present within the broncho-alveolar lavage 
(BAL) post vaccination. This began on day 7 post vaccination as the larvae reached the 
lungs in substantial numbers (Mastin et al., 1983; Mastin et al., 1985b), reached a peak 
fifteen fold increase in leukocyte numbers on day 21 and persisted for at least 10 weeks 
post vaccination. The lymphocyte influx consisted of both CD4+ and CD8+ cells and the 
extent of increase was shown to correlate with protection. It was proposed that the arrival 
of the irradiated parasites serves to attract the circulating population of sensitized T cells 
which then infiltrate the lung parenchyma and airways and "arm" the lung against a 
challenge infection. 
(E) Immune Mechanisms in Multiply Vaccinated Mice: 
Repeated vaccination of mice with irradiated cercariae results in development of a mixed 
Thl/Th2-type or Th2-biased response, with increased production of antigen-specific IL-4 
and IL-5 cytokines by SLN cells and spleen cells (Caulada-Benedetti et al., 1991). 
Schistosome specific serum antibody levels also rise, notably IgG 1 and reach levels such 
that significant protection can be passively transferred with serum (Mangold and Dean, 
1986; Mclaren and Smithers, 1988; Wynn et al., 1996). 
(F) Neither a Thl nor a Th2 skewed response is essential for optimal immunity: 
Hoffman et al., (1999) showed that in IL-10/IL-4-deficient (highly polarized type 1) or IL- 
1 O/IL-12-deficient (highly polarized type 2) mice exposure to a single vaccination with 
radiation-attenuated cercariae both develop immunity. Vaccinated IL-10-deficient mice, 
exhibit a non-polarized or mixed ThO-like phenotype (a mixed and elevated type-1 and 
type2-associated immune response) and developed higher anti-schistosome immunity than 
wild-type mice. This immunity correlated with higher parasite-specific antibody titres, 
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greater proliferative lymphocytes, increased frequency of IFN-gamma and IL-4 secreting 
cells, and elevated perivascular/peribronchial inflammatory responses in the lung. These 
results suggest that optimal vaccine-induced immunity even following a single vaccination 
does not require a highly polarized response, but both type 1- and type 2-associated 
immune responses can act together to optimize protection. During single vaccination of 
wild type mice it appears that induction of IL- 10 serves to prevent the optimal stimulation 
of both types of response. 
(G) Mechanisms of Immunity against CHALLENGE infection: 
In order to determine the site of elimination of challenge parasites, recovery and 
autoradiographic tracking studies showed that the schistosomula of the challenge infection 
were also found to die predominantly in the lungs in both vaccinated mice and rats (Bickle 
et al., 1979a, b; Mastin et al., 1983 ; Ford et al. 1984a, b; Mangold and Dean, 1983). 
(i) IFN-7y Mediated Attrition: 
In one-time vaccinated mice Vignali et al. (1989a) demonstrated that the depletion of Th 
cells by administration of an anti-CD4+ monoclonal antibody at the time of challenge 
resulted in abrogation of vaccine immunity whereas depletion of CD8+ve cells was 
ineffective indicating a role for CMI mediated protection. Aitken et al. (1988) 
demonstrated that on the arrival of the challenge parasites in the lung a second influx of T 
lymphocytes is observed similar to that following arrival of the irradiated vaccinating 
parasites. The majority of these T-cells also secreted IFNy and IL-3 in response to 
antigenic stimulation suggesting that an anamnestic Thl type response occurs (Smythies et 
al., 1993). Upregulation of surface molecules (e. g. MHC Class II) expressed by alveolar 
macrophages occurs following vaccination and increases following a challenge infection 
(Menson and Wilson, 1990). Wynn et al. (1994) described a more mixed Th l /Th2 
response after administration of a challenge infection. Neutralization of IFN-y in these 
animals resulted in a decrease in IL-12 p40, TNF-a and IFN-y mRNA expression but a 
significant expression of several Th2 cytokines including IL-4, IL-5 and IL-13. 
However, a crucial role for IFN-y in mediating challenge attrition has been confirmed by 
the use of monoclonal antibody against this cytokine which reduced the development of 
vaccine immunity when administered at the time of challenge although there is debate 
about whether IFN-y is solely responsible (Smythies et al., 1992b) or contributory (with 
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antibody) (Jankovic et al., 1999) to challenge attrition. In contrast, treatment with 
antibodies against IL-4 and IL-5 are without effect (Sher et al., 1990). 
(ii) Antibody-mediated Attrition: 
In B cell-deficient mice an important role for antibody even in the one-time vaccine model 
was suggested by Jankovic et al., (1999). Vaccine-induced immunity in B-cell deficient 
(µMT) and IFN-y knockout (GKO) animals were compared. After a single vaccination, B 
cell knockout (KO) mice displayed reduced protection against challenge infection, 
although they developed a normal IFN-y-dominated cytokine response. This defect in 
resistance could be restored by passive transfer of immune sera from one-time vaccinated 
wild type mice confirming that the defect in host resistance in vaccinated B cell-KO mice 
results from the absence of humoral antibody and supporting the concept that one-time 
vaccine immunity involves both B cell and non-B cell-dependent mechanisms. 
In multiply vaccinated mice immunity is enhanced to a degree and there is a qualitative 
change in the mechanisms of immunity reflecting the Th 1 -Th2 cytokine switch: CD4+ve 
T-cells (Kelly and Colley, 1988) and IFN--y (Wynn et al., 1996) are no longer required at 
the time of challenge and serum is able to transfer resistance. Some experiments using 
fractionated sera have indicated that the IgG fraction (Mangold and Dean, 1986) or more 
specifically IgGI, (Delgado and McLaren, 1990) is wholly responsible for the protective 
capacity of sera from multiply vaccinated mice (VMS). However, the studies of Jwo and 
LoVerde (1989) suggested that the non-IgG fraction which contains mainly IgM and IgA, 
is also able to confer some protection but IgE has not been identified (Sher et al., 1983). 
In singly or multiply vaccinated rats IgG2a antibody is passively protective but IgE is not 
involved (Ford et al., 1987b). 
(iii) Mixed Cell-Mediated Immunity and Antibody response is desirable for optimal 
immunity : 
Repeat vaccinations of mice significantly increases the level of immunity in wild-type 
mice, however the protection in B cell KO animals remained unchanged (Jankovic et 
al., 1999). In contrast, multiple vaccination resulted in increased but, nevertheless, 
defective resistance in GKO mice. Together these findings further support the 
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conclusion that optimally effective vaccination against schistosomes at least by 
irradiated infections, depends on the simultaneous induction of both humoral and cell- 
mediated immunity. 
(H) How are challenge schistosomula killed in the immune lung? 
Exactly how the lung stage larvae are actually killed is still unclear. Whether by IFN-y (in 
singly vaccinated mice) or by antibody (in multiply vaccinated mice and vaccinated rats) 
there is an accelerated and enhanced inflammatory response around the larvae in 
vaccinated animals. Once trapped in inflammatory foci, larvae may then be killed by 
toxic cell products or by the effects of antibody (McLaren, 1989). 
(i) Cell-mediated Effector Mechanisms: 
The cellular infiltrate is rich in activated macrophages, and in mice has been shown to 
contain inducible NO synthase-(iNOS)-producing cells (Wynn et al,, 1994). Nitric oxide 
(NO) has been shown to kill skin stage schistosomula in vitro but not lung stage (Pearce 
and James, 1986), and the role of NO in vivo is also doubted as inhibition of NO by N- 
monomethyl-L-arginine (L-NMMA) fails to deplete vaccine immunity (Smythies, et al., 
1993). Furthermore, although significantly reduced when compared with vaccinated 
wild type animals, iNOS-deficient mice maintained a marked level of vaccine-induced 
immunity (Coulson et al., 1998; James et al., 1998). Interestingly, the decrease in 
protection in iNOS-deficient mice was associated with marked increases in IFN-, y, TNF- 
a, and IgG antibodies. The significance of this for understanding exactly how larvae are 
killed is uncertain but this does show that NO serves as a potent immunoregulatory 
factor downregulating the Th 1-type cytokine response. As suggested recently (Maclean 
et al., 1998) these studies indicate that iNOS-inhibitors may, in fact, be useful adjuvants 
for vaccination where an enhanced Th 1-type response is required for protective 
immunity. Because direct killing of the lung stage larvae has not been shown, it has 
been suggested that the inflammatory focus may simply block the migratory route of the 
challenge infection and result in a greater number of these parasites being shunted into 
the alveoli from where they cannot return (Coulson and Wilson, 1988). 
While lung stage attrition is widely accepted there has been some controversy about 
whether any killing occurs in the skin in vaccinated mice (Ward and Mclaren, 1988). 
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Similar foci to those seen in the lungs have been described in the skin although these 
contain radiosensitive leucocytes in addition to monocytes and T cells (Piper and 
McLaren, 1993; McLaren and Smithers, 1988) and these authors considered skin phase 
attrition to be important. It was suggested that trapping of parasites in these inflammatory 
foci may be aided by eosinophil cationic proteins which have been seen to paralyse lung 
worms in vitro (McLaren et al., 1984) and by macrophages which can mediate damage of 
the schistosomula musculature (McLaren and James 1985). 
(ii) Antibody Mediated Effector Mechanisms: 
The role of antibody in the killing of the schistosome in vivo is not fully understood. 
Following the challenge of passively immunised rats cellular reactions can be seen 
surrounding the dying parasites (Vignali et al., 1989b) but the lung stage schistosomula 
which forms the target of immunity in vivo, has been shown to be refractory to the 
antibody dependent mechanisms which kill freshly transformed schistosomula in vitro 
(Ramalho-Pinto et al., 1978; Incani and McLaren, 1989). 
Several suggestions have therefore been put forward regarding the role of antibody in the 
killing of parasites in vivo. Firstly, immune complexes which incorporate IgGl, IgG2a or 
IgE and circulating antigens could activate macrophages to release lysosomal proteins or 
trigger complement. The anaphylotoxins produced in this way would then attract more 
macrophages and eosinophils in addition to enhancing the expression of surface receptors 
on the latter. Products of both eosinophils and macrophages are known to damage the 
musculature of young schistosomula, hence parasite migration could be delayed and an 
inflammatory response induced which traps the parasite and prevents further migration 
(McLaren and Smithers, 1988). Alternatively, antibodies may bind to the lung stage larvae 
hence hindering their migration through capillary beds and enabling them to become good 
targets for an antibody mediated inflammatory response (Dean et al., 1987). Studies have 
demonstrated that although the lung stage parasite is refractory to antibody mediated 
killing in vitro, sera from vaccinated mice (Bickle and Ford, 1982), is able to bind to the 
lung stage schistosomula. However, more recently it has been shown that FcyR KO mice, 
which lack functional FcyRI, FcyRIII, and Fc E RI (the major cell surface receptors 
involved in positive antibody/Fc-mediated triggering) showed no defects in vaccine- 
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induced resistance after immunization either one or three times. This indicates that 
antibody-mediated protection does not require FcR signalling (Jankovic et al., 1999). 
1.9.2.2 The Drug-attenuated Vaccine Model: 
The observation that optimal immunity with irradiated cercariae requires the larvae to 
survive to the lung stage whereas more highly irradiated cercariae which die at the skin 
stage are poorly effective suggested that the lung stage schistosomula might be uniquely 
antigenic and/or that death in the lungs was crucial. To investigate these possibilities 
Bickle and Andrews (1985) set out to immunize mice by killing developing schistosomula 
at specific points in migration using schistosomulicides i. e., at skin, lung or liver stages. 
Somewhat unexpectedly it was demonstrated that high levels of protection were induced 
by treatment with the benzodiazepine derivative Roll-3128 just 24-48 hours after 
percutaneous exposure when the larvae would still be in the skin, external to the 
epidermal basement membrane (Crabtree& Wilson, 1985). In vitro, serum from drug 
treated mice ("serum-derived drug", SDD) induced rapid changes to larval motility and to 
the larval surface resulting in death (Bickle et al., 1990). In vivo, very few schistosomula 
could be recovered by mincing and incubation of skin at 24 hours post treatment relative to 
untreated controls. Larval arrest predominantly in the skin was confirmed by 
autoradiographic tracking (Mastin et al., 1985a). 
This suggested that lung stage antigens or larval death in the lungs was not crucial to 
development of immunity, but rather that release of protective antigens by protracted 
survival of the drug-damaged schistosomula in the skin was important. The levels of 
immunity induced by this model were as high if not higher than the irradiated cercariae but 
it appeared that there was a briefer and more focal exposure of the host to living larval 
antigen than with the irradiated vaccine. For these reasons it is considered that this model 
is more similar to the requirements of a defined vaccine and so may provide insight into 
the key antigens, antigen processing and immune responses which could help develop 
defined vaccines. Further work on this model is the subject of this project. 
" Roll-3128 is superior to other drugs in inducing immunity: 
In contrast to Rol 1-3128, termination of infection with other drugs such as Ro 15-5458 and 
Oxamniquine which also kill at the larval stage induces only low or insignificant levels of 
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protection (Bickle et al., 1990; Bickle and Andrews, 1985). This may result from the 
specific effects, which this drug has on the early schistosomulum. Treatment of 
schistosomula in vitro with native Rol 1-3128 or with sera from mice treated with curative 
doses of the drug results in the rapid formation of membraneous 'blebs'. In contrast, sera 
from mice given curative doses of Ro15-5458 or oxamniquine do not have these effects on 
the larval tegument. Smith et al., (1994) also demonstrated that, following incubation with 
antigen presenting cells (APC), drug-treated MS were better able to present antigen and 
hence stimulate the proliferation of T cells sensitised by immunisation with crude antigen. 
The soluble antigens and isolated `blebs' released after Rol 1-3 12 8 -treatment could be 
separated from the otherwise intact schistosomulum. The enhanced proliferation occurred 
largely in response to the isolated `blebs', which also contained the majority of the 
proteinaceous material. Thus, it has been suggested that if such `blebs' were formed 
following drug treatment in vivo, the presentation of antigen to APC in the form of 
membranous vesicles may well be responsible for the development of an enhanced 
antibody response. The antigenic composition of these blebs has been shown to be 
qualitatively different from that of the rest of the larval surface. For example, the 
membrane glycoprotein Sm 16 a vaccine candidate antigen (Bickle et al., 1986) is present 
in the blebs. Sm 16 was found to be associated with the preformed membranous bodies 
which give rise to the schistosomular membrane (Hockley and McLaren, 1973), as was 
demonstrated by IFAT labelling (indirect fluorescent antibody tests) using a mAb against 
surface antigen Sm 16 (Bickle et al., 1990), suggesting that Rol 1-3128-induced blebs may 
originate from this membrane reservoir. The production of membranous material may 
explain why Rol 1-3128-abbreviated infections stimulate strong antibody responses to 
larval surface antigens (Bickle et al., 1990). 
Apart from differential effects on the larval surface it is not known how long 
schistosomula treated with these other drugs survive or whether they reach the SLN so it is 
possible that they are rapidly killed and do not show the protracted contact with the SLN 
which has been suggested to be responsible for the immunity 
induced by Rol 1-3128 
treated schistosomula. 
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" Roll-3128-treated infections with 20krad-irradiated schistosomula induce 
poor levels of protection: 
In the early drug termination studies using doses of 150-175mg/kg an occasional worm 
survived to adulthood in a small proportion of mice. To try to avoid this complication 
experiments were carried out using 20krad cercariae so that any survivors of drug 
treatment would not develop to adulthood. However, it was found that when this was done 
poor levels of immunity were observed, significantly lower than non-irradiated cercariae 
(Bickle & Andrews, 1985). Such irradiated drug-treated infections were also studied by 
(Mountford et al., 1988; Mountford et al., 1989) who reported that such larvae survive for 
less time in the skin and fail to reach the SLN. 
9 Current studies: 
Despite the report of the migration of a small proportion of schistosomula to the lungs 
following treatment on day 2 it is clear that the 24 or 48 hr Rol 1-3128 attenuation 
protocols result in marked parasite attrition in the skin. Such focal antigen release is 
more similar to a defined antigen, the goal of vaccine research, than the irradiated 
vaccine which is required to reach and stimulate the lung in order to stimulate optimal 
immunity. Regarding the mechanism(s) involved, immunity was found to be abrogated 
following anti-CD4 treatment at the time of challenge (Vignali et al., 1989a) indicating 
a protective Th 1 response as in the one-time irradiated vaccine. To date relatively little is 
known of the nature of the protective immune response induced in the Ro 11-3128 model. 
Preliminary studies by Smith (1992, PhD thesis) showed a predominantly Thl type 
response in the SLN following Rol 1-3128 terminated infections but relatively little is 
known about the nature and kinetics of the induction of the immune response in the skin 
and SLN or the systemic spread of the response to the spleen in this model. One of the 
main objectives of this thesis was to characterise the in vivo immune response induced 
by the Rol 1-3128 model focussing on the SLN and spleen cell responses and to 
compare this with the responses stimulated in these organs by the protective 20krad 
vaccine and the poorly protective Rol 1-3128 treated 20krad regimen. The relevance of 
such observations was then investigated using anti-cytokine or KO mice to define the 
protective mechanisms. 
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Because of the proposed damage and death of drug treated parasites in the skin it was 
considered that skin dendritic cells would play a major role in processing of parasite 
antigen. Furthermore, it has been shown (Smith et al., 1994) that Rol 1-3128-treated 
schistosomula were more effective in presenting antigen to macrophages (as antigen 
presenting cells) compared with untreated schistosomula. So another aspect of this work 
focussed on in vitro interactions between DCs and normal and drug-treated 
schistosomula, to determine if schistosomula led to DC maturation and if this was 
affected by drug treatment. In view of this the following section reviews the relevant 
literature on DCs and DC maturation. 
1.10 Dendritic cells: 
Dendritic cells (DCs) are a migratory group of bone marrow-derived leukocytes that are 
sparsely distributed, in the body tissues, and are specialized for the uptake, transport, 
processing and presentation of antigens to T cells (Steinman, 1991; Hart, 1997; 
Matzinger, 1994). At an "immature" stage of development, DCs are very efficient in 
antigen capture and act as sentinels in peripheral tissues, continuously sampling the 
antigenic environment. Encountering with Microbial products or products released by 
tissue damage are thought of as "Danger signals" (Matzinger, 1994) and initiate the 
migration of the DCs to the lymph nodes (LNs). The antigens represented at the time 
including any microbial products, are processed and fixed on the DC surface as peptides 
that are presented by upregulated major histocompatibility complex (MHC) molecules. 
DCs also upregulate a variety of co-stimulatory molecules that are also required for 
effective interaction with T cells. In the LNs, the now-'mature' DCs efficiently trigger 
an immune response by any naive T cells with a receptor that is specific for the foreign- 
peptide-MHC complexes on the DC surface. The variety of DCs is complex as also is 
the nature and outcome of their interaction with pathogen molecules but this has a major 
bearing on the nature of the immune response that ensues e. g., an active Th 1- or Th2- 
biased response or even a suppression of response. This is a rapidly growing field but 
some of the relevant literature is considered below. 
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1.10.1 Dendritic cell subtypes: 
" Mouse DCs: 
In normal uninfected mice, DCs are heterogeneous. The expression of certain surface 
markers is used to segregate DC subtypes (Iwasaki & Kelsall, 2000; Anjuere et al., 
1999; Henri et al., 2001; Vremec et al., 2000). For example the T-cell markers CD4 and 
CD8 are expressed on mouse DCs. Others markers such as CD 11 b (the integrin (XM 
chain of Mac-1) and the interdigitating DC marker CD205 (the multilectin domain 
molecule DEC-205, originally known as NLDC-145) are also used in this 
differentiation. Using these surface markers, at least five phenotypically defined 
populations of DCs have been identified in the mouse (Henri et al., 2001). Three exist in 
the spleen: CD 11 c+CD 11 b+CD4"CD8a", CD 11 c+CD 11 b+CD4+CD8a" and CD 11 c+CD4" 
CD8a+CD 11 b- (Vremec et al., 2000). The CD 11 c+CD4-CD8a+CD 11 b- (which is DEC- 
205) is also found in moderate levels in LNs, but is the dominant subtype among 
thymic DCs (Anjuere et al., 1999), whereas the peripheral lymph nodes (LNs), Peyer's 
patches and mesenteric LNs contain two additional DC subtypes that are not normally 
found in the spleen, but which have apparently arrived in the LNs through the lymphatic 
system (Iwasaki & Kelsall, 2000; Anjuere et al., 1999; Henri et al., 2001). One of these, 
found in all LNs (CD 11 c+CD 11 b"'CDB(x-CD4"DEC-205moderate) is believed to be the 
mature form of tissue interstitial DCs. The other, found only in skin-draining LNs, 
express high levels of langerin, a characteristic marker of epidermal LCs 
(CD 11 c+langerin+ CD8ab°W CD 11 b+DEC-205high ) and is thought to be the mature form 
of this LC (Henri et al., 2001). In vitro bone marrow-derived (bm-DCs), as used in parts 
of this thesis, are CD8a"DEC-205+CD 11 b+CD 11 c+ (Lutz et al., 1999). 
Previously, CD8a+ DCs were thought to originate from the lymphoid-restricted 
precursors (Ardavin et al., 1993), and all CD8cC DCs to derive from myeloid-restricted 
precursors (Izon et al., 2001; Bjorck et al., 1998), leading to the terms `lymphoid' and 
`myeloid' DCs. However this concept was found to be incorrect. Both lymphoid- 
restricted and myeloid-restricted precursors were isolated from BM. However, each 
precursor could produce all the mature splenic and thymic DC subtypes (Traver et al., 
2000; Manz et al., 2001; Wu et al., 2001). Therefore, the terms `lymphoid' and 
`myeloid' DCs no longer denote haematopoietic origin but are still commonly used. 
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" Human DCs: 
In contrast to the many studies on mouse DCs, there are relatively few studies on 
mature human DCs freshly isolated from tissues. Blood, being the only readily available 
source, is more a source of immature DCs and precursor DCs. Human blood DCs are 
heterogeneous in their expression of a range of markers, many of which reflect 
differences in the maturation or activation states of DC rather than separate sublineages 
(Hart et al., 1997). In comparison to mouse DCs, human DCs lack the expression of 
CD8. However, as in the mouse, human Langerhans cells comprise a separate DC 
subtype with distinct markers, including the presence of Birbeck granules and the 
expression of CD 1a and langerin. Splenic and tonsillar DCs isolated from human 
lymphoid tissues show heterogeneity in the expression of CD4, CD 11 b and CD 11 c, 
(Mcllroy et al., 1995). Human thymic DCs are CD ll c+CD 11 b-CD45R0l°"' and lack 
myeloid markers, so resemble mouse thymic CD8a+ DCs. A minority of human thymic 
DCs are CD 11 chighCD 11 b+CD45ROhigh and express many myeloid markers, so resemble 
mouse CD8c('myeloid' DCs. 
1.10.2 Dendritic Cell Activation: 
(a)Antigen sampling by DCs in the peripheral tissues: 
Immature DCs possess an array of mechanisms for sampling antigen. These include (a) 
macropinocytosis, where fluid from the extracellular environment is taken up into 
pinocytic vesicles and antigen is concentrated by expelling excess water via channels 
called aquaporins (Norbury et al., 1997), (b) receptor-mediated endocytosis, which takes 
place via a repertoire of receptors expressed on the DC. These receptors include FcyRII 
(CD32), FcyRI (CD64) (Fanger et al., 1996; Fanger et al., 1997), FcERI (Maurer et al., 
1998) and C3 bi complement receptors (CD 11 b) (Green et al., 1980), which increase the 
efficiency of immune complex endocytosis. Dendritic cells also express C-type lectin 
receptors such as the macrophage mannose receptor and DEC-205, which bind bacterial 
carbohydrates (Sallusto et al., 1995, Jiang et al., 1995), and (c) phagocytosis of particles 
such as latex beads (Matsuno et al., 1996), apoptotic and necrotic cell fragments (Albert 
et al., 1998), viruses, and bacteria including mycobacteria (Rescigno et al., 1999), as 
well as intracellular Leishmania major (Moll, 1993). The Immature DCs in the 
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peripheral tissues express low to modest levels of antigen presentation molecules (MHC 
I, II, and CD 1) (Porcelli & Modlin, 1999; Mellman & Steinman, 2001) and express no 
costimulatory molecules. These are increased on the surface of the DCs once the DCs 
have stopped capturing antigen and are moving to the lymph nodes to present the 
antigen to the naive T cells there. 
(b)Dendritic Cell/ T-cell interactions in the Lymph Nodes: 
Once triggered by antigen and `danger signals', in the form of microbes and/or their 
released or breakdown products (e. g., LPS, CPG motifs in bacterial DNA, double 
stranded RNA) and necrotic cell products (such as heat shock proteins) (Hartmann G. et 
al. 1999; Sparwasser et al., 1998; Verdijk et al., 1999; Singh-Jasuja et al., 2000), 
immature DCs in peripheral tissues migrate and carry antigen via the lymphatic system 
into the T cell regions of draining lymph nodes where they stimulate primary and 
memory T cell responses. Chemokines such as SLC (secondary lymphoid-tissue 
chemokine) and MIP-3 ß (macrophage inflammatory protein) direct maturing peptide- 
laden DCs from inflamed tissues into the lymphatics towards the draining lymph node 
and subsequently to the para-cortical area of the lymph node, to ensure an encounter 
with naive T cells (Sozzani et al., 1999; Saeki et al., 1999; Sallusto et al., 1998). 
In the LNs, these primed DCs direct the fate of naive Th cells by 3 signals. The first 
signal, Signal 1, determines the antigen-specificity of the response by ligation of Th cell 
receptors by peptides presented by MHCI, II, and CD 1. An antigen-independent 
mechanism is required to promote efficient sampling by naive T cells of peptide-bearing 
antigen-presenting cells (APCs) (Hauss et al., 1995; Flechner et al., 1988), since the 
naive T cells bearing the T cell receptor (TCR) specific for a particular antigen are rare 
(< 1 in 50-100 x 103). The multiple transient interactions of T cells with antigen-loaded 
APCs is described as `clustering' or aggregate formation (Hauss et al., 1995; Flechner et 
al., 1988; Galkowski & Olszewski, 1992). These interactions are facilitated mainly by 
integrins and several members of the immunoglobulin superfamily (Starling et al., 1995; 
Hart, 1997). Once recognition takes place by the TCR of the correct peptide in the 
context of self-MHC class II, I or CD 1, the DC-T cell interaction is further stabilized by 
increased expression of the appropriate adhesion molecules. Intercellular adhesion 
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molecule-1 (ICAM-1) expression, present at low levels on immature DCs, is rapidly 
increased as a result of the interaction with T lymphocytes (Scheeren et al., 1991). Two 
other adhesion molecules ICAM-2 and ICAM-3 (CD50) (expressed on both DCs and T 
cells) are involved in this interaction between DCs and T cells, however ICAM-2 is 
reported to contribute little during the initial interaction (Hart, 1997; Hart & Prickelt, 
1993), whereas ICAM-3 is reported to promote the initial cluster formation as it is 
expressed at high densities on DCs. A novel DC-specific molecule known as DC-SIGN 
(DC-specific ICAM-3-grabbing nonintegrin, also referred to as CD209) has been 
suggested to be the main adhesion receptor involved in the initial adhesive contacts with 
naive T cells (Geijtenbeek et al., 2002). DC-SIGN (CD209) is a Type II transmembrane 
protein belonging to the C-type lectin family and has very high affinity for ICAM-2 and 
ICAM-3 (on T-cells). The initial clustering of DC-SIGN (on DCs) with ICAM-3 on 
resting T cells facilitates the formation of multiple low-avidity LFA-1 (lymphocyte 
function-associated antigen-1) (on T-cells)-ICAM-1 (on DCs) binding engagements and 
thus allows the TCR to sample MHC-peptide complexes within the contact area 
(Geijtenbeek et al., 2000; Engering et al., 2002). 
Costimulation events involving costimulatory molecules are necessary to sustain T cell 
activation and provide Signal 2, and these include specific interactions between co- 
stimulatory molecules on the T cells and their specific ligand(s) on DCs (Schwartz, 
1996). CD28, present on most T cells, is the primary costimulatory molecule that is 
required for delivering Signal 2 (Chambers & Allison, 1997). Both CD80 (B7.1) and 
CD86 (B7.2) are increased on the surface of DCs following DC activation (McLellan et 
al., 1996; Fagnoni et al., 1995). A number of other molecules in the CD28 family have 
been discovered and share common structural and functional elements with CD28 
(Chambers & Allison, 1997). These include inducible costimulator (ICOS), cytotoxic T 
lymphocyte antigen-4 (CTLA-4), and programmed death-1 (PD-1). Despite their 
homology to CD28, both CTLA-4 and PD-1 function as negative regulators of T cell 
activation. ICOS maps to the same genetic region as CD28 and has costimulatory 
properties (Chambers & Allison, 1997). OX40 a member of the TNF/nerve growth 
factor receptor family, is another molecule that shows costimulatory properties 
(Calderhead et al., 1993). Accordingly, its expression is restricted to activated CD4+ 
and CD8+ lymphocytes, and its binding partner OX40 ligand (OX40L) which 
is found 
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on DCs and CD40L-activated B lymphocytes (Godfrey et al., 1994, Stuber et al., 1995). 
CD40 another member of the TNF receptor family is expressed at low levels on 
immature DCs, and it is rapidly induced upon DC maturation. Its ligand, CD40L is 
expressed on the surface of T cells during early activation (Grewal et al., 1996). The 
interaction of CD40 with CD40L stimulates the upregulation of both CD80 and CD86 
expression on the DC surface, which results in increased engagement of CD80 and 
CD86 with CD28 (Yang & Wilson, 1996). 
In summary, Signal 2, initiates the immune response by TCR stimulation and costimulation 
of naive T cells by molecules found on the surface of DCs after ligation of pattern 
recognition receptors. This allows naive Th cells to develop into protective effector cells, a 
process accompanied by the high level of expression and release of selective sets of 
cytokines. The final signal, Signal 3, is again provided by DCs and is the polarizing signal 
that is mediated by various soluble or membrane-bound factors, such as the IL-12 family 
members IL-12, IL-23 and IL-27 (Trinchieri, 2003), Type I interferons (IFNs) (Kadowaki et 
al., 2000), and cell-surface expressed intercellular adhesion molecule 1 (ICAM-1) (Salomon 
& Bluestone, 1998), all of which polarize the Th effector cells towards the Thl type. Th2- 
cell-polarizing factors include monocytic chemotactic protein 1 (MCP1, also known as 
CCL2) and OX4OLigand (Ohshima et al., 1998), while the regulatory T-cell polarizing 
factors include IL-10 and transforming growth factor-ß (TGF-ß) (Groux et al., 1996; Zeller 
et al., 1999). The conditions of activation and the degree of maturation of immature DCs are 
important for the way in which these 3 signals are delivered to the T cells. 
(c) DC+Pathogens: Toll-like receptors: 
Production of Signal 1 and Signal 2 depends on DC activation. 
DCs recognize pathogens through a separate signal for cellular activation via pattern- 
recognition receptors (PRRs), such as Toll-like receptors (TLRs), that recognize 
conserved microbe-associated molecules termed `pathogen-associated molecular 
patterns' (PAMPS) (Underhill et al., 1999). Once these 
TLRs recognize a specific 
microbial structure they trigger differential signalling pathways within 
DCs that then 
controls DC maturation and ultimately the differentiation of 
Th cells along a specific 
pathway (i. e., development of Thl, Th2 or regulatory 
T-cell subsets). It is also reported 
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that pathogens will not affect DCs only directly, but indirectly through the large series 
of inflammation-associated tissue factors that are expressed by tissue cells in response 
to pathogen invasion. These include pro- or anti-inflammatory cytokines, chemokines, 
eicosanoids e. g. PGE2, heat-shock proteins, extracellular matrix components, necrotic 
cell lipids released by dying cells and others (Beg, 2002). 
The exposure of immature DCs to PAMPs and their recognition via specific TLRs, and 
the contact with modulatory tissue factors, all direct the functional polarization of these 
immature DCs to mature effector DCs that express high levels of MHC and co- 
stimulatory molecules and migrate to the draining LNs where they present pathogen- 
derived antigens to naive T cells. There they selectively bias the development of Th 1, 
Th2 or regulatory T-cell subsets. 
The increasing body of data on TLR by murine and human DCs is showing that there is 
significant heterogeneity of TLR expression among DC populations (Medzhitov, 2001; 
Kapsenberg, 2003). So far there are now ten human and nine mouse TLR-family 
members identified, which recognize various microbial molecules (Kapsenberg, 2003). 
Since different TLRs are specific for products expressed by certain classes of microbes, 
the DC subset that becomes activated by a pathogen or product will depend on the 
specific TLRs expressed by that subset. 
Many TLR can recognize several, structurally unrelated ligands. Even though the actual 
mechanism of ligand recognition is still unknown, available evidence indicates that 
mammalian TLRs recognize their ligands by direct binding. For example, TLR2 has 
been shown to be involved in the recognition of a broad range of microbial products, 
including peptidoglycan from Gram-positive bacteria (Takeuchi et al., 1999), bacterial 
lipoproteins (Takeuchi et al., 2000), mycobacterial cell-wall lipoarabinomannan (Means 
et al., 1999), glycosylphosphatidylinositol lipid from Trypanosoma cruzi (Campos et al., 
2001), a phenol-soluble modulin produced by Staphylococcus epidermidis (Hajjar et al., 
2001), and yeast cell walls (Underhill, 1999). TLR2 is also receptor for atypical LPS 
produced by Leptospira interogans (Werts et al., 2001) and Porphyromonas gingivitis 
(Hirschfeld et al., 2001), both of which are structurally different from Gram-negative 
LPS. This broad range of ligands recognized by TLR2 is done, in part, by cooperation 
between TLR2 and at least two other TLRs: TLR1 and TLR6 (Takeuchi et al.. 2001; 
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Ozinsky et al., 2000). This means the formation of heterodimers between TLR2 and 
either TLR1 or TLR6 dictates the specificity of ligand recognition. For example. 
mycoplasma-derived lipoprotein triggers TLR2 that forms heterodimers with TLR-6 
(Takeuchi et al., 2001), whereas bacterial lipoproteins triggers TLR2-TLR 1 
heterodimers (Takeuchi et al., 2002). 
Recognition of PAMPS by TLRs induces the activation of signal transduction pathways 
within DCs leading to the induction of various genes that function in host defence, 
including inflammatory cytokines, chemokines, major histocompatibility complex and 
co-stimulatory molecules. For example, a 19 kDa lipopeptide of intracellular 
Mycobacterium tuberculosis was reported to induce only low levels of the bioactive IL- 
l2p70 in monocyte-derived DCs (Thoma-Uszynski et al., 2000), in contrast to the high 
levels of IL-12p70 induced by TLR4-agonist LPS (Langenkamp et al., 2000) which 
primes DCs to direct the development of Thl cells, both in human and in mice. On the 
otherhand, mycoplasma-derived lipopetide 2, a ligand for TLR2-TLR6 heterodimer, 
does not induce the production of IL-12 by human monocyte-derived DCs, but instead 
the production of IL-10 (Weigt et al., 2003), and the lipopeptide-primed DCs induce 
unpolarized T-cell responses. The yeast cell-wall component Zymosan also induces IL- 
10 production by classical CD 11 chi h mouse DC subsets (Qi, et al., 2003). However, this 
IL-10 production was independent of TLR-2 triggering (Edwards et al., 2002), and 
instead it was found that zymosan binds concomitantly to other receptors such as the C- 
type lectins dectin-1 (Gantner et al., 2003) and DC-SIGN (Cambi et al., 2003) of which 
the latter is associated with the production of IL-10. 
1.10.3 Interaction of DCs with whole Pathogens or their antigens: 
1.10.3.1 DC stimulation by protozoa promoting Thl responses: 
(i) Toxoplasma gondii: A variety of protozoa have been shown to stimulate DC (of the 
myeloid lineage) function (Reis e Sousa et al., 1999). In mice exposed to Toxoplasma 
gondii, the ability to produce IL-12 is limited to CD8a+ DC subset. This response has 
not yet been attributed to any known Toll-like receptor (TLR) (Mason et al., 
2002) but it 
is known to involve a synergist interaction of MyD88 (a TLR-adaptor molecule) and 
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chemokine receptor 5 (CCR5) signalling (Aliberti et al., 2000; Scanga et al., 2002) on 
the DC. The parasite molecules that trigger DC activation are present in tachyzoite 
extracts but are also secreted by the pathogen. One of these components has recently 
been identified as a parasite-derived CCR5 ligand mimic (Aliberti et al., 2003). 
Recently findings that T gondii-infected IL-12-1" mice developed Th 1 responses that are 
protective in the absence of IL-10 (Jankovic et al., 2002) questioned the view that IL-12 
production by DCs is essential for Thl response induction. However, MyD88-/- animals 
infected with T. gondii fail to make Thl responses or survive (Scanga et al., 2002, 
Jankovic et al., 2002). 
T. gondii infection selectively activates human DCs by increasing MHC class II, CD86 
and CD83 but not CD40, CD54 (ICAM-1) or CD80 expression. However, these DCs 
induced apoptosis in T cells (Wei et al., 2002). Non-viable tachyzoites, or apoptotic 
fibroblasts loaded with tachyzoite antigens, on the otherhand, did not have this effect 
and activated T cells. In the same study, Wei et al., (2002), reported that parasite 
replication, rather than the involvement of different DC receptors for uptake, was 
essential to induce this form of immunosuppression. The latter studies suggests that 
DCs are initially activated by released parasite products (e. g., those released by T 
gondii) or through cross-presentation from other infected cells but can become 
functionally impaired when directly invaded by the same pathogens. Indeed, as 
indicated by recent in vivo studies in the T gondii system, co-stimulation by CD40L 
may be intrinsically required for continued DC activation once host infection has been 
initiated (Straw et al., 2003). 
(ii) Leishmania spp.: Different species of Leishmania parasites have quite different 
effects on DCs and this is believed to be critical to the outcome of the infection. In 
human myeloid DCs, the metacyclic promastigotes of L. major, unlike those of L. 
donovani or L. tropica, efficiently primed for CD40L-induced IL-12 p70 secretion 
(McDowell et al., 2002). L. major also induced IL-12 production by murine bone 
marrow-derived DCs but uptake of L. amazonensis amastigotes or metacyclic 
promastigotes, while upregulating expression of MHC class II, CD40, 
CD80 and CD86, 
induced production of IL-4 but not IL-12, suggesting that the DCs are conditioned by 
the parasite to prime the pathogenic Th2 cells that dominate the response in Oho (Qi et 
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al., 2001). Clinically, L. major produces self-limiting infections that are controlled in 
the skin, but L. donovani, L. tropica and L. amazonensis are capable of disseminating to 
the viscera or to other cutaneous sites. One possibility that accounts at least in part for 
the differences in DC response patterns and in determining the different clinical 
outcomes observed, is polymorphism in the surface-associated and secreted glycan 
structures expressed by the different Leishmania species (Turco et al., 2001). A recent 
observation showed that DC-SIGN, is a major ligand for the amastigote stage of L. 
pifanoi (Colmenares et al., 2002) and it has also been shown to bind the mannose- 
capped lipophosphoglycan of L. mexicana (Appelmelk et al., 2003). 
(iii) Trypanosoma cruzi: In T. cruzi studies, GPI anchors and 
glycoinositolphospholipids induce TLR2-dependent IL-12 production (Campos et al., 
2001). Further studies into the same parasite now show that a member of the 
glutathione-S-transferase superfamily, Tc52, can also induce TLR2-dependent 
signalling, NFkB activation and cytokine production ( IL-12) (Ouaissi et al., 2002). Tc52 
binds to human monocyte-derived DCs and signals through TLR2. Inhibition studies 
suggest that this response requires TLR2 recognition of the active glutathione binding 
site present in Tc52. T cruzi HSP-70 fusions also induces DC maturation (Planelles et 
al., 2002). 
(iv) Malaria: In malaria, Seixas et al., (2001) reported that bm-DCs cultured with 
Plasmodium. c. chabaudi schizonts were induced to produce TNF-a, IL-6 and IL-12p40 
and p70, and the upregulation of MHCII, CD40, and CD86 but not CD80. In addition, 
these P. c. chabaudi did not inhibit the upregulation of MHCII, CD86 and CD40 induced 
by LPS-stimulated bm-DCs. Therefore, the erythrocytic stages of P. c. chabaudi are able 
to activate DCs directly. 
1.10.3.2 DC stimulation by helminths promoting Th2 responses: 
It has become increasingly clear that DCs are able to interpret information from 
helminth antigens to induce antigen-specific Th2 responses (MacDonald et al.. 2002 a; 
de Jong et al., 2002; Faveeuw, 2002; MacDonald et al., 2002 b). As yet, however, there 
is no clear explanation of how this is accomplished. 
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A study carried out by Whelan et al., (2000) showed that a phosphorylcholine- 
containing glycoprotein ES-62, of the filarial nematode Acanthocheilonema vitae. 
which was known to be associated with Th2 cell responses in vivo, induced the in vitro 
maturation of DCs that induced Th2 cells. So far the binding sites of this type 2 PAMP 
are unknown. It is anticipated that there are many undiscovered PRRs capable of 
recognizing unique molecular features in helminth antigens to induce Th2 maturation 
pathways in DCs (Barton & Medzhitov, 2002) and there is some evidence for these 
from studies on interactions of human and mouse DCs with schistosome egg antigens 
(SEA) which are associated with induction of Th2 responses in vivo. 
" Human DC: 
Human myeloid DCs conditioned by SEA to induce Th2 responses were found to 
express the surface marker OX40L, whereas DCs that were conditioned by microbial 
stimuli, e. g., toxin from the intracellular bacterium Bordetella pertussis, did not but 
rather induced the development of DC 1s with enhanced IL-12 production, which 
promotes a Thl cell development (de Jong EC et al., 2002). Regarding the nature of the 
parasite molecules responsible for this induction, there has been a particular interest in 
sugar moieties as ligands for hypothetical Th2-response-associated PRRs, as 
carbohydrates in SEA have been shown to be essential for Th2 response induction by 
this antigen (Okano et al., 2001). Although currently no DC lectin was identified that is 
acting as a PRR to condition DC to promote Th2 immunity, recent studies have shown 
that an extract of S. mansoni eggs (a glycoprotein found in the eggs called Lewis X 
antigen [Le']) binds to DC-SIGN (DC specific ICAM-3-grabbing nonintegrin) 
(Appelmelk et al., 2003). 
" Mouse DC: 
In spite of the evidence from human DC/SEA interactions of DC surface marker 
upregulation studies using murine bm-DC/SEA have failed to show surface marker 
activation but nevertheless the resulting DCs were able to confer Th2 responsiveness 
(MacDonald et al., 2001). Thus, there was no upregulation of MHC II, CD86 or CD80. 
CD40, CD54 or OX40L following culture of bm-DCs with SEA. Similarly there was no 
production of IL-12, IL-4, or IL-10. However, when the SEA-pulsed 
DCs were injected 
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to naive mice, spleen cells recovered at 7 days and treated in vitro with SEA induced 
splenocytes from mice injected with SEA-pulsed DCs to make IL-4, IL-5 and IL-13. but 
no IFN-y. In contrast, splenocytes from mice injected with DCs pulsed with the Thl 
inducing antigen Propionebacterium acnes produced IFN-y, but no IL-4, IL-5 or IL- 13 
in response to stimulation with P. acnes. MacDonald and Pearce (2002b), demonstrated 
that Th2 induction by DC occurs independently of DC IL-4 , as was shown when the 
splenocytes from naive mice that had been injected 1 week before with SEA-pulsed IL- 
4-/- DCs were still able to mount a marked SEA-specific Th2 response (high levels of 
IL-4, IL-5, IL-13 and no IFN-y). However, recipient derived IL-4 is vital for DC- 
induced Th2 development, as was shown when splenocytes from IL-4-/- recipients of 
SEA-pulsed wild type DCs failed to produce IL-4, IL-5 or IL-13 in response to SEA 
restimulation. It was suggested that the production of polarizing cytokines by cells 
other than transferred DC was vital for expansion/amplification of the T cell response 
initiated by DC. DCs could initiate Th polarization but selection, survival and expansion 
of such cells then becomes reliant upon cytokines from other sources. The source of 
recipient IL-4 is not yet known. 
The fact that conventional DC maturation was not induced during schistosome infection 
raised the question of how these cells are able to activate naive antigen-specific Th 
cells, especially as immature DCs are usually thought of as good inducers of tolerance 
rather than of productive Th responses. A clue was provided by the observation that 
CD40L-/- mice do not mount Th2 responses when infected with schistosomes 
(MacDonald et al., 2002c). Studies on CD40-'- bone-marrow-derived DCs revealed that 
these cells are incapable of initiating SEA-specific Th2 responses when injected into 
wild-type mice, raising the possibility that CD40 ligation by CD40L 
is an essential 
endogenous signal for DC maturation during Th2 response 
intiation. That this is the 
case was suggested by the finding that DCs from schistosome-infected 
CD40L-'- mice 
exhibit a phenotype equivalent to that of DCs from uninfected animals, which contrasts 
with the more activated phenotype of splenic DCs 
in infected wild-type mice (Straw et 
al., 2003). 
Regarding the molecular nature of the SEA stimulus to DCs , 
in contrast to DCs pulsed 
with SEA, DCs pulsed with periodate-treated 
SEA were recently reported to be 
incapable of inducing Th2 responses (Faveeuw et al., 2002). 
However, the finding in 
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the same study that CD 1d is essential for DCs to prime SEA-specific Th2 responses 
suggests that the important polarizing glycoconjugates in SEA might be glycolipid(s) 
that are presented on CD ld to NK T cells, since in mice glycolipids or lipids are 
preferentially presented via the CD 1d molecule expressed on DCs to receptors on 
CD 1 d-restricted NK T cells (Godfrey et al., 2000). NK T cells have been previously 
reported to be an early source of the IL-4 essential for polarizing Th-cell responses 
(Miyamoto et al., 2001). 
1.10.3.3 Impaired DC function during parasitic infection: 
It is important for both host and parasite that immune responses are carefully regulated 
in time and magnitude. For the host, excessive, potentially lethal, pathology of chronic 
Thl- or Th2-cell-mediated inflammation needs to be avoided. As for parasites the need 
to survive within the host is the ultimate aim. Some parasites appear to avoid activating 
DCs in the first place, and there is growing evidence for more selective forms of 
functional impairment. 
S. mansoni: Langerhans cells in the skin of mice percutaneously infected with S. 
mansoni become activated but are unable to migrate from the epidermis. This inhibition 
appears to be mediated by prostaglandin D2 produced by the parasite and may help 
delay the subsequent adaptive response (Angeli et al., 2001). It was observed that 
patients with chronic schistosomiasis have profound in vitro hyporesponsiveness to 
specific antigen restimulation. Although it was initially proposed that this might be due 
to loss of T cells from the periphery, a recent study showed that in vitro responses could 
be restored by the addition of autologous monocyte-derived DC, implicating that the 
DC function in vivo is defective (van den Biggelaar et al., 2000a). 
Malaria: In the case of the malaria parasite Plasmodium falciparum infections immune 
response is not just delayed, but chronically compromised, involving the impaired 
maturation and function of the appropriate DC subpopulations (Urban & Roberts, 
2002). Malaria-infected erythrocytes were found to bind to the surface of human 
monocyte-derived DCs in vitro and to markedly suppress the LPS-mediated 
upregulation of MHC class II, adhesion molecules (e. g., ICAM-1) and co-stimulatory 
molecules (CD40, CD80, CD83 and CD86) on DCs. Those resulting DCs are severely 
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impaired in their capacity to induce allogeneic as well as antigen-specific primary and 
secondary T-cell responses (Urban et al., 1999). The parasite subsequently paralyse DCs 
by binding to receptors on the surface of DCs, mediating this inhibitory effect, the 
integrins CD36 and CD51 (Urban et al., 2001). The major parasite ligand P. falciparum 
erythrocyte membrane protein 1 (PfEMP 1), a conserved domain of a molecule that 
undergoes antigenic variation, appeared to be involved in this DC interaction. In 
addition, DCs exposed to blood-stage malaria parasites also suppress CD8+ T cell 
responses against the liver stages of this parasite, and inhibit CD8+ T-cell priming 
following vaccination with irradiated sporozoites. This method of immunosuppression 
may benefit the parasite by leaving individuals open to constant reinfection (Ocana- 
Morgner et al., 2003). 
Leishmania: In visceral leishmaniasis, chronic immunosuppression is also an important 
clinical outcome. In recent studies in an experimental model it was suggested that this 
impaired responsiveness may stem in part from a parasite-induced defect in DC-T cell 
contact. DC from mice chronically infected with L. donovani failed to migrate from the 
marginal zone to the T cell areas of the spleen due to TNF-dependent IL-10-mediated 
inhibition of CCR7 expression on the DC (Ato, et al., 2002). Poor DC migration may 
also explain why individuals with visceral leishmaniasis tend to succumb to secondary 
infection. 
Other Pathogens: There are pathogens that affect DC activation in such a way that 
those DCs induce the development of regulatory T-cells, i. e., T cells that neither bias 
the immune response towards a specific Thl- nor Th2-cell response but instead will 
develop some form of tolerance. Some microbes may use DC-SIGN or similar ligands 
to subvert the immune system, for example Mycobacterium species induce regulatory 
DCs with an immature phenotype by binding to DC-SIGN with their mannosylated 
lipoarabinomannan (Geijtenbeek et al., 2003). Viruses such as Hepatitis C virus which 
bind by means of its core protein and non-structural protein 3 (Dolganiuc et al., 2003), 
herpes simplex virus (Salio et al., 1999) and cytomegalovirus (Moutaftsi et al., 2002) 
are all reported to inhibit DC function and delay or prevent the generation of virus- 
specific cytotoxic T cells. Amongst the pathogens that prime 
for regulatory DCs with a 
mature phenotype are Bordetella pertussis that uses 
filamentous haemagglutinin 
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(McGuirk et al., 2002), and S. mansoni that uses lysophosphatidylserine to ligate TLR2 
(van der Kleij et al., 2002). 
1.10.3.4 Dendritic cells and attenuated schistosomula in the Skin and Skin draining 
Lymph Nodes (SLN): 
Because exposure to attenuated larvae is the most effective way of inducing immunity 
in schistosomiasis there is interest trying to understand how this protection is initiated. 
The retarded migration of optimally irradiated (20krad) larvae from the skin and 
persistence in the skin draining lymph nodes produce a Th 1 dominated response in the 
SLN which is crucial for immunity (Coulson, 1997). More highly irradiated cercariae 
(80krad) all die in the skin but fail to induce protection (Mountford et al., 1992) whereas 
infections drug terminated in the skin can stimulate high levels of immunity (Bickle and 
Andrews, 1985). So how does theThl response develop and why do the different 
protocols differ so much in protection? The following section considers what little is 
known about the reaction to parasites in the skin and the involvement of DC in the skin 
phase. 
In contrast to normal cercariae, irradiated larvae were observed in the dermis for >10 
days often surrounded by aggregates of macrophages and dendritic cells. This results in 
inflammation and skin thickening up to 75% increase on day 4 (Hogg et al,, 2003 ). 
Riengrojpitak et al., (1998) investigated the interactions of vaccinating parasites with 
host leucocytes in both the skin and/or draining lymph nodes of C57BL/6 mice. They 
observed extensive lateral spreading of cercarial secretions along layers of the stratum 
corneum but the contents of the pre- and post-acetabular glands, potentially rich in 
antigenic proteins (Harrop & Wilson, 1993), remains superficial and is sloughed off 
rather than remain a major stimulus for the immune system. Parasites migrated into the 
stratified epidermis and there was little direct contact with host leucocytes during the 
first 1-2 days when the parasites lay at the base of the epidermis, but cells accumulated 
in the underlying dermis. The lack of leucocytes adhering to both attenuated and normal 
parasites at this stage of penetration suggested that they are not `leaking' significant 
quantities of antigen. Cells bearing MHC II, CD 11 b or CD 11 c markers were present in 
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the lymph nodes, particularly in the periphery and paracortical areas, no obvious 
redistribution was seen as a result of parasite residence there for 5-15 days 
(Riengrojpitak et al. 1998). Interactions between parasites and potential antigen- 
presenting cells in the SLN's were much less marked than in the skin. Ultrastructural 
studies did reveal cells with characteristics of DC/macrophage lineage in the vicinity of 
the parasites but there were no qualitative differences in the interactions of normal or 
irradiated larvae with constituent leucocytes and again the conclusion was just the 
protracted exposure of living larvae with the SLN. 
Hogg et al., (2003b) analyzed the innate response to radiation-attenuated schistosome 
larvae in order to define the cellular constituents and cytokines in the skin which are 
likely to stimulate a Th 1-mediated protective response at the skin infection site. At 24hr 
post infection the cytokines IL-1p, IL-6, IL-10 and IL-12 p40 and various chemokines 
were all significantly increased. IL-12 p40 was also elevated in mice given unirradiated 
cercariae at day 1 but the levels then dropped whereas they remained high until at least 
day 14 in mice given irradiated cercariae. A similar pattern was found in the SLN. IL-12 
plays a key role in differentiation of Thl cells (O'Garra, 1998) and is necessary for the 
Thl mediated protection in the irradiated cercaria model (Anderson et al, 1998). 
Compared with non-protective non-irradiated larvae, the irradiated larvae induced the 
production of high levels of IL-12 and IL-18 until at least day 14 after the infection. IL- 
10 was produced from both vaccinated and infected mice, and it was shown to regulate 
IL-12-associated dermal inflammation, since in the ear pinna thickness of vaccinated 
IL-10-/- mice was greatly increased concurrent with elevated levels of IL-12p40 (Hogg 
et al., 2003b). Regarding the cell source of the IL-12p40, the majority of the IL-12p40+ 
cells in the skin infection site were found to be myeloid DCs, although a proportion 
were CD 11 c- F4/80+, suggesting that macrophages were an additional source of IL- 12 
in the skin. 
1.11 Focus of the present study: 
As described above after inducing priming in the skin, the migration of the majority of 
the irradiated larvae to the lungs is necessary in order to attract circulating cells and so 
arm the lung tissue in order to arrest larvae of a challenge infection. As a model for 
development of a defined antigen vaccine this requirement for priming in the skin 
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followed by inflammation in the lungs is rather complex. Infections treated at the skin 
stage with the drug Rol 1-3128 seem to arrest predominantly in the skin raising the 
question as to the nature and level of response in the skin to this regimen compared to 
the irradiated infection and the nature of the protective mechanisms. This was the 
starting point of the studies in this thesis (Chapter 3). Earlier work had shown that 
termination of infection with Rol 1-3128 could lead to much higher levels of protection 
than other drugs tested and so the studies in Chapter 4 were aimed at trying to explain 
the individual effects of the drug e. g. enhanced antigen presentation or adjuvanticity. 
The demonstration of a Thl dominated response in the studies in Chapter 3 led to 
studies aimed at defining if and how DCs are activated by interaction with 
schistosomula (Chapter 5). 
1.12 Aims of the Project 
1) To determine the sites of antigen presentation/stimulation and the key features of the 
induction and operation of immunity induced by Rol 1-3128 attenuated larval infections 
by: 
(i) Defining the nature and kinetics of the cytokine responses to larval antigens in 
the SLN, at intervals post vaccination with Rol 1-3128-terminated infections 
compared to radiation-attenuated infections (both of which elicit high levels of 
protection) and to Rol 1-3128-terminated irradiated infections (which elicit poor 
levels of protection). 
(ii) Determining the nature and level of the systemic spread of this response as 
judged by responses in the spleen following these different immunizing 
regimens. 
2) To establish the in vivo relevance of the protective mechanism(s) predicted 
from the 
work in (1) by: 
(i) immunization of immunodeficient, targeted knockout mice. 
(ii) immunization followed by cytokine neutralization with monoclonal antibodies. 
3) To investigate the properties and effects of Rol 1-3128 in in vitro cultures: 
(i) To compare the effects of Rol 1-3128 on normal and 
irradiated schistosomula. 
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(ii) To test if Rol 1-3128 has adjuvant properties. 
(iii)To test if Rol 1-3128 induces enhanced antigen presentation. 
(4) To investigate the interaction of normal and drug-treated worms with DCs by: 
(i) Establishing an in vitro system of interacting DCs and living normal/drug- 
treated schistosomula. 
(ii) Defining the effects on DC maturation of co-culture with live normal/drug- 
treated schistosomula on surface maturation markers (CD40, CD86, MHCII). 
(iii) Defining the effects on DC maturation of co-culture with live normal/drug- 
treated schistosomula on cytokine production (IL-12p70, IL-10, TNF-a, IL-6). 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Mice: 
Outbred, CD-1 strain, Swiss albino mice were used to maintain the Puerto Rican strain 
of Schistosoma mansoni life cycle. Five to eight-week-old C57BL/6 wild type mice 
were used in most of the experiments. Other strains used were BALB/c mice and 
C3H/HeJ and C3H/OuJ mice (non- and responders to LPS, respectively). The mice 
were either bred and maintained at the London School of Hygiene and Tropical 
Medicine (LSHTM) Biological Services Facilities according to the UK Home Office 
guidelines, or purchased from Charles River, UK. B6. RAG 1-/- (Recombinase activation 
gene knockout) (RAG on C57BL/6 background) (deficient in both T&B cells), mice 
with a targeted disruption of the IFN-7 gene on the C57BL/6 background (B6. IFN-y-/-) 
also called C57BL/6.12957, and B-cell knock out mice on the same background 
(C57BL6/µMT) were bred and maintained in the Biological Services Facilities of 
LSHTM. All experiments were performed under the regulations of the Home Office 
Scientific Procedures Act (1986). 
2.2 Production of Cercariae: 
As part of the life cycle, the Puerto Rican strain of Schistosoma mansoni was 
maintained in laboratory-reared Biomphalaria glabrata snails. The snails were kept in 
clean tap water at 24-26°C. Cercariae were shed in a minimum volume of clean tap 
water at 28-30°C under direct illumination for 1-2 hours. Where sterile parasites were 
required for tissue culture, snails were washed several times in clean tap water before 
shedding, and snail faeces were allowed to settle before decanting the cercarial 
suspension. These S. mansoni cercariae were either used for infecting mice within a 
few 
hours of collection either directly or after exposure to radiation, or transformed to the 
equivalent of skin-stage schistosomula for tissue culture experiments. 
2.3 Irradiation of Cercariae: 
Freshly shed cercariae were poured into a 30m1 `Universal' tube 
(Sterilin. UK) and 
exposed to a Cesium 137 source at the LSHTM 
(Gammacell 1000 Elite). The irradiation 
dose used was 20 krad y-radiation (Bickle et al., 1979a). 
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2.4 Preparation of Schistosomula: 
2.4.1 Mechanical Transformation of Cercariae to Schistosomula: 
The method of transformation of schistosomula from S. mansoni cercariae was modified 
from methods previously described by Ramalho-Pinto et al., (1974), Basch (1981), and 
James and Taylor (1976). Cercariae were collected and concentrated in clean tap water, 
as described in section 2.2.1 Oml aliquots of the cercarial suspension were then pipetted 
into 15m1 glass conical centrifuge tubes and cooled in an ice bath for 10 minutes to 
reduce motility of the organisms and facilitate concentration of cercariae (Ramalho- 
Pinto et al., 1974). These were centrifuged at 400 xg for 2 minutes at 4°C and the upper 
90% of water was carefully removed leaving behind packed cercariae (Basch, 1981). 
They were then quickly resuspended in 2m1 cold E/LAC medium (see Appendix A. 1), 
and pooled from all the glass tubes into a conical-based plastic 30m1 `Universal' tube 
(Sterilin, UK). E/LAC was supplemented with 300U/ml Penicillin (Gibco, UK), 
300µg/ml Streptomycin (Gibco, UK) and 160µg/ml Gentamicin (Sigma, UK). 
Mechanical transformation of cercariae into schistosomula (MS) was done by the 
disruption of cercarial heads from tails by the `Syringe method' (James and Taylor, 
1976). Briefly, cercariae were forced through a 21-guage needle (0.8mm x 40mm, 
Becton Dickinson, MicrolanceTM 3, UK) attached to a Luer Lock Syringe (Becton 
Dickinson, UK) a total of 20-22 times. The cercarial heads were left to settle by 
sedimentation in a 15m1 plastic tube (Scientific Laboratory Supplies [SLS], UK) at 37°C 
and 5% CO2 for 10-15 minutes. After this, the tail-rich supernatant was carefully 
removed, and the remaining 1-2mis of the heads-rich supernatant were carefully 
pipetted on the top of a sterile Percoll gradient which consisted of 3 layers of 50%, 60% 
and 70% densities, in a 15 ml plastic tube (procedure modified from Lazdins et al., 
1982). The tube was spun for 10 minutes at 350 xg and 4°C. After centrifugation, each 
of the 3 layers was carefully removed, under sterile conditions, and placed in a 60mm 
diameter petri-dish (Nunc, UK). Heads were mostly observed in the 60% gradient (as 
was seen under the microscope), and were free of tails. This portion of the gradient was 
then transferred into a 50m1 plastic tube (SLS, UK) and washed 2x in 20-25mis of 
E/LAC supplemented with 300U/ml Penicillin, 300µg/m1 Streptomycin and 160µg/ml 
Gentamicin at 400 xg and 4°C for 2 minutes. The medium was carefully removed 
leaving behind about 2mls containing a pellet of `heads'. This was transferred to a new 
sterile 15m1 plastic tube and topped up with IOml of 
fresh medium. Heads were then 
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left to sediment at 37°C and 5% CO2 for 10 minutes. This washing step was repeated 3x 
after which heads were washed 1-2x in exactly the same way but with either M 169S 
(Basch, 1981, see section 2.8.1) or cDMEM (complete Dulbecco's Modified Eagle's 
Medium, Sigma, UK) (see section 2.8.1) depending on the experiment. Then the heads 
were counted and resuspended in an appropriate volume of medium to obtain required 
concentration of parasites. Transformation and washing were all done at room 
temperature and under sterile conditions. 
2.4.2 Preparation of Density Gradients: 
Solutions of Percoll (p olyvinylpyrolidone-coated colloidal silica particles, Sigma, UK) 
of different densities were prepared by diluting the stock suspension with the 
appropriate volumes of lOx concentrate Minimal Essential Medium (MEM) (Sigma, 
UK) and sterile double processed tissue culture water (Sigma, UK). The solutions were 
then buffered with 1M HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic 
acid] to a final concentration of 25mM and the pH adjusted to 7.0-7.2 with IN NaOH. 
Three density gradients were prepared at 50%, 60% and 70% of original Percoll density. 
These sterile solutions were prepared fresh and kept at 4°C until use on the same day. 
To achieve sharp interfaces, 3 ml of each of these solutions was layered from the bottom 
of sterile 15ml plastic conical centrifuge tubes using a 19-gauge, 5-inch-long (spinal) 
needle (Becton Dickinson, UK) placed in the tube. Care was taken not to introduce air 
bubbles into the gradients. This needle was connected to a 10 ml syringe via a two-way 
stopcock that allowed regulation of the flow rate of the Percoll solutions. 
2.4.3 Assessing schistosomula viability: 
The viability of schistosomula in cultures was assessed by direct microscopic 
examination of parasite motility and appearance. Parasites were scored as dead if they 
were immotile and had become granular and opaque in appearance. 
2.5 Preparation of Antigens: 
Soluble cercarial antigen preparation (SCAP) and deoxycholate cercarial antigen 
preparation (DOC-SCAP) were prepared from S. mansoni cercariae (as 
described 
previously for preparing adult worm antigens in Zhang et al., 1999). 
Care was taken to 
prevent the cercarial suspension being contaminated by snail 
faeces and the cercariae 
washed by sedimentation on ice. The eventual pellets of cercariae were 
homogenized on 
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ice in PBS in the presence of 1 mM phenylmethanesulfonyl fluoride, 0.2mM tosyl-L- 
phenylalaninechloromethyl ketone, 0.1µM aprotonin and 1µM leupeptin. The 
homogenate was centrifuged at 100,000 xg for 1 hour at 4°C using a Beckman L8-80 
ultracentrifuge. The supernatant (SCAP) was filter sterilised through a 0.22µM filter 
(Sartorius, UK) and aliquoted and stored in -70°C. The pellet was resuspended in PBS 
containing 4mM sodium deoxycholate (DOC) and protease inhibitors. The resuspension 
was sonicated and then left on ice for 1 hour. This was then centrifuged as for SCAP. 
The supernatant (DOC-SCAP) was, filter sterilized, aliquoted and stored at -70°C. The 
protein concentration was determined using a Biorad protein estimation kit. 
For the initial experiments in section 5.2.1 (Chapter 5) two antigen preparations kindly 
supplied by Dr Mike Doenhoff, (University of Bangor) were used: SCA (soluble 
cercarial antigen) which had been prepared from pelleted cercariae in a similar way to 
the preparation of SCAP; Cercarial transformation fluid (CTF) was prepared by 
resuspending pelleted cercariae in RPMI-1640, mechanically transforming them as 
described above (section 2.4.1) and collection of the medium used for transformation 
after centrifugation of the parasites at 1000 xg for 5 minutes. 
2.6 Preparation of Rol1-3128: 
2.6.1 For Mouse administration: 
Rol 1-3128 powder had kindly been provided by Dr H Stohler (Hoffman-La Roche, 
Basle, Switzerland). It was dispersed by sonication in distilled water containing 2.5% 
Cremaphor El (Sigma, UK) and administered orally 2 days after infection (Bickle and 
Andrews, 1985) at a dose of 200mg/kg body weight. This dose was increased from that 
previously used (Bickle &Andrews, 1985; Mountford et al., 1989; 
Bickle, Sacko & 
Vignali, 1990) in order to enhance skin phase arrest. 
2.6.2 For in vitro culture assays: 
Since Rol 1-3218 is not soluble in medium, the drug was first dissolved in DMSO 
(Dimethyl Sulfoxide) (Sigma, UK) and then added to medium in in vitro cell cultures. 
In some experiments absolute ethanol was used to 
dissolve Rol 1-3128. 
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2.7 Mouse infections and measurement of resistance: 
2.7.1 Immunizations and Challenge Infections: 
Mice were first anaesthetized with sodium pentobarbitone (0.06 mg/g body weight 
Sagatal; May and Baker Ltd., Dagenham, England) and then percutaneously infected on 
the shaved belly by the `Ring Method' of Smithers and Terry (1965) as adapted by 
Doenhoff et al., (1978). A suspension (0.2-0.5m1) of normal or irradiated S. mansoni 
cercariae was placed in a plastic ring retained on the skin of the belly region with the aid 
of transparent self-adhesive tape. This was left on the skin for about 20 minutes, at 
which time fluid and rings were removed and the animals allowed to recover over gentle 
warmth. Mice that were infected with a primary infection of 500 cercariae were then 
given an oral dose of 200mg/kg of Rol 1-3128 2 days (40 h) post-infection. Those mice 
to be challenged were exposed again at 5-6 weeks to another infection of 100-200 
cercariae in the same way as above but on a different site, the flank of the mouse, and 
perfused 3 weeks later. 
2.7.2 Immunization and drug administration regimes: 
For the different vaccination/infection regimes mice were infected percutaneously as 
follows: NI, 500 normal S. mansoni cercariae on day 0; RoNI, 500 normal S. mansoni 
cercariae on day 0 and treatment with Rol 1-3128 on day 2 (40 h pi); GI, 500 'y- 
irradiated cercariae on day 0; RoGI, 500 y-irradiated cercariae on day 0 and treatment 
with Rol 1-3128 on day 2 (40 h p. i). Controls were naive mice (CC) for NI and GI or 
Roll -3128 treated naive mice (RoCC) for RoNI and RoGI. 
2.7.3 Perfusion technique: 
Challenged mice were perfused as described by Doenhoff et al., (1978). Mice were 
killed with an overdose of sodium pentobarbitone (100µl Sagatal containing 10 units of 
sodium heparin [Sigma, UK]/mouse) given intraperitonally. The thoracic and peritoneal 
cavities were opened, the mouse suspended over a conical funnel leading into a 30m1 
Universal tube, the hepatic portal vein cut and 25m1 of citrate/saline perfusion fluid 
(8.6g NaCl and 15. Og trisodium citrate/litre) was injected into the left ventricle, the liver 
and intestines were gently massaged and the perfuseate emerged from the cut hepatic 
portal vein and was collected in the tube. Parasites were allowed to settle and excess 
solution was removed by suction, leaving behind 1-1.5m1. More perfusion buffer was 
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added, allowing 5-10 minutes for worms to settle and the supernatant similarly 
removed. This was repeated to remove most of the erythrocytes. A drop of 1% aqueous 
saponin (Sigma, UK) solution was added to lyse the remaining erythrocytes and the 
solution poured into a 6cm Petri dish. The tube was rinsed with perfusion fluid and this 
poured into the Petri dish. The worms were counted under a dissecting microscope. 
2.7.4 Measure of Level of Resistance: 
The level of resistance for vaccinated mice was calculated from the worm burdens 
recovered using the following formula: 
% Resistance = (Control Worm Recovery - Vaccinated Worm Recovery) x 100 % 
Control Worm Recovery 
2.7.5 Statistical Analysis: 
Data for worm burdens and cytokines were compared using two-tailed Student's t-test 
or the Mann-Whitney U test. P-value of < 0.05 was considered statistically significant. 
2.8 In vitro cultures of parasites and cells: 
2.8.1 In vitro culture of Schistosomula: 
(A) Preparation of M 169: 
Medium 169 (M169), a medium specially developed for culturing schistosomula, was 
prepared as defined by Basch (1981) and as shown in Appendix A. 2. The freshly 
prepared medium was filter sterilized and stored at 4°C. 
(B) Culturing of schistosomula: 
Sedimented schistosomula were cultured in either pre-warmed complete schistosome 
culture medium M169 supplemented with 300U/ml Penicillin 
(Gibco, UK), 300µg/ml 
Streptomycin (Gibco, UK), 160µg/ml Gentamicin (Sigma, UK) and 5% Foetal Calf 
Serum (FCS) (Sigma, UK), or cultured in Dulbecco's Modified Eagle's Medium 
[DMEM] (Sigma, UK) supplemented with 10% FCS (Sigma, UK), 1 mM Sodium 
Pyruvate (Sigma, UK), 2mM L-glutamine (Sigma, UK), 50µM 2-Mercaptoethanol 
(Gibco, UK), 100U/ml Penicillin and 100µg/ml Streptomycin (Gibco, UK) and 160µ 
g/ml Gentamicin (Sigma, UK). Complete media containing 
FCS were referred to as 
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cDMEM and M169S. In cultures where parasites were required to develop for 4 days. 
mouse red blood cells were added to the cDMEM. For this purpose, a mouse was killed 
by cervical dislocation and blood withdrawn from the heart into aI ml syringe 
containing 20units sodium heparin. The cells were washed by adding to 10ml DMEM 
containing 5units/ml sodium heparin and centrifuging at 1500 xg for 5 minutes and then 
resuspending in 1 ml DMEM. 
Cultures were incubated at 37°C in 5% CO2 for 1-4 days, according to the conditions of 
the specific experiment. When the parasites were to be cultured ultimately with 
splenocytes or lymph node cells the medium in which the schistosomula were pre- 
cultured in was cDMEM. 
2.8.2 Preparation and culture of lymphocytes in in vitro culture assays: 
(A) Cell Culture Media: 
The medium used for experiments involving cultures of cells with schistosomula was 
Dulbecco's Modified Eagle's Medium (Sigma, UK). For other experiments RPMI-1640 
medium (Gibco, UK) was used. Both were supplemented with 10% heat-inactivated 
FCS (Sigma, UK), 1mM Sodium Pyruvate (Sigma, UK), 2mM L-glutamine (Sigma, 
UK), 50µM 2-Mercaptoethanol (Gibco, UK), 100U/ml penicillin and 100µg/m1 
streptomycin (Gibco, UK). 
(B) Spleen and Lymph node cell preparation: 
Spleens or lymph nodes from mice were removed aseptically on days 7 and/or 21 post- 
infection (pi). For spleen cell preparations, spleens were passed gently through a 100- 
µm sieve (Becton Dickinson-Falcon, UK), using a 5ml syringe plunger to 
disrupt the 
tissue. The cell suspension was centrifuged once in complete medium, at 1200 
revolutions per minute (rpm), for 10 minutes at 4°C, and the supernatant 
discarded. Red 
blood cells were lysed by the addition of cold 1x Gey's Solution (see Appendix A4) 
for 
7-8 minutes at room temperature (9m1 of 1x Gey's solution: 
l ml of cell suspension). The 
cell suspension was then diluted in complete cell culture medium and centrifuged once 
at 1200 rpm, for 10 minutes at 4°C. After discarding the supernatant 
the cell pellet was 
resuspended in fresh complete medium and washed twice at 
1200 rpm, for 10 minutes at 
4°C. Viable cell counts were made using Trypan Blue solution (Sigma, UK), where 
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Trypan Blue negative cells were counted as viable under the microscope in a 
Haemocytometer. 
The axillary and inguinal, skin-draining lymph nodes (SLN) and popliteal lymph nodes 
were passed gently through a 100-µm sieve as above and the cell suspension was 
centrifuged once in complete cell culture medium, at 1200 rpm for 10 minutes at 4°C. 
Lymph node cells were not resuspended in Ix Gey's solution. Cells were counted in 
Trypan Blue as above. 
(C) Cell cultures: 
Single cell suspensions of either spleen or lymph node cells were seeded in 96-well flat- 
bottomed tissue culture plates (Nunc, UK) at either 3 or 5x105 and 2.5 or 5x 105 
cells/well, respectively, in 200µl final volumes/well, depending on the experiments. In 
some experiments immature dendritic cells (DCs) were added to lymph node cells at a 
concentration of 2.5x104 DCs: 2.5x105 LN cells, such that the DC: T cell ratio was 1: 10 
(Semnani et al., 2001; Whelan et al., 2000). Cells were either stimulated with 
Mycobacterium bovis Bacillus-Calmette Guerin (BCG), the mitogen Concanavalin A 
(ConA), antigens e. g., SCAP or DOC-SCAP, or live schistosomulae (+Rol 1-3128). All 
cultures were incubated at 37°C in the presence of 5%CO2. Cell supernatant fluids were 
collected at 24 hours for IL-4 assays and 72 hours for IFN-y, IL-5 and IL-10 assays as in 
other similar studies (Grzych et al., 1991; Pearce et al., 1991; Mountford et al., 1999). 
IL-4, IL-5, IFN-, y and IL-10 levels in the cell culture supernatant were measured using 
PharMingen OptEIATM ELISA kits according to manufacturer's instructions (section 
2.11). 
2.9 Preparation of mouse bone marrow derived Dendritic Cells (bm-DCs): 
2.9.1 Producing GM-CSF from a GM-CSF secreting cell line (x63-GM-CSF): 
The mouse gene for GM-CSF (PCR derived) has been cloned into a mammalian 
expression vector (BCMGSNeo; Karasuyama et al., 1990) and transfected into the 
plasmacytoma line X63-Ag8 (Stockinger et al., 1996). This x63-GM-CSF cell line was 
obtained from Prof. D. Gray, University of Edinburgh. 
The cells were grown in selection medium, made of cDMEM containing 1 mg/ml of the 
selective antibiotic G418/Geniticin Sulphate (Sigma, UK), until the cells had grown to 
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`medium' density. These were harvested, washed twice in cDMEM and returned to 
culture for 2-4 days in medium without G418. The supernatant was then harvested by 
centrifugation and aliquoted to be stored at -80°C. Filtration was not used as filtering 
causes loss of GM-CSF activity (Professor Gray - personal communication). Specific 
GM-CSF activity of each batch was checked by titrating the collected GM-CSF 
supernatant into bone marrow cultures and assessing generation of dendritic cells. 
Initially a supernatant dilution of 1: 40 dilution of GM-CSF was used, but this was 
increased to 1: 10 GM-CSF as recommended by Lutz M. et al., (1999). 
2.9.2 Bone marrow preparation : 
The principle for culturing bm-DC with GM-CSF was according to Lutz et al., (1999). 
Under sterile conditions the femurs of female C57BL/6 mice were removed and 
surrounding muscle tissue cut away. Both ends of the femur were then cut with scissors 
and the marrow flushed by inserting aI ml syringe with a 0.5mm diameter needle 
containing warm cDMEM. The flushed marrow was collected in a 90 mm diameter 
Sterilin grade petri-dish (Sterilin, UK). Clusters within the marrow suspension were 
dispersed by vigorous pipetting. The bone marrow cells were washed once in cDMEM 
at 1200 rpm for 10 minutes at 4°C, and cell counts were obtained by staining an aliquot 
volume of cells mixed 1: 1 in Trypan blue solution (Sigma, UK). Erythrocytes were 
excluded by size and shape, and viable cells (i. e. not staining) were counted under the 
microscope in a Neubauer haemocytometer. About 1-1.5x107 cells were obtained per 
femur. 
2.9.3 Bone marrow cell culture with GM-CSF: 
At day 0 bone marrow leukocytes were seeded at 2x 106 cells per 90mm bacterial grade 
petri-dishes Triple Vent (Sterilin, UK) in 10 ml cDMEM containing 10% GM-CSF 
supernatant. These were incubated at 37°C and 5% CO2. At day 3 another 10 ml 
cDMEM containing 10% GM-C SF supernatant was added to the plates. At days 6 and 8 
half of the culture supernatant was carefully aspirated from the surface of the liquid 
using a pastette with a 200µl Gilson pipette tip (Sarstedt, UK) attached. Another 10 ml 
of fresh cDMEM containing 10% GM-CSF supernatant was gently added dropwise. 
Care was taken not to aspirate non-adherent cells, and not to move plates to avoid 
stimulation and therefore maturation of DCs in culture. 
On day 10 all culture 
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supernatants containing the non-adherent cells were gently transferred to a 50ml Falcon 
tube and centrifuged at 1200rpm for 10 minutes at room temperature to pellet the cells. 
Pelleted bm-DCs were then quickly resuspended and washed once in fresh cDMEM 
containing 5% GM-CSF (at 1200rpm for 10minutes, at room temperature), counted in a 
haemocytometer as described above, and used as immature bm-DCs in in vitro 
experiments. DCs were identified as granular, irregularly shaped cells with small 
protrusions. In cultures containing DCs ± parasites ± other antigens, supernatants were 
collected 19-24 hours after culture and tested for the presence of IL-12p70, IL-6, IL- 10 
and TNF-a using standard ELISA kits as explained in section 2.11. 
2.10 Ex-vivo Surface Cytokine Staining for Flow Cytometry Analysis : 
Bm-DCs were carefully collected from the culture wells and transferred to 50 ml Falcon 
tubes. If schistosomula were present in the cell cultures, these were first separated from 
the cells by passing the parasite-cell mix carefully through a 25µm filter mesh (Allied 
Filter Products Ltd., UK) attached to the top of 50m1 Falcon plastic tubes via autoclave 
tape. Preliminary experiments were carried out to determine the optimal mesh size for 
this purpose. The collected DCs were then washed once in ice-cold FACS-EDTA buffer 
(Appendix A. 3) at 1200 rpm and 4°C for 10 minutes. Supernatants were discarded and 
the cells, at the bottom of the tube, were gently flicked and then removed and placed 
into FACS tubes (Becton Dickinson-Falcon, No. 352052, UK) at 1-5x105 cells/tube. 
These tubes were spun again at 1200 rpm and 4°C for 10 minutes, and supernatants 
were poured off. Non-specific binding of the cells was blocked by adding 5µl of 
Blocking Buffer (1: 1 Horse serum [Sigma, UK] : 24G2 [Fc blocking antibody, 
supernatant from a negative control rat cell hybridoma grown in-house, obtained from 
C. Meier, LSHTM], filtered before use) to l00µ1 of cell suspension in a 1: 20 dilution, 
and cells were left to incubate for 15 minutes on ice. Anti-cell-surface marker antibodies 
or isotype controls were then added to the cells and tubes gently flicked to ensure good 
mixing of cells with antibodies. Staining was done in the dark. See Table 2.1 for details 
of anti-cell-surface monoclonal antibodies and isotype controls used, and the dilutions 
they were used in. Tubes were incubated for 30 minutes at 4°C in the dark. Cells were 
then washed once in 3ml cold FACS-EDTA buffer at 1200rpm for 10 minutes at 4°C 
and the supernatant discarded. To those cells stained with biotinylated antibodies, 
Streptavidin-Quantum Red (SA-QR) was added at 1µl: 100µl/sample and the tubes 
gently flicked and incubated in the dark for another 30 minutes at 4°C, after which these 
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cells were washed once more in FACS-EDTA buffer. All the cells were fixed with 1% 
cold Paraformaldehyde and stored at 4°C until analysis, which was done within 1 week 
of staining. Cells were analysed on a FACScan (Fluorescence-Activated Cell Sorter) 
flow cytometer with CELLQuest software (Becton Dickinson, USA). 
2.11 Cytokine detection using Enzyme linked Immunosorbent Assays (ELISA): 
The cyokines IFN-y, IL-4, IL-5, IL-10, IL-12p70 and IL-6 were detected using 
PharMingen OptEIATM ELISA kits (PharMingen, UK), and TNF-a using an R&D kit 
(R&D systems, UK) according to manufacturers instructions. Briefly, 96-well Nunc 
Maxisorp plates were coated with 50µl/well of anti-mouse capture antibody to the 
specific cytokine being tested. Plates were sealed and incubated overnight at 4°C. The 
following day, plates were aspirated and washed as required with freshly prepared Wash 
Buffer (0.05 % Tween-20 in Ix PBS, pH 7.4). Plates were then blocked with Assay 
Diluent (10% FCS in PBS, pH 7.0) for one hour, or for overnight, at room temperature. 
Wells were then aspirated and washed with Wash Buffer as above. 50µ1 of appropriately 
diluted supernatant specimens were added in duplicates into the wells, alongside serial 
dilutions of standards (i. e., recombinant mouse-IFN-?, IL-4, IL-5, IL-10, IL-12p70, 
IL-6, or TNF-a) run also in duplicates. The plates were then sealed and left to incubate 
for 2 hours at room temperature, after which they were aspirated and washed as 
required. 50µ1 of Working Detector, which is a combination of biotinylated anti-mouse- 
detection antibody to the specific cytokine tested and avidin-horseradish peroxidase 
conjugate enzyme reagent, were added to each well and the plates sealed and incubated 
for 1 hour at room temperature. Finally the wells were aspirated/washed as required. 
100µl of TMB-ELISA solution (Gibco, UK) was used as substrate and added to each 
well, and plates incubated for 10-30 minutes at room temperature in the dark. The 
reaction was stopped by adding 50µl/well of Stop Solution (2N H2SO4). The optical 
density was read at an absorbance of 450 nm using an ELISA reader (MRX microplate 
reader, Dynex Technologies, UK) within 30 minutes of stopping the reaction. The 
cytokine levels in the samples were calculated according to the standard curve obtained 
for each ELISA plate. 
2.12 Measuring Apoptosis and Necrosis by Flow Cytometry: 
Annexin V-FITC is used to quantitatively determine the percentage of cells undergoing 
apoptosis. It relies on the property of cells to lose membrane asymmetry 
in the early 
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phases of apoptosis. In these cells, the membrane phospholipid phosphatid`lserine (PS) 
is translocated from the inner leaflet of the plasma membrane to the outer leaflet, 
thereby exposing PS to the external environment. Annexin V is a Ca 2+-dependent 
phospholipid-binding protein that has a high affinity for PS, and is useful for identifying 
apoptotic cells with exposed PS. Propidium iodide (PI) is a standard flow cytometric 
viability probe and is used to distinguish viable cells from nonviable cells. Viable cells 
with intact membranes exclude PI, whereas the membranes of dead or damaged cells are 
permeable to PI. Cells that stain positive for Annexin V-FITC and negative for 
Propidium iodide (PI) are in the early stages of apoptosis. Cells that stain positive for 
both Annexin V-FITC and PI are either in the end stage of apoptosis, are undergoing 
necrosis or are already dead. Cells that are negative for both Annexin V-FITC and PI 
staining are alive and not undergoing measurable apoptosis. 
The procedure and reagents required for measuring apoptosis in cells were all obtained 
from the Annexin V-FITC Apoptosis Detection Kit I (PharMingen, UK). Bm-DCs and 
bm-DCs separated from parasites via the 25µm filter mesh were washed twice in cold 
sterile lx PBS (Dulbecco's Phosphate Buffered Saline solution, Sigma, UK) by 
spinning at 1200 rpm for 10 minutes at 4°C. These cells were then resuspended in l00µ1 
of Ix Binding Buffer (Appendix A. 6) at a concentration of 1-5 x 105 cells on ice. 5µl of 
Annexin V-FITC and IOµ1 of Propidium Iodide (Appendix A. 6) were added and the 
tubes were gently flicked to mix the cells and stains, and incubated for 15 minutes at 
room temperature in the dark. 200µl of Ix Binding Buffer were then added to each tube 
and cells were analysed by flow cytometry within 1 hr of staining. For setting up 
compensation and quadrants for staining controls were set up: (i) unstained cells, (ii) 
cells stained with Annexin V-FITC alone (no PI), and (iii) cells stained with PI alone 
(no Annexin V-FITC). 
2.13 Preparation of anti-IFN-y monoclonal antibody: 
2.13.1 Culture of anti-IFN-y monoclonal antibody secreting cell line: 
The rat cell line (XMG 1.6, secreting IgGI anti-mouse IFN-y; initially from ATCC 
(American Type Culture Collection, Bethseda, MD, USA) and kindly provided by Dr C. 
Engwerda, (LSHTM) was cultured in RPMI-1640,5% CO2 and 37°C. For collection of 
tissue culture supernatants, cell lines were harvested in log phase growth, cells removed 
by centrifugation, and the supernatant collected. 0.01% sodium azide (NaN3) was added 
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to the supernatant. The supernatants were then stored in 4°C until purification by 
affinity chromatography using a protein G column. 
2.13.2 Purification using Protein G affinity Chromatography: 
Cell culture supernatant was filter sterilized. Protein G Sepharose Fast Flow gel 
(Pharmacia Biotech, UK) was packed in a plastic column (Sigma, UK). The column 
was connected to a pump and equilibrated by running 5 column volumes of Running 
Buffer (0.02 M phosphate buffer, pH 7.0) through it. The supernatant was then passed 
directly over the column at a slow rate, at 4°C. To dissociate antibody that had attached 
to Protein G, the column was washed with Running buffer until non-specific protein 
ceased to be washed from the column. At this point Elution Buffer was run through the 
column (0.1 M glycine-HC1, pH 3.0-2.7) to dissociate specific IgG. The antibody was 
collected. To preserve the activity of acid labile IgG 50µ1 of IM Tris-HCI, pH 9.0 
(Neutralizing Buffer) was added to every 1 ml of eluate collected to bring back its pH to 
7.0. This antibody was then dialysed against 0.09% NaCl for 72 hours at 4°C, freeze- 
dried and then resuspended in 1/10th the original volume with sterile distilled water. 
This was mixed well and then filter sterilized using 0.2µm filter (Pall Gelman Lab., 
UK). The concentration of the antibody was calculated by diluting antibody in distilled 
water, measuring the optical density at 280nm using a spectrophotometer (UV-1201, 
spectrophotometer, Shimadzu, UK) and then using the following formula: 
Concentration of sample = Optical Density at 280nm x10 mg/ml x dilution factor. 
Extinction Coefficient at 280nm 
The antibody was kept at -20°C, until required. 
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CHAPTER 3 
IN VIVO AND IN VITRO STUDIES ON THE MECHANISMS OF 
IMMUNITY IN DRUG-TERMINATED INFECTIONS. 
3.1. Introduction: 
High levels of immunity against schistosomes can be induced in experimental animals by 
exposure to radiation attenuated infections (Taylor, 1994). Although such live vaccines are 
not feasible for field use, studies of attenuated Schistosoma mansoni vaccines have 
provided some insight into the mechanisms of immunity that are effective against infection. 
Both antibody (Ford et al, 1984 b; Mangold and Dean, 1986; McLaren and Smithers, 1988; 
Jankovic et al., 1999) and CD4+ T-cell mediated IFN-y-dependent effector mechanisms 
(Jankovic et al, 1999; Kelly and Colley, 1988; Vignali et al., 1989a; Sher et al., 1990; 
Smythies et al., 1992a; Wynn et al., 1994) have been demonstrated, depending on the host 
species and the number of vaccinations. However, relatively little is known about how 
living irradiated or drug-terminated infections are so effective at inducing immunity. The 
relatively poor results obtained to date with dead parasite antigens or defined candidate 
vaccine antigens (Dean, 1983; Bergquist and Colley, 1998) demonstrate that a better 
understanding of the induction of protective immunity by such attenuated vaccines may be 
needed to allow development of effective defined vaccines. 
Studies in mice have shown that the optimum doses of radiation for induction of immunity 
are of the order of 15-20 krad (Bickle et al., 1979b; Reynolds and Ham, 1992) which 
produce a slight delay in the skin, but then arrest and death of many of the larvae takes 
place in the lungs around 21 days post infection (Mastin et al., 1983; Mangold and Dean, 
1984). Significantly lower levels of immunity are induced when either lower doses of 
irradiation, that resulted in the larvae reaching the liver and producing sterile stunted 
worms, or higher doses of irradiation which arrested the larvae in the skin were tested 
(Minard et al., 1978; Bickle et al., 1979b; Mountford et al., 1992). The predominant death 
in the lungs of 20krad infections, which is thought to be due to radiation-induced damage to 
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the neuromuscular coordination of the parasite preventing migration (Harrop and Wilson, 
1993), raised the question whether death in the lungs or exposure to lung stage-specific 
antigens released by death of the lung stage schistosomula were crucial features of inducing 
protection. So experiments were carried out to drug attenuate the infection in either the 
skin, lungs or liver to see if the level of immunity also correlated with the site of death. The 
drug, Rol 1-3218, was found to be able to kill all of the larvae when given at the skin, lung 
and/or liver stages (Bickle and Andrews, 1985). High levels of immunity could be induced 
when the drug was given at the lung stage and poor levels of immunity occurred when the 
drug was given at the liver stage. Unexpectedly though, high levels of immunity could also 
be induced when the drug was given at day +1 or +2 post infection when the larvae were in 
the skin. Mincing and incubation (Bickle and Andrews, 1985) and quantitative histology 
(Mastin et al., 1983) showed that following day +1 treatments the larvae were retained in 
the skin. Similar experiments with other drugs (Oxamniquine - Bickle and Andrews, 1985, 
or Ro 15-5458 - Bickle et al., 1990) failed to induce such high levels of immunity. Ro 15- 
5458, like Rol 1-3128 seemed to arrest the larvae in the skin (Bickle et al., 1990) but the 
quantitative histology indicated that following oxamniquine treatment a significant 
proportion of parasites reached the lungs. Exposure of cercariae to a high dose of radiation, 
80krad, also arrests the larvae in the skin but fails to induce significant protection 
(Mountford et al., 1992). These studies indicated that arrest of the larvae in the skin could 
induce levels of immunity comparable to the optimal irradiated infections which reached 
the lungs, but that there were unexplained differences between the potential of infections 
terminated with different drugs or with high doses of radiation to induce immunity. 
The optimally irradiated (20krad) larvae show a protracted migration in the skin-draining 
lymph nodes (SLN) compared with a normal infection and release greater amounts of 
parasite antigen in the nodes (Mountford et al., 1988). This is believed to result 
in the 
increased level of priming of responses in the SLN compared with infections with 
unirradiated cercariae, but in both cases the response which 
develops following single 
exposure to irradiated cercariae is a Th 1 dominated response with 
IFN-y the dominant 
cytokine (Mountford et al., 1988; Constant et al., 1990; 
Pemberton et al., 1991). 
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Surgical removal of the SLN before vaccination showed that priming in the SLN plays a 
major role in inducing immunity (Mountford and Wilson, 1990). The subsequent migration 
of the majority of the optimally irradiated larvae to the lungs (Bickle et at, 1979b; Mastin et 
al., 1983; Mangold and Dean, 1984) induces marked and persistent cellular infiltration and 
elevated expression of various cytokines notably antigen-specific IFN-7 production (Aitken 
et al., 1988; Smythies et al., 1992b; Wynn et al., 1995). The larval stimulation of both the 
skin and the lungs are features considered crucial for the optimal efficacy of the 20krad 
irradiated vaccine (Coulson, 1997). This conclusion was supported by the more recent 
demonstration of significantly lower protection in the non-vaccinated partners of vaccinated 
parabiotic pairs compared with the vaccinated partner (Coulson and Wilson, 1997). The 
data indicate that the inflammatory responses induced by the death of the irradiated larvae 
in the lung leads to recruitment of a persistent population of sensitized Thl cells which can 
react quickly to larvae from a challenge infection and produced focal inflammatory 
responses which trap the migrating larvae (Crabtree and Wilson, 1986; Coulson, 1997). 
Although the work on the optimally irradiated vaccine has supported the feasibility of 
developing a schistosome vaccine for humans, this requirement for priming in the skin 
followed by inflammation in the lungs in order to "arm" the lungs is a complicated model 
on which to base a defined antigen vaccine. In contrast the Rol 1-3128 terminated 
infections seem to provide a focus of antigen presentation in the skin, i. e., more similar to 
what a defined antigen vaccine could produce. For this reason it was thought that studies of 
the mechanisms of immunity in this model might prove valuable. So this Chapter contains 
in vitro and in vivo experiments on the type of immune responses stimulated in the skin 
draining lymph nodes and the spleen and on the mechanisms of immunity in Roll-328 
terminated infections. 
Comparisons are made with the 20 krad irradiated vaccine and with 20krad infections 
which were also drug treated which are interesting because they 
induce markedly less 
protection than drug treated unirradiated infections (Bickle and 
Andrews, 1985; Mountford 
et al., 1989; Bickle et al., 1990). Such drug-arrested unirradiated and 
irradiated infections 
would both be expected to induce marked responses 
in the skin draining lymph nodes and 
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so it was hoped that a comparison of the immune responses induced would show some 
differences which would shed light on the key requirements for immunity. 
At the start of this study all that was known about the immunity induced by the drug 
terminated infections was that depletion of CD4+ve but not CD8+ve cells during the 
challenge phase of immunized mice led to a marked reduction in protection (Vignali et al, 
1989a) suggesting the involvement of CMI effector mechanisms in the immunity. 
The following abbreviations have been used for the different vaccination protocols: 
9 NI - (Normal Infection) i. e. percutaneous exposure to 500 unirradiated 
cercariae. 
" RoNI - (Rol 1-3128 treated Normal Infection) i. e. percutaneous exposure to 
500 unirradiated cercariae followed by treatment with 200mg/kg Rol 1-3128. 
" GI - (Gamma irradiated infection) i. e. percutaneous exposure to 500 
cercariae irradiated with 20krad. 
9 RoGI - (Roll-3128 treated Gamma irradiated infection) i. e. percutaneous 
exposure to 500 cercariae irradiated with 20krad followed by treatment with 
200mg/kg Rol 1-3128. 
The control groups are: 
" RoCC - (Rol 1-3128 treated Challenge 
Controls) i. e. naive mice used as 
controls for mice given drug-terminated infections and so they are treated with 
200mg/kg Rol 1-3128 at the same time as the immunized groups. 
0 CC - (Challenge Controls). 
Naive mice. 
3.2 Results 
3.2.1 RoNI induces very high levels of protection. 
In previous studies using Rol 1-3128 terminated infections to 
induce immunity (Bickle and 
Andrews, 1985; Mountford et al., 1989; Bickle et al., 1990) 150-175mg/kg of drug were 
used. Using radio-labelling of the parasites and autoradiography, 
Mountford et al. (1989) 
reported that following treatment with 175mg/kg at 
48hr a significant minority of the 
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applied cercariae showed a very delayed migration to the lungs. Because we wanted to 
focus on the skin responses the dose of RoNI was increased to 200mg/kg in order to 
maximise the attenuation possible with this drug (200mg/kg is close to a dose which would 
cause mortality to the mice due to the sedative side effects of this benzodiazepine). Several 
experiments were carried out to assess the use of the 200mg/kg RoNI protocol and to 
compare this with the RoGI one (Table 3.1). Three separate experiments showed very high 
levels of protection. An average of almost 90% worm reductions, were seen with RoNI. 
In a direct comparison using 200mg/kg Rol 1-3128 (Experiment 3) RoNI induced 84.5% 
protection compared with only 27.9% with RoGI. This shows that the superiority of RoNI 
over RoGI referred to above also holds for the use of the higher drug dose. Although not 
tested in direct comparison the 20krad, GI induced rather lower levels of protection than 
RoNI (Experiments 4 and 5). 
Table 3.1. Levels of resistance in C57BL/6 mice 
Experiment Regimen Worm burden + SD Worm p 
No. Vaccinated Control reduction 
(%) 
1 RoNI 8.5 ± 3.9 64.8 ± 15.4 86.9 <0.01 
2 RoNI 4.0 ± 1.9 51.0 ± 6.5 92.2 <0.01 
3 RoNI 6.5 ± 2.7 42.0 ± 8.7 84.5 <0.01 
RoGI 30.3 ± 7.0 42.0 ± 8.7 27.9* <0.05 
4 GI 29.2 ± 8.7 88.7 ± 11.5 67.1 <0.01 
5 GI 30.9 ± 11.7 83.9 ± 10.4 63.2 <0.01 
Table 3.1. C57BL/6 mice (n = 4-8) were vaccinated with 500 cercariae as described in 
Materials and Methods. They were challenged percutaneously with 100 (Experiments 1-3) 
or 150 (Experiments 4 and 5) normal cercariae on day 35 and perfused on day 56. 
Significant levels of protection were achieved in vaccinated mice compared with controls. 
*Significantly lower than in RoNI-vaccinated mice (P<0.001). 
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3.2.2 RoNI: Double treatment with Roll-3128 (at days +2 and +4) also results in 
very high levels of protection. 
Apart from increasing the dose of drug to 200mg/kg to increase attenuation at the skin stage 
experiments were also carried out giving either one dose of Rol 1-3128 at day +2 or two 
doses, one at day +2 and the other at day +4. Treatment of mice with Rol 1-3128 at each of 
these times has been shown to kill all larval stages (Bickle & Andrews, 1985) and so it was 
considered that fewer if any larvae would have migrated beyond the skin in the double 
treatment regimen. The results are shown in Figure 3.1. 
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Figure 3.1 C57BL/6 mice (6/group) were infected with 500 normal cercariae and drug 
treated orally with 200mg/kg Rol 1-3128 40 hr later (1 x Ro 11) or at 40 hr and then again 
at 96hr (2x Ro 11). The mice were challenged with 150 cercariae 
5 weeks later and 
perfused 3 weeks post challenge. The control mice were given the 
double drug 
treatment. The bars show mean ± SD. 
High levels of protection were seen with both a single and double treatment 
but the double 
treatment was even more effective than the single (94.3 compared with 
86.9% protection 
respectively, both P<0.0001). 
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3.2.3. Comparison of cytokine responses in skin draining lymph nodes (SLN) and 
spleen of mice given normal cercariae or y-irradiated cercariae with or without Rol 1- 
3128 treatment (NI, RoNI, GI or RoGI). 
3.2.3.1 Comparison of the responses in different SLNs following different routes of 
infection: 
An initial experiment was carried out to compare the response and cell yield from either the 
popliteal or the axillary and inguinal lymph nodes (LN) after RoNI treatment in order to 
decide on the best source of cells for later experiments. Following percutaneous infection 
on the mouse foot the popliteal node is the sole draining lymph node, but following 
infection on the mouse belly the axillary and inguinal nodes on each side of the body 
respond and so there is potentially a larger cell source, but it was unknown how the levels 
of cellular stimulation would compare. Two antigen preparations were used, SCAP, 
(Soluble Cercarial Antigen Preparation - an aqueous extract of cercariae) and DOC-SCAP 
(a Deoxycholate extract of cercariae made following the SCAP extraction) [see Materials 
and Methods, section 2.5]. These were used to restimulate the LN cells in vitro. IL-4 and 
IFN-y were both measured but low levels of IL-4 were produced and only the IFN-'y is 
shown (Figure 3.2). 
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Figure 3.2 Three mice (C57BL/6) were infected on the foot or the belly skin with 500 
cercariae and treated with 200mg/kg Rol 1-3128 40 hr later. Lymph nodes were removed 
7 
days post infection. Culture wells contained 5x 105 cells/well 
lymph node cells from 
different sites (A=inguinal+Axillary LNs [from RoNI mice], B=Popliteal LN 
[from RoNI 
mice], C=inguinal+Axillary LNs [from Control mice]). 
Cells were stimulated with Con A 
(2.5µg/ml), SCAP (10µg/ml) and DOC-SCAP (5µg/ml), respectively. 
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Comparable and high levels of IFN-y were produced by the Inguinal+Axillary and popliteal 
lymph node cells from RoNI mice to both antigen preparations. Control mice made 
negligible amounts of IFN-y with antigen. All cell types responded to Con A and this was 
highest with the Inguinal+Axillary cells. All of the nodes were greatly increased in size 
following RoNI and given the much higher yield of cells from the inguinal and axillary 
nodes these were chosen for all later studies. 
3.2.3.2. Experiment 1: responses in the Skin draining lymph nodes (SLN): 
This first experiment was carried out to compare the cytokine responses in the SLN of mice 
given different infection/immunisation regimes. The experiment was set up as follows: 
Group 1, normal cercarial infection (NI); Group 2, normal cercarial infection with Ro II- 
3128 treatment (RoNI) [induces high levels of protection]; Group 3, gamma-irradiated 
cercarial infection (GI) [induces high levels of protection]; Group 4, gamma-irradiated 
cercarial infection with Rol 1-3128 treatment (RoGI) [induces poor levels of protection]; 
Group 5, normal control mice (CC); and Group 6, normal control mice given Rol 1-3128 
treatment control (RoCC). Lymph nodes were removed at days 7 or 21 and cultured as 
described in the Legend to Figure 3.3. Initially, IFN-y and IL-4 were measured from culture 
supernatants as indicators of induction of Thl and Th2 responses respectively, and because 
IFN--y has been implicated as the mediator of immunity following single vaccination with 
irradiated cercariae. IL-10 was measured later to see if the differences observed in IFN--y 
levels could be explained by differences in this regulatory cytokine. Data for LN IL-4 are 
from pooled supernatant of triplicate wells and data for LN IFN-y and IL-10 are mean ± 
SEM of triplicate wells. The results are shown in Figure 3.3. 
IL-4 levels 
At day 7 post-infection cells from mice in all groups showed raised IL-4 levels in the 
presence of Con A and this was highest in the different 
infected groups compared with 
controls. A similar difference between infected and control groups was seen at 
day 21 with 
Con A, but the levels were very low. When cells were stimulated with specific antigen 
(SCAP or DOC-SCAP) there was no difference between infected and control groups 
but 
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Figure 3.3. C57BL/6 mice (3/group) were infected percutaneously with: - 500 normal 
cercariae (NI); 500 normal cercariae and drug treated orally with 200mg/kg Rol 1-3128 40 
hr later (RoNI); 500 gamma irradiated cercariae (GI): 500 gamma irradiated cercariae and 
drug treated as above (RoGI). CC were normal control mice and RoCC were normal mice 
treated with Rol 1-3128 as for RoNI. Cells prepared from pooled lymph nodes removed at 
7 or 21 days post infection were cultured in triplicate at 5x 10 /well in 96-well tissue 
culture plates, and stimulated with Con A (2.5µg/ml), SCAP (10µg/ml) and DOC-SCAP 
(5µg/ml), respectively. IL-4 was tested by ELISA using 48h supernatant and IFN-y and 
IL-10 using 72h supernatant. 
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SCAP induced non-specific responses in all of the groups relative to the IL-4 levels in the 
control (RPMI) cultures. 
IFN-y levels 
By comparison with the IL-4 levels it should be noted that the IFN-y levels were markedly 
higher (note the IFN-'y is reported in ng/ml but the IL-4 in pg/ml). 
Con A responses were seen in all of the groups at day 7 and 21. These were generally 
comparable at day 7 apart from the highest level in the RoCC group. At day 21 all three of 
the attenuated infections (RoNI, RoGI and GI) were still higher than controls with the RoNI 
now being the highest but the level in the NI was similar to the controls. 
Most significantly, there were high antigen-specific responses in the various infected 
groups but not in the controls. At day 7 the highest responses were seen with the RoGI, 
next highest in the NI and GI, but the RoNI response was lowest. By 21 days after infection 
there was a marked change in the relative responses of the different infected groups. At this 
time cells from the NI mice, relative to control mice, did not produce IFN-y with specific 
antigen but each of the three vaccinated groups did show markedly higher responses. 
However, with both of the schistosome antigens, the responses were noticeably higher for 
both of the drug-terminated infections compared with the GI. This clearly shows more 
pronounced, protracted stimulation of the SLN with the drug-terminated infections 
compared with the GI. 
IL-10 levels 
At day 7 and in particular at day 21 the NI cells showed the highest levels of IL-10 
production relative to the other groups in wells without stimulation, i. e., RPMI alone. At 
day 21 this was higher than following Con A or specific antigens. The reason for this is 
unknown. This does give some uncertainty about the interpretation of the 21 day results but 
below the results are basically considered relative to the other groups given the same 
stimulus, Con A or antigen. 
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With Con A, IL-10 production was higher and similar in all infected groups compared ý ith 
control responses at both day 7 and day 21 but responses were somewhat higher at day 7 
compared with day 21. 
The antigen-specific responses showed a rather similar pattern to the IFN-y response 
especially at day 7. As with IFN-y, the antigen specific responses at day 7 were highest in 
the RoGI group, a little lower in the GI group and again somewhat lower in the RoNI and 
NI. The specific antigen IL-10 response was also similar to IFN-y at day 21 showing the 
highest response with RoGI and RoNI and lower levels with GI. The NI cells also made 
highish IL-10 levels at day 21 and this was in contrast to an absence of IFN-y production by 
NI (see above). 
3.2.3.3. Experiment 2: responses in the Skin draining lymph nodes (SLN) and spleen: 
This last experiment was repeated essentially as before but this time extending the 
observations to the spleen also (see Figures 3.4. and 3.5. ). 
Lymph nodes 
TT _d 
lPVPlc 
As in Experiment 1 absolute levels of IL-4 were low throughout. With medium alone and 
with Con A there was an indication that exposure to unattenuated or attenuated worms 
induced increased IL- 4 production and this was greater at day 7 than day 21. But with the 
schistosome antigens there was no evidence of antigen specific IL-4 production in any of 
the groups. 
IFN-y levels 
With Con A stimulation there was, as in Experiment 1, greater production of IFN-y in 
RoCC compared with CC which could indicate an immunomodulatory role for Rol 1-3128 
(See Chapter 4) at day 7. At day 7 each of the groups exposed to attenuated infections 
showed markedly higher IFN-y production compared with the control mice or the NI. By 
day 21 a pattern very similar to Experiment 1 was clear - RoNI showing the highest 
response, RoGI and GI lower and similar responses to each other, and NI 
lower again. 
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Figures 3.4. C57BL/6 mice (3/group) were treated (NI, RoNI, GI, RoGI, CC and RoCC) as 
described in legend to Figure 3.3. Cells prepared from pooled lymph nodes removed at 7 or 
21 days post infection were cultured in triplicate at 5x 105 /well in 96-well tissue culture 
plates, and stimulated with Con A (2.5µg/ml), SCAP (10µg/ml) and DOC-SCAP (5µg/ml), 
respectively. IL-4 was tested by ELISA using 48h supernatant and IFN-y and IL-10 using 
72h supernatant. 
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In terms of antigen specific responses at day 7, IFN-y production with RoGI and GI was 
again high as in Experiment 1 but in contrast to this experiment the RoNI IFN-y response 
was also relatively high and the NI response relatively very much lower. The responses at 
day 21 were very similar to Experiment 1 with the GI IFN-'y response having dropped 
substantially both in absolute and relative terms compared with day 7, whereas the RoNI 
resulted in an interesting increase in the absolute and relative levels of IFN-y production in 
the presence of both antigens notably to DOC-SCAP. In both experiments this relative 
increase between day 7 and 21 for IFN-'y production by RoNI was more marked for the 
DOC-SCAP than the SCAP. 
IL-10 
As in Experiment 1 at day 7 the RoGI induced the highest IL-10 production and the RoNI 
raised but lower levels. This again paralleled the IFN-, y responses. In contrast to 
Experiment 1 the GI in experiment 2 resulted in substantially lower levels of IL-10 
compared with RoNI and RoGI at day 7. The NI also induced lower IL-10 responses 
relative to RoNI at day 7. By day 21 the IL-10 levels had dropped in all groups. This had 
also been seen for most of the groups in the first experiment but was more marked in the 
second experiment. It is interesting to note that IFN-y and IL-10 levels tended to show 
similar relative patterns. However, the persistent or raised IFN-y production for RoNI and 
RoGI between days 7 and 21 contrasted with a decline in IL-10 levels between these time 
points indicating that the relationship between production of IFN-'y and IL-10 is not a 
simple one. 
Spleen 
IL-4 
As seen in Figure 3.5. the IL-4 results show higher background levels in RPMI at day 7 
than day 21. Even so there was little evidence of IL-4 production either to ConA or specific 
antigen at either day 7 or day 21. 
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Figure 3.5. See legend to Figure 3.4. Cells prepared from individual spleens removed at 7 or 
21 days post infection were cultured in triplicate at 5x 105/well in 96-well tissue culture 
plates, and stimulated with Con A (2.5µg/ml), SCAP (10µg/ml) and DOC-SCAP (5µg/ml), 
respectively. IL-4 was tested by ELISA using 48h supernatant and IFN-y and IL-10 using 
72h supernatant. 
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With Con A all groups showed comparable production at day 7 and day 21. With the 
specific antigens, RoGI and RoNI showed elevated IFN-y production compared with the 
other groups especially with the DOC-SCAP at day 7. 
With regard to antigen specific responses at day 21, there was a high background response 
in the control cells in DOC-SCAP but all three attenuated groups showed similar raised 
IFN-y production relative to the controls and to NI. Although all three attenuated infections 
looked similar, however, there was quite high variation within the group results and 
overlapping standard deviations. With SCAP there were much lower responses with the 
control mouse cells and all of the attenuated infections induced significantly elevated levels 
of IFN-y compared with controls but this was most noticeable for the RoNI which was 
elevated 5-6 fold relative to GI or RoGI. But this difference was not statistically significant. 
IL-10 
Apart from the RoGI response with Con A there was little IL-10 production with any of the 
infected groups at day 7. At day 21 however, all of the infected mice showed elevated IL- 
10 production compared with controls. This was also seen but to a lesser degree with the 
schistosome antigens. 
Antibody responses 
Serum antibody levels were also compared in the above experiment using serum taken at 
day 21. The results are shown in Figure 3.6. 
Higher values were obtained with DOC-SCAP than SCAP, the same result as seen 
in the 
cytokine cultures. With both antigens there was the same pattern of response, 
i. e. 
comparable and significantly raised responses with RoGI , 
RoNI and GI and raised but 
lower responses with NI. 
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Figure 3.6 Optical density values for IgG measured in serum taken at day 21 after 
treatment of mice as described in legend to Figure 3.3. (NI, RoNI, GI, RoGI, CC, RoCC). 
SCAP or DOC-SCAP were coated at 2µg/ml. Sera were tested at 1: 100 dilution. Mean 
plus SD for data from three mice is presented. (RoNI, GI and RoGI vs CC or RoCC, 
P<0.01). 
The major distinguishing feature between the highly protective RoNI and the poorly 
protective RoGI in the above experiment was the difference seen in the spleen IFN-y 
response at day 21. It was thought that this might indicate that the RoNI caused a more 
protracted stimulation of the host leading to more systemic spread of antigen-specific IFN-y 
effector/memory Th 1 cells. The RoNI splenic IFN-y response was also higher in RoNI than 
GI so this was compared again also. 
3.2.4. Further comparison of the IFN-y responses in spleen between RoNI and GI or 
RoGI. 
3.2.4.1 Comparison of the splenic IFN-y response in RoNI and RoGI. 
This was carried out exactly as above and the LN and spleen removed for culture on day 
21. The results are shown in Figure 3.7. 
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Figure 3.7. C57BL/6 mice (3/group) were treated with RoNI, RoGI or RoCC as described in 
legend to Figure 3.3. Cells prepared from pooled lymph nodes (top figure) or spleens 
(bottom figure) removed at 21 days post infection were cultured in triplicate at 5x 10'/well 
in 96-well tissue culture plates, and stimulated with SCAP (10µg/ml) and DOC-SCAP 
(5µg/ml). IFN-y was tested by ELISA using 72h supernatant. Results represent the mean 
plus SD from the three individual mice. 
The lymph node cells from both RoNI and RoGI responded as in Figure 3.4., both showing 
high and comparable levels of IFN-y production with both SCAP and DOC-SCAP. 
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The spleen cells also showed a similar pattern of response to Figure 3.5. With DOC-SCAP 
there was a generally lower IFN-y response in RoGI compared with RoNI but owing to a 
high response in one mouse there was a high standard deviation. The response to SCAP 
was again lower and as in Figure 3.5. the RoNI response was lower. The variation was less 
in this group but, with only three mice in the group, the difference did not reach 
significance (P=0.07). 
3.2.4.2 Comparison of the splenic IFN-y response in RoNI and GI. 
The data from this repeat of RoNI vs GI is shown in Figure 3.8., and this is again similar to 
Figure 3.5. except that the GI IFN-y response was lower than the RoNI in this experiment 
and this was nearly statistically significant (P=0.06). The SCAP response was as in Figure 
3.5., i. e., the GI IFN-y production lower than the RoNI, and this was statistically significant 
(P<0.006). 
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Figure 3.8 C57BL/6 mice (3/group) were treated with RoNI, GI or RoCC as described in 
legend to Figure 3.3., or NC (Normal Control mice). Cells prepared from individual 
spleens removed at 21 days post infection were cultured in triplicate at 5X105/well 
in 96- 
well tissue culture plates, and stimulated with Con A (2.5µg/ml), DOC-SCAP 
(5µg/ml) or 
SCAP (10µg/ml). IFN-y was tested by ELISA using 72h supernatant. Results represent the 
mean plus SD from the three individual mice. 
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3.2.5. In vivo experiments on the mechanism of RoNI immunity. 
The above experiments had shown that all of the attenuated infections are associated with 
induction of ThI type responses as seen by high IFN-y production in the SLN but low IL-4. 
This remains high in both drug treated infections but declines in the GI which is assumed to 
be due to the migration away by the GI. The SLN IFN-y production by highly protective 
RoNI and poorly protective RoGI could not be distinguished but responses in the spleen 
were elevated for longer indicating that the RoNI induces a Th 1 response that spreads 
systemically more effectively than in RoGI. Further experiments were aimed at trying to 
confirm that the IFN-'y responses seen were involved in protection. 
3.2.5.1 Vaccination of B6. RAG 1-/-mice shows the specific immune requirement for RoNI 
induced resistance 
RAG 1-/- mice are deficient in both T and B cell responses (Mombaerts et al., 1992) and so 
this experiment was carried out to show that the protection was fully dependent on specific 
immunological responses. 
This experiment was carried early on in the studies for this thesis when it was not clear if 
the Rol 1-3128 treatment would be given at 24hr or 40hr. It was eventually decided to go 
for 40hr but for this experiment 24hr treatment was used. 
Two groups of B6. RAG 1-/- strain (Recombinase activation gene knockout) (RAG on 
C57BL/6 background) were vaccinated with RoNI or Sham treated with Rol 1-3128 
(RoCC). They were challenged, perfused and the worm burdens are shown in Figure 3.9. 
The level of immunity in the C57BL/6 mice given RoNI (53%, P =0.001) was lower than 
when treatment was delayed until 40 hr as in the other protection experiments in this 
Chapter. This difference between protection induced by Roll -3128 treatment at either I or 
2 days post infection is consistent with previous work (Bickle & Andrews, 1985). It is clear 
that the RoNI vaccinated B6. RAG1-/- mice failed to develop any resistance, and actually 
having slightly higher worm burdens than controls although not significantly so. 
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Figure 3.9 C57BL/6 (Wild Type) or B6. RAGI-/- mice (6/group) were treated (RoNI or 
RoCC) as described in the legend to Figure 3.3. The mice were challenged with 200 
cercariae 4 weeks later and perfused 3 weeks post challenge. The bars show mean ± SEM 
worm burden. 
3.2.5.2. RoNI vaccination of IFN-'y (IFN-y KO mice). 
The above in vitro studies have implicated Th 1 responses in the immunity induced by RoNI 
by showing that there is a prolonged Thl biased response in the SLN and spleen following 
exposure. The idea that cell mediated responses are involved in RoNI protection is 
supported by the earlier demonstration (Vignali et al., 1989a) that depletion of CD4+ve 
cells at the time of challenge depletes immunity. To directly test if IFN-y is involved in 
RoNI protection, experiments were carried out in IFN-, y KO mice based on the C57BL/6 
background. In this first experiment groups of 6 male mice were used. The protection data 
is shown in Figure 3.10. 
The mean worm burdens in the control mice were nearly identical (42.0 and 42.5 for the 
WT and KO respectively) so that statistical comparison between the vaccinated mice was 
possible. The WT RoNI vaccinated mice showed 85% reduction in worm recoveries 
compared with RoCC (P< 0.0001) and the KO mice 39% (P< 0.05). So the KO mice 
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showed a 54% reduction in protection compared with the WT and the worm recoveries 
from the vaccinated mice were significantly different (P<0.01). 
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Figure 3.10 Male C57BL/6 (Wild Type) C57BL/6.12957 (IFN-y KO) mice 
(6/group) were treated (RoNI or RoCC) as described in the legend to Figure 3.3. The 
mice were challenged with 200 cercariae 6 weeks later and perfused 3 weeks post 
challenge. The bars show mean + SEM worm burden. 
3.2.5.3. Repeat of vaccination of IFN-y-/- mice 
The above experiment was repeated and because nearly all the other work in this thesis had 
used females mice these were used in this repeat experiment. The data is shown in Figure 
3.11. In this experiment there was a difference between the mean worm burdens from the 
WT and KO RoCC mice but this was not significant. The percentage protection in the WT 
RoNI compared with the WT RoCC was 93.7% (P<0.0001) and in the KO mice the 
protection was 43.8%. (P<0.01). So, very similar to the previous experiment, the 
percentage difference between WT and KO was 53%. 
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Figure 3.11 Female C57BL/6 (Wild Type) C57BL/6.12957 (IFN-'y KO) 
mice (6/group) were treated (RoNI or RoCC) as described in the legend to 
Figure 3.3. The mice were challenged with 200 cercariae 6 weeks later and 
perfused 3 weeks post challenge. The bars show mean±SEM worm burden. 
3.2.5.4. Effect of depletion of IFN-y at the time of challenge following RoNI. 
IFN-y KO mice lack IFN-y throughout the generation and effector components of the 
immune response and so in order to find out if the immune effector mechanisms which 
actually kill the challenge infection depend on IFN-y an experiment was carried out in 
which RoNI vaccinated mice were depleted of IFN-y by injection of the neutralizing anti- 
mouse IFN-y monoclonal antibody (mAb), XMG 1.6, during the challenge period only 
(day-1 to +15 relative to the challenge infection). The cell line for this antibody was a gift 
from Prof. Paul Kaye and the antibody was purified from cell culture supernatant as 
described in section 2.13. To test the in vivo effectiveness of the antibody, l mg was 
injected i. p. into each of three BALB/c mice one day before injection of virulent 
Berkholderiapseudomelliae which is normally lethal to mice in a few weeks but is rapidly 
fatal in the absence of IFN-y. This experiment was carried out in Category III conditions in 
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collaboration with Dr Debbie Smith. Two of the mice injected with the XMG 1.6 died on 
day 2 post infection and the third on day 3. Three control mice were still alive 3 weeks later 
and were then culled. This result demonstrated the potent in vivo neutralizing effect of the 
purified antibody. 
The results of the neutralization experiment in RoNI mice is shown in Figure 3.12. 
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Figure. 3.12 Two groups of C57BL/6 mice (6/group) were treated with RoNI and two 
others with RoCC, as described in the legend to Figure 3.3. On day 34,38,42,46 and 50 
post vaccination one of the RoNI and one of the RoCC groups were injected i. p with 1mg 
of purified rat anti-mouse IFN-7 mAb (XMG 1.6) (aIFN-y). The other RoNI and RoCC 
groups were similarly injected but with Img purified rat immunoglobulin (Control Ig). 
The mice were challenged with 200 cercariae on day 35 post vaccination and perfused 3 
weeks post challenge. The bars show mean + SEM worm burden 
The worm recoveries were more variable than usual in this experiment particularly in the 
RoCC treated with rat anti-IFN-y. Despite this, when compared to the respective RoCC 
controls, the percentage reduction in worm burden in the mice given the anti-IFN-7 was 
18.7% which was not statistically significant and that in the group given control rat Ig the 
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protection was 80.6% (P<0.001). So it is clear from this that IFN--y is required for the 
immune response which eliminates the challenge larvae. 
The two experiments in IFN-y KO mice showed protection reduced by 53 and 54%. The 
fact that the immunity was not reduced completely could be due to the development of 
protective Th2 responses to vaccination as a result of the absence of the Th 1 promoting 
IFN-y during the vaccination as suggested for IFN-, y receptor KO mice vaccinated with 
RoNI. The low level of protection (18.7%, NS) in the RoNI mice depleted of IFN-y at the 
time of challenge suggested that the immunity was almost exclusively dependent on CMI 
mechanisms of attrition. But in view of the residual immunity in the treated mice and the 
variability seen in the worm recoveries in this depletion experiment, experiments were 
carried out to test if antibody might contribute in any way to the protection in RoNI as was 
shown in some of the studies on single exposure to GI (Jankovic et al., 1999). 
3.2.5.5. Vaccination of B cell deficient µMT mice 
Wild type C57BL/6 and µMT mice (C57BL/6 background) were exposed to RoNI and 
challenged along with appropriate controls. The results of two experiments are shown in 
Figures 3.13 and 3.14. There were no significant differences between the worm recoveries 
from the RMT and WT RoCC mice. In both experiments high levels of protection were 
seen in the RoNI WT mice (94.3 and 96.2% in Figures 3.13 and 3.14 respectively). High 
levels of protection were also seen in the RMT RoNI mice (78.7 and 86.1% respectively). 
In both experiments this was lower than the WT mice (16.5 and 10.5% respectively in the 
two experiments) and the worm burden differences in the RoNI groups were significantly 
different in the first experiment (P=0.036) but not in the second. 
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Figure 3.13 C57BL/6 (Wild Type) and µMT (B-cell KO) mice (5/group) were 
treated (RoNI, black bars or RoCC, open bars) as described in the legend to 
Figure 3.3. The mice were challenged with 200 cercariae 6 weeks later and 
perfused 3 weeks post challenge. The bars show mean ± SD worm burden. 
Figure 3.14. 
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Figure 3.14 C57BL/6 (Wild Type) and µMT (B-cell KO) mice (6/group) 
were treated (RoNI, black bars or RoCC, open bars) as described in the 
legend to Figure 3.3. The mice were challenged with 200 cercariae 6 weeks 
later and perfused 3 weeks post challenge. The bars show mean ± SD 
worm burden. 
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3.3. Discussion 
RoNI induces very high levels of protection 
Very high levels of protection were shown to be produced by RoNI using the dose of 
200mg/kg, higher than used in earlier studies (Table 3.1). The mean percentage reduction 
from 8 experiments in this chapter is 89.9%. This was higher than the 63 and 65% 
protection seen in two GI experiments (Table 3.1). Similarly Mountford et al. (1992), 
reported a mean level of protection of 61% in 5 separate experiments using GI in the same 
C57BL/6 strain of mice. Levels of protection comparable to the RoNI (-P90%) can be 
achieved with GI but only by repeated exposure or simultaneous administration of rIL-12 
(Jankovic, et al., 1999; Wynn et al., 1995). So for a single vaccination in mice the RoNI is 
consistently more effective than any other reported vaccination regimen. Since both the GI 
and the RoNI induce high levels of protection and the RoGI poor levels of protection 
(Table 3.1) the focus of interest was to try to understand what the key features of the 
protective regimens were. 
Induction of the T cell response in the skin-draining lymph nodes (SLN): 
The importance of the SLN for the induction of protective responses in the GI was shown 
by the 70% reduction in protection by regional lymphadenectomy before vaccination with 
GI (Mountford and Wilson, 1990). So in the present studies immune responses in the SLN 
were compared in RoNI, RoGI, GI and NI. NI is considered not to be able to induce 
protection. It is not possible to formally demonstrate this as the unattenuated NI would 
proceed to develop into a huge worm and egg burden, which would kill the mice in 5-6 
weeks. However, when equally large infections with 500 unirradiated cercariae were given 
and treated with Rol 1-3128 on day 15 after which they had undergone a normal migration 
through skin and lungs the immunity seen was poor (Bickle and Andrews, 1985). This 
strongly suggests that the immune responses demonstrated following the skin and lung 
migration of normal parasites would not be protective especially compared with the RoNI 
and GI. 
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Considering cytokine production in the SLN no schistosome specific IL-4 was produced by 
any of the infected groups at either 7 and 21 days post vaccination, although there was 
some evidence of generally raised IL-4 production in all groups of infected mice as seen by 
the Con A responses in infected compared with control mice especially at day 7. Pemberton 
et at. (1991) reported some antigen specific IL-4 production with GI at day 5 but this had 
declined by 18 days. 
All of the attenuated infections (RoNI, RoGI and GI) induced highly elevated levels of 
antigen-specific IFN-y at day 7, and there was a tendency for the irradiated infections GI 
and RoGI to induce higher levels than the corresponding unirradiated infections (NI and 
RoNI). This supports the idea that irradiation can enhance/alter antigen presentation at least 
by the early schistosomula. Wales et al. (1993), for example, have suggested that irradiation 
can change the larval surface carbohydrate antigens making them more immunogenic. 
It is interesting that of the three attenuated infections, RoNI produced the lowest levels of 
IFN-'y at day 7 and in fact in one of the two experiments the NI induced comparable IFN-y 
levels at this time (Fig 3.3. ). By day 21 there was a significant change in IFN-y levels. Of 
particular note is the fact that the drug treated infections (RoNI and RoGI) showed 
markedly higher IFN-y responses than the GI and NI. The antigen specific NI response had 
disappeared and there was a substantial drop in the level of IFN-y produced by GI 
compared with day 7 which can be explained by the fact that the vast majority of the NI and 
GI larvae would have left the skin and migrated to the lungs long before day 21 (Mangold 
and Dean, 1983). IFN-'y production by GI was still substantially higher than by the NI as 
emphasized by Pemberton et al. (1991), but clearly substantially lower than either RoGI or 
RoNI. The RoGI response remained at a similar high level as at day 7 but notably the RoNI 
response was increased substantially at day 21 compared with 
day 7, so that at day 21 the 
IFN-7 levels following Con A or DOC-SCAP stimulation were higher than in any group. 
This pattern of higher IFN-y production with RoGI than RoNI at 
day 7 and the reversal at 
day 21 was consistent in both experiments and must reflect 
important differences in the 
survival/antigen presentation of these two types of protocols. 
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Do attenuated infections inhibit IL-10 in the skin/SLNs and does this result in increased 
IFN-y production? 
In both of the SLN cytokine experiments, NI induced much lower IFN-y production both to 
Con A and antigen compared with attenuated parasites at day 21. The NI responses were 
also lower than the GI and RoGI at day 7. Ramaswamy et al. (2000) has suggested that 
normal schistosomula (as in NI)produce prostaglandin E2 which results in IL- 10 production 
(Harizi et al., 2002) which in turn inhibits IL-12 production (van der Pouw Kraan et at, 
1995) and so development of Thl responses and inflammation, which may facilitate 
parasite survival. Furthermore, they suggest that the reduced capability of gamma-irradiated 
larvae (as in GI) to induce prostaglandin E2 results in lower IL-10 and so more pro- 
inflammatory IL-12. This may be true early post vaccination as Hogg et at. (2003b) also 
showed highly elevated IL-10 at day 4 in the skin of NI mice and lower although still raised 
levels in GI mice. However, by days 8 and 14, the IL-10 produced by skin was actually 
higher in the GI than the NI (Hogg et al., 2003b). So it may be true that during the skin 
migration of normal schistosomula IL-10 stimulation inhibits inflammation which may help 
parasite survival and that irradiation reduces this immunomodulation resulting in greater 
inflammation. The present studies show that by the time they reach the SLN this pattern no 
longer holds as both GI and RoGI induced higher antigen specific IL-10 than the NI in the 
SLN at day 7. It is interesting that although IL-10 is known to be anti-inflammatory (e. g. 
De Smedt et al., 1997) there was generally a positive correlation between IL-10 levels and 
IFN-y levels at day 7. Perhaps as suggested by others (Wynn et al., 1994) IL-10 rises along 
with IFN-y until it is able to terminate the IFN-y response. For the NI and GI this may be 
what happens in the SLN between day 7 and day 21 as the antigenic stimulus declines but 
for the RoNI which induces high levels of IL-10 at day 7, the IFN-y levels continue to rise 
between days 7 and 21 showing that some feature of this protocol overcomes any such IL- 
10 mediated suppression. A possible reason for the more rapid decline in IFN-y responses 
between days 7 and 21 in RoGI is that, along with the high IFN-y levels at day 7 there were 
also higher levels of IL-10, perhaps again related to higher early antigen release, which 
could result in more rapid down-modulation of the IFN-y response. 
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Normal schistosomula have also been shown to stimulate production of prostaglandin D2 
(Angeli et al, 2001) and IL-7 (Wolowczuk et al., 1997) which inhibit immune responses in 
the skin/SLN and, as suggested prostaglandin E2 above, drug-treated parasites may be less 
effective at this inhibition and so induce more inflammation and more sensitization. 
The potential immunomodulatory role of IL-10 in vaccine efficacy has been demonstrated 
for the GI. GI vaccinated IL-10-/- mice show a highly polarized Thl response and high 
levels of protection and it has been suggested that effective vaccines may need to avoid 
stimulating regulatory IL-10 (Hoffmann et al, 1999). 
What features of the parasite migration/survival may underly the pattern of cytokines? 
GI parasites have been reported to undergo slower migration away from the skin infection 
site than NI such that even at day 14 post infection there were 23% of parasites remaining 
in the skin of GI compared with 4% in the NI (Mountford et al., 1988). A proportion (10-15 
%) of both NI and GI parasites were found in SLN and again GI parasites were present for 
longer. Material released from radiolabelled parasites was found in the SLN in somewhat 
greater amounts in the GI cf NI on days 5 and 7. So it was suggested that: "The attenuated 
parasites deliver themselves to a site where antigen processing and presentation is most 
intense. Then, by releasing macromolecules over an extended period, they provide a 
continuing stimulus for lymphocyte proliferation". This idea was supported by the 
demonstration that very highly irradiated, 80krad, parasites which die before day 14 in the 
skin and do not reach the lymph nodes (Constant et al., 1990), initially induced comparable 
levels of IFN-y to the 20krad GI at day 4 post vaccination but then the levels in the 80krad 
dropped such that at day 11 the levels were ten times lower than in the 20 krad GI. Also 
there were much lower increases in cell content in the SLN (Mountford et al., 1988). So it 
is concluded that the schistosomula antigens released into the lymphatics or processed in 
the skin by DCs is less effective in sustaining the response than the protracted survival 
living parasites in the SLN. 
As discussed above both of the drug attenuation regimens, RoGI and RoNI, induce 
markedly higher IFN-y responses in the SLN than both the NI and the GI and so what is 
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known about where they reach and survive? Mountford et al (1989) carried out tracking 
studies on the RoNI infection. The larvae were clearly retained in the skin with nearly 40% 
still present at day 7 (when the NI was around 5%) and 25% still present at day 10. This 
was very similar to the numbers of GI parasites reported to be in the skin in an earlier study 
(Mountford, et al., 1988). However, there seemed to be a delay in the arrival of the RoNI 
parasites in the SLN because at day 5 post infection the GI parasites peaked at around 11% 
of the applied larvae but few RoNI larvae were found in the SLN. By day 7 however, GI 
numbers were similar and RoNI numbers had increased to around 8%. Interestingly, in the 
RoNI this number was still maintained at day 14 but had dropped to around 2% in the GI. 
Although this is comparing single experiments carried out at different times it does suggest 
that the increase in IFN-y production by SLN cells in RoNI between day 7 and day 21 to a 
level notably higher than the GI is due to persistent residence in and stimulation of the 
SLNs. 
The pattern of higher IFN-y production with RoGI than RoNI at day 7 and the reversal at 
day 21 is consistent with the larvae in RoGI dying more rapidly after infection than in RoNI 
leading to higher initial antigen production and cytokine responses but less persistent 
responses. In the above tracking studies RoGI involving treatment at 48hr [RoGI(48)] was 
not studied but a similar regimen in which treatment was given at 24hr [RoGI(24)] was 
studied. It was concluded that with the RoGI(24) the majority of parasites were dead or 
dying in the skin infection site rather than the SLN, and Mountford et al., (1988) also 
demonstrated that large quantities of antigenic material are released from dying parasites in 
the skin, bloodstream and liver of RoGI(24) mice, but negligible levels in the draining 
lymph nodes. So a similar pattern may be involved in the RoGI(48) as studied here, i. e., 
more death of the RoGI compared with the RoNI in the skin and less protracted persistence 
in the SLNs. However, this does not explain the fact that the RoGI induced the higher 
levels of IFN-y compared with NI, GI or RoNI at day 7 post vaccination and substantially 
higher levels than NI and GI at day 21. But these drug terminated infections involve more 
than just the SLN. Studies on cytokine expression in the skin following RoNI (Dr Yaobi 
Zhang - personal communication) show marked expression of pro-inflammatory 
IL-Iß 
(elevated 25 fold and 10 fold higher than GI or NI), IL-6 (elevated 5 fold compared with NI 
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or GI) and IFN-y (elevated 10 fold compared with NI or GI). Additional comparative 
studies on tracking of these larvae in the SLN and histology of the skin and SLN may give 
some explanations for these observations. 
The SLN cytokine data on RoGI is important because it shows that high and persistent 
levels of antigen specific IFN-y production by sensitised SLN cells (higher than GI) is not 
sufficient to induce high levels of protection, i. e., antigen specific SLN IFN-y production 
does not predict immunity. So what other components are involved? 
The importance of the lung in the GI model 
Following the delay in migration through the skin and SLNs a large proportion of the 
20krad schistosomula, as in GI, reach the lungs (57% of the applied larvae on day 7) and 
persist there until at least day 21 post infection (Mastin et al., 1983). Unlike the unirradiated 
infection none reach the liver (Mountford et al., 1988). Arrival of the parasites in the lungs 
induces inflammation with a 4-5 fold increase in lymphocytes, macrophages and 
eosinophils present in broncho-alveolar lavage (BAL). T lymphocyte numbers in the 
airways peak on day 21 and remain elevated for up to 10 weeks (Aitken et al., 1988). As 
judged by oxidation index (10 times normal levels) activated alveolar macrophages also 
peak at day 21 but remain in an activated state for weeks (Menson and Wilson, 1989). In 
addition to the influx of lymphocytes into the lung there was a marked increase in 
production of IL-3 and IFN--y by BAL cells T at day 21. 
That this lung migration was important in recruiting cells sensitized in the skin to the lungs 
was suggested by the fact that the 80krad irradiated infections which did not stimulate 
protection did not reach the lungs (Mountford et al., 1992) but if mice were given an 80krad 
infection and then also injected intravenously with irradiated lung stage parasites (which on 
their own do not stimulate immunity) the mice were immune (Mountford et al, 1992). So 
Coulson (1997) concludes: "It would appear that irradiated larvae must persist in both the 
(skin-draining) lymphatic tissue and lungs in order to generate an optimum immune 
response. The lung phase was considered to be important either (i) to present antigens in the 
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pulmonary tissues and/or (ii) for the inflammatory response induced by the larvae to simply 
act as a stimulus for the recruitment of reactive cells from the circulation. " 
Although the majority of the GI parasites reach and die in the lungs, Mountford et al., 
(1989) dismiss the possibility that the lungs are an important site for the induction of 
immunity based on the observations that (i) they did not find parasites or released material 
in the lung draining LNs, (ii) a significant proportion of normal (unirradiated) 
schistosomula die in the lungs but as discussed above the NI is assumed not to stimulate 
high protective responses. Also it has been shown that irradiated LS (Lung Stage) parasites 
injected into the lungs fail to stimulate significant immunity (Coulson and Mountford, 
1989). Interestingly, however, in GI the IFN-y levels in the SLN follow a decline between 
days 4 and 11 post vaccination but then there was 2.5 fold increase in IFN-y production by 
day 15 which was retained at day 20. This did not happen with the 80krad infection and it 
seems possible that this increase is associated with boosting of the immune response by 
death of the 20krad larvae in the lungs which coincides with this increase in the SLN 
response. Nevertheless, the favoured idea is that the irradiated larvae embolising in the lung 
act as a stimulus for recruiting sensitized cells. 
The crucial importance of the death of the irradiated larvae in the lungs was shown by 
experiments in which a mouse vaccinated with GI was joined in parabiotic union two days 
post vaccination to a naive mouse (Coulson and Wilson, 1997). After 28 days the mice 
were separated and then challenged. In this way the systemic response generated by the 
response in the skin and SLN would be shared by the mice but that only the vaccinated 
partner would have the irradiated larvae reaching and dying in the lungs and so recruiting 
cells to the airways. In four such experiments the mean level of protection in the vaccinated 
partner was 61% and in the non-vaccinated partner only 41%. It was assumed that the 
protection in the non-vaccinated partner arose from the stimulation of secondary responses 
prior to arrival of the challenge larvae in the lungs and when this was avoided by 
intravenous injection of challenge larvae directly into the lungs the vaccinated partners 
showed 47% immunity and the non-vaccinated partners no protection. These elegant 
experiments clearly show that in the GI the systemic response stimulated 
is only able to 
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confer around 40% protection and the physical presence of the irradiated larvae in the lungs 
is necessary to stimulate recruitment of sensitized cells to the lungs so arming them. Only 
then can high levels of protection be stimulated. 
In the vast majority of studies on this mouse model the vaccinated mice are challenged at 4- 
5 weeks post vaccination i. e., at a time when significant numbers of sensitized T cells and 
activated alveolar macrophages are persisting in the lung airways after the inflammation 
induced by the death of the irradiated larvae. The challenge larvae are eliminated 
predominantly in the lungs due to focal inflammatory reactions (Crabtree and Wilson 1986) 
which as discussed later depend on IFN-y. It is believed that the recruited schistosome- 
specific lymphocytes "pre-arms" the lung so that there is a rapid recall response (Wilson 
and Coulson, 1989). Following challenge, one study (Aitken et al, 1987) reported a 
significant rise in total leucocyte and T lymphocyte recoveries from the lungs at day 14 
post challenge, but another study showed no evidence of further cellular recruitment above 
that persisting post vaccination. However, there was an increase in the oxidation index of 
the alveolar macrophages (increased nearly three fold in vaccinated mice compared with 
control challenged mice) (Menson and Wilson, 1989). So this protection is rather different 
from recall of a resting memory cell response from secondary lymphoid organs (spleen and 
lymph nodes). 
Is the lung involved in the RoNI? 
In contrast to the GI there is strong evidence that the RoNI does not rely on this arming of 
the lung by death of attenuated larvae. Early studies using mincing and incubation 
techniques indicated that the effect of the drug on early infections was rapid. Following 
treatment of a 24-h-old infections no lung stage parasites were recovered by the lung-chop 
method 5 days post-infection and following 72 hr treatment only 8% of the number 
reaching the lungs of control animals was found (Bickle et al, 1985). Autoradiographic- 
tracking studies by Mastin et at., (1985) confirmed that 24 hr treatment prevented parasites 
reaching the lungs. However, by autoradiographic tracking Mountford et al (1989) reported 
that, in RoNI treated at 48 hr as in our studies, a significant proportion of the drug treated 
larvae also undergo a very delayed migration to the lungs following treatment with 
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175mg/kg Rol 1-3128 (peaking at 20% of the infective larvae on day 14). This compares 
with 30-35% reported to reach the lungs in the GI (Mountford et al., 1988). However, we 
do not believe that, in our current RoN1 regimen using the increased dose of 200mg/kg 
Roll-3128, there is significant lung involvement for the following reasons. Firstly, 
extensive histology of the lung has failed to find either parasites or reactions at day 14 or 21 
after RoNI in contrast to a parallel study using GI (Quentin Bickle- personal 
communication). Secondly, there was no evidence of inflammatory responses in the lungs 
at any time following RoNI, as judged by extensive studies of cytokine and chemokine 
mRNA production or presence of antigen specific or non-specific IFN-y producing cells in 
the lung tissue or in broncho-alveolar lavage during the time the schistosomula might be 
expected to reach and die in the lungs, i. e., up to day 21 (Dr Yaobi Zang, personal 
communication). This was in contrast to highly elevated responses in control animals given 
GI as reported earlier (Smythies et al, 1992a; Smythies et al, 1993). 
This data strongly suggests that the RoNI does not involve the migration and death of 
vaccinating larvae in the lungs and the inflammation this induces. But the presence of 
antigen specific Th 1 cells has been demonstrated in the lungs/ lung lymph nodes at day 35 
(Zhang - personal communication) which are believed to represent systemic spread of the 
responses stimulated in the skin as was also demonstrated in the spleen. That recruitment of 
sensitised cells to the lungs does not depend on antigen presentation there as has been 
shown for other systems e. g. following i. p. administraion of allo-antigens (Liu et al, 1982). 
Further evidence that the lung is not involved in the RoNI protection came from the 
demonstration of the double Roll-3128 treatment (on days +2 and +4). This was 
considered likely to cause even more restriction on the survival of the RoNI, and again 
histology failed to demonstrate any parasites or parasite reactions in the lungs at day 14 
post infection, in contrast to the GI (Quentin Bickle- personal communication). But this 
regimen induced even higher levels of protection than the single treatment RoNI. As this 
regimen is thought likely to truncate the larval survival even more than the single treatment 
this raises some doubts about the explanation for the lack of resistance in the RoGI being 
due to shorter persistence compared to RoNI. Further work on the survival/migration and 
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SLN immune response following the double treatment protocol would be of particular 
interest. 
Why does the RoGI fail to stimulate protection? 
It is clear from the present studies that low stimulation of the SLN does not on its own 
explain the poor protection because RoGI induced stronger and more persistent Th I 
responses in the SLN compared with the protective GI. This also shows that stimulation of 
high Th 1 cell responses in the SLN is not sufficient to lead to immunity because the RoGI 
induces only poor levels of protection. 
The major distinguishing features between the highly protective RoNI and the poorly 
protective RoGI in the above experiment were: (i) the fact that the IFN-y levels were 
highest with the RoGI at day 7 and tended to decline by day 21 whereas in the RoNI the 
levels at day 7 were lower but increased significantly to day 21 (ii) the higher IFN-y 
response in the spleen at day 21. It may be that the combination of irradiation and drug 
results in earlier death and so higher early but less persistent stimulation. The fact that the 
double treatment of RoNI at day +2 and +4 led to even higher protection than the single 
treatment raises some doubts about whether persistence itself is the key factor. It would be 
valuable to compare the persistence in the skin/SLN of the RoNI single and double 
treatment and the RoGI and also the SLN and spleen IFN-y responses. 
However, it may be too simple to just look at levels of antigen specific IFN-'y production as 
an indicator of protection. In studies on the P strain of mouse which develops poor levels 
of immunity following irradiated cercarial vaccination it was shown using spleen cells 
taken 4 weeks after vaccination and stimulated with F/T schistosomula, ConA or soluble 
SWAP that P strain mice did not make less macrophage activating IFN--y than the highly 
protective C57BL/6. But interestingly they did make nearly 3x more 
IL-10 and >2x IL-4 
than C57BL/6. Depletion studies showed that both the Th 1 (IFN-y and IL-2) and Th2- 
related (IL-4 and IL-10) cytokines were totally dependent on 
CD4+ve T cells (Oswald et 
al., 1998). It was concluded that the skewed balance of counter-regulatory cytokine 
production in P strain mice happens early post vaccination with raised IL- 10 inhibiting IL- 
12 synthesis (D'Andrea et al., 1993) and thus promoting the raised IL-4 production. So the 
determining immunological abnormality in P strain mice is the production of high IL-10 
early on in infection. It is interesting to note that this does not result in lower IFN-y and the 
deficiency in immunity is put down to the inhibitory effects of the raised IL-10 and IL-4 on 
IFN-y mediated macrophage activation. 
In the present studies, antigen specific IL-10 production by SLN cells from RoGI was 
higher than in the RoN1 at day7 post infection in both the experiments in Figure 3.3. and 
3.4. especially in Figure 3.3. But by day 21 post vaccination when the levels of IL-10 had 
dropped there was no significant difference between RoNI and RoGI IL-10 levels. As 
described for the P strain mouse above, this higher IL-10 at day 7 did not cause lower IFN- 
y responses but rather correlated with higher levels. Whether the presence of the higher IL- 
10 responses only during the early part of the RoGI results in more rapid attenuation of the 
IFN-y response or could inhibit later macrophage mediated inflammatory responses to 
challenge larvae is not known. 
Mechanisms of RoNI. 
Before these studies little was know about the mechanisms of immunity in the RoNI model. 
It had been shown that immuity in both the GI and the RoNI models could be 
ablated/reduced by treatment during the challenge phase with anti-CD4 antibody but not 
with anti-CD8 antibody (Vignali et al., 1989a). Any antibody responses would not have 
been affected by this treatment and so this strongly suggested that the effector mechanism 
of elimination of the challenge parasites was due to CD4 cytokine mediated CMI responses. 
The demonstration that IFN-y KO mice show a 53-54% reduction in immunity clearly 
shows that IFN-y plays a major role in RoNI immunity but this did not prove that IFN-y 
was involved in the protective mechanism. This was demonstrated by the 
failure of mice 
treated with neutralising mAb to IFN-y to develop specific immunity. The fact that 
immunity was not completely ablated in IFN-, y KO mice could be due to a switch towards 
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Th2 protective mechanisms as has been suggested to occur with the GI in such deficient 
mice (Wynn et al., 1994; Wilson et al., 1996; Hoffmann et al, 1999). The fact that the 
antibody deficient µMT mice (Kitamura et al, 1991) showed no defect in immunity, shows 
that antibody is not involved in this model and so the data is consistent with the high level 
of immunity in RoNI (-90%) being entirely IFN-y mediated. 
The single GI vaccine induces 60-70% immunity and a key role for IFN-y in immunity has 
also been demonstrated (Coulson, 1997; Jankovic et al., 1999) but even in the same 
C57BL/6 strain of mice two different studies differ about the relative importance of IFN-y 
and antibody. One concludes that only IFN-y is involved because neutralisation of IFN-y 
ablates immunity (Smythies et al, 1992a) but another study shows that the immunity drops 
to 40% in B cell deficient mice and that this deficiency can be replaced by serum transfer 
from WT GI mice so they conclude that both IFN-y and antibody plays a role after single 
vaccination (Jankovic et at., 1999). The reasons for the difference in these different studies 
is not certain, although different doses of radiation were used (20krad in Smythies et al., 
1992a and 50krad in Jankovic et al., 1999). Following repeated GI vaccination the levels of 
immunity increases a little (e. g. up to 85%) (Jankovic et al., 1999). B cell deficient mice do 
not show an increase in resistance following multiple vaccination but IFN-y KO mice do, 
which indicates that the increased immunity is not due to boosting of the IFN-y response 
but rather to the boosting of the antibody response and indeed sera from mice given repeat 
vaccination becomes passively protective (Mangold and Dean, 1986). 
So in conclusion, exposure to RoNI induces greater immunity than a single exposure to GI 
and equal to or greater immunity than repeated GI vaccination. This immunity seems to 
depend exclusively on IFN-y and to be generated by a high and persistent Th I response in 
the skin/SLN resulting in systemic spread of the sensitized memory/effector cells as seen 
by persistent responses in the spleen but which does not seem to require parasite induced 
inflammation in the lungs as is needed for high levels of immunity in the GI. The 
conclusion that very high levels of immunity can be induced by vaccination restricted to the 
skin focuses interest on possible ways of delivering defined antigens so as to mimic this 
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mechanism of immunity. It is interesting to note that the most effective non-living vaccine 
against S. mansoni (James et al., 1985) has important features in common with the RoNI. 
This vaccine consisted of i. d. injection of large numbers of freeze/thawed schistosomula 
plus BCG (FT/BCG) and was designed to produce CMI responses like the GI. It is of 
particular interest that the same vaccine given by different routes is far less effective than 
the i. d. route and was associated with induction of immunomodulatory cytokine, TGF-ß 
(Williams et at., 1995). The ability of the W. FT vaccine to induce significant protection 
shows that it is not vital that living parasites migrate to the SLN in order to induce 
significant protection but in this case 10,000 larvae were administered compared with the 
500 in the RoNI which also stimulated much higher levels of protection. So it would still be 
of great interest to know more about the nature of the persistence of antigen presentation in 
the skin/SLN in the RoNI and a more complete understanding of the cytokine response 
which may promote the Thl response e. g. IL-12, IL-23 and IL-27. Ultimately it may be 
possible to simulate the features of the RoNI e. g., by prime-boost vaccine strategies based 
on T cell priming with DNA vaccines or recombinant virus followed by boosting with a 
heterologous recombinant virus expressing the same antigen(s). Such strategies induce 
pronounced T cell responses and have recently been shown to induce protection against a 
number of infections including human immunodeficiency virus (Amara et at., 2001), Ebola 
virus in subhuman primates (Sullivan et at., 2000) and malaria (Bruna-Romero et al., 2001; 
Gilbert et al., 2002; Rogers et al., 2002). 
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CHAPTER 4 
IN VIVO AND IN VITRO INVESTIGATIONS INTO THE EFFECTS 
OF Rol1-3128 ON ANTIGEN PRESENTATION AND AS AN 
IMMUNOMODULATOR 
4.1. Introduction: 
Earlier studies (Bickle & Andrews, 1985; Mountford et al, 1989) and those in Chapter 3 
demonstrated that RoNI and GI are highly protective regimens. The conclusions from 
Chapter 3 were that GI can prime a response during protracted survival in the SLN 
followed by boosting of this response and attraction of effector cells to the lung by 
death of the irradiated larvae there, whereas the RoNI induced a stronger response in the 
skin which resulted in a strong systemic response. 
However, it is also clear from various studies that death of large numbers of 
schistosomula in the skin is not guaranteed to induce optimal levels of protection i. e. 
exposure of cercariae to very high doses of radiation such that they are arrested in the 
skin infection site induces poor levels of protection. For example, cercariae irradiated 
with 80krad produces similar skin retention as the RoNI but poor levels of resistance 
(Mountford et al, 1992). Also in baboons vaccinated with irradiated S. haematobium 
(Harrison et al., 1990) exposure to 60krad resulted in markedly lower protection than 
20krad. By comparison with studies on migration of irradiated S. mansoni, the majority 
of the 20krad larvae would be expected to reach the lungs (Mastin et at., 1985b) but a 
large proportion of the 60krad cercariae would be expected to die in the skin 
(Mountford et at, 1992). These observations, together with the fact that 20krad 
infections treated with Rol 1-3128 at the skin stage (RoGI) are poorly protective, 
indicate that there is something special about the immunogencity of Rol 1-3128 treated 
non-irradiated infections. 
It has also been shown that Rol 1-3128 is particularly effective compared with other 
drugs in inducing protection after treatment of skin phase infections. Pellegrino and 
Katz (1974) failed to induce immunity by therapeutically killing developing 
schistosomula with the tetrahydroquinoline compound, 
UK 3883 (Pfizer). administered 
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around the time of infection. This produced efficient killing of parasites but induced no 
resistance to a challenge. Bickle and Andrews (1985) found that Oxamniquine (Pfizer) 
administered at 24hr post infection was able to kill infecting larvae but did not induce 
resistance. However, Mastin et al. (1985a) using autoradiographic tracking showed this 
treatment did not kill the parasites in the skin but allowed them to develop at least to the 
lung stage. But later studies showed that another drug, Ro15-5458, which functioned 
similarly to Rol 1-3128 in arresting parasites in the skin was significantly less effective 
in stimulating immunity than Rol 1-3128 (Bickle et al., 1990). This again points to the 
need to understand the effects that Rol 1-3128 in particular has on the immunizing 
infections. The experiments in this chapter are concerned with investigating different 
possibilities concerning the way in which Rol 1-3128 might contribute to the high levels 
of immunity induced and they were carried out in parallel with the studies described in 
the other two chapters. 
One possibility which has been suggested is that the better protective effect of Ro 11- 
3128 compared to other drugs and very highly irradiated parasites which die in the skin, 
may result from unique effects which Rol 1-3128 has on antigen release by the early 
schistosomulum. Bickle et al. (1990) showed that in vitro the drug caused the 
production of membraneous vesicles and other exudates at the surface of the skin stage 
parasites. It was suggested that this altered antigen release may be involved in the 
induction of immunity in this model. 
The poor efficacy of Rol 1-3128 treated irradiated larvae (RoGI) in inducing immunity 
(Bickle & Andrews, 1985 and Chapter 3) seems to pose a problem for the idea that 
Rol 1-3128 is effective because of uniquely altered antigen expression by the drug- 
affected schistosomula. But it was considered possible that unirradiated parasites may 
respond differently to the effects of the drug compared with the irradiated ones. 
Perhaps, in attempting to repair the drug induced damage, normal schistosomula may 
synthesize and release antigenic material including protective antigens but irradiation- 
induced damage may interfere with such synthesis and repair mechanisms resulting in 
more rapid death or reduced production of protective antigens. Firstly the 
irradiated 
larvae may simply produce less of the released material including the membraneous 
blebs. Secondly they may fail to synthesize and release other soluble molecules 
including protective antigens. The first of these possibilities was assessed in this chapter 
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by comparing `blebbing' by normal and irradiated larvae in vitro. These studies also had 
another purpose. In the previous tests of the effects of Rol 1-3128 on schistosomula 
Bickle et al. (1990) and Smith et al. (1994) used 50% serum taken from mice given 
curative doses of Rol 1-3128 (serum-derived drug [SDD]) in order to induce parasite 
`blebbing'. In other studies in this Chapter and in Chapter 5 drug cultures were set up 
using live schistosomula, drug and responding sensitized T cells. For such cultures it 
was thought that the use of SDD was undesirable as high concentrations of mouse 
serum are not optimal for cell culture and also inconvenient to produce. So the effect of 
different concentrations of native drug on the schistosomula was investigated. 
The possibility that Rol 1-3128 is effective because it simply promotes 
production/release of protective antigens was also investigated by drug treating 
schistosomula in vitro and then vaccinating mice intradermally with the killed (by 
freezing) schistosomula and released products. 
The possibility that the Rol 1-3128 treated schistosomula were able to present antigen 
differently from non-treated larvae was tested in a different and more sensitive way by 
Smith et al., (1994). They reported that, in vitro, Roll-3128 treated schistosomula 
resulted in triggering T-cell proliferation (as measured by [3H] thymidine uptake) by 
primed T cells from the skin draining LNs of mice sensitized with crude schistosomula 
antigen plus Complete Freund's Adjuvant (CFA), in the presence of fixed macrophages 
(pre-exposed to the drug-treated parasites before fixation) than normal larvae. Since that 
time the critical key role of the dendritic cell in antigen presentation leading to the 
initiation and regulation of immune responses has been recognised (Reis e Sousa et al., 
1999). The focal and synchronised release of larval antigen occurring in the skin and/or 
in the draining lymph nodes following Rol 1-3128 treatment provides a model for 
studying the release of protective antigen and its early processing and presentation, 
notably by dendritic cells. So a series of experiments were designed to extend the 
studies of Smith et al., (1994) by using a culture system that was closer to the in vivo 
environment involving the co-culture of (i) sensitized SLN cells from mice exposed to 
the protective regimen, RoNI, (ii) living schistosomula with or without drug (iii) 
dendritic cells. 
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Since the work in Chapter 3 demonstrated the importance of Th 1 responses in RoNI 
immunity another possibility considered was that Roll-3128 can act as an 
immunostimulant or adjuvant promoting the Thl arm of the immune response to 
antigens produced by the drug arrested larvae. In the present Chapter some studies 
addressed the possibility that the early induction of Thl responses might be induced by 
the drug non-specifically enhancing the immune response. For this purpose an in vitro 
system known to generate Thl responses was used, i. e., generation of an IFN-y response 
to BCG cultured with spleen cells. In this system BCG is taken up by splenic 
macrophages or dendritic cells and this has been shown to result in production of IL- 12 
and TNF-a which act on NK cells to produce IFN-y (Bancroft, 1993). This in turn acts 
on developing Thl cells promoting production by them of IFN-y after they have been 
presented with antigen by the infected macrophages. In this system cultures were looked 
at 5 days after being set up which is time for the Thl cell response to have developed. 
So any effect that Rol 1-3128 would have on any of these early steps i. e., activation of 
macrophages, NK cells, specific T cells should be identified in this model. 
4.2 Results: 
4.2.1 In vitro effects of Roll-3128 (dissolved in DMSO) on irradiated and non- 
irradiated schistosomula. 
As was mentioned earlier, Bickle and Andrews (1985) had shown that if irradiated 
cercariae were used drug-terminated infections were significantly less protective than 
when unirradiated larvae were used. Possible explanations included that irradiated 
cercariae may respond differently to Rol 1-3128 by either producing fewer membranous 
blebs/secrete less soluble antigen, or that the combination of irradiation and drug 
treatment may either reduce the overall viability of the parasites so that they survive for 
a shorter time and so provide less antigenic stimulation or alter migration of the 
parasites thus changing the site of antigen presentation and priming. To investigate the 
first of these possibilities the effects of native Roll-3128 on production of the 
characteristic membraneous blebs by irradiated and normal schistosomula were 
compared. 
Both 20krad-irradiated and non-irradiated cercariae were transformed and cultured for 2 
days in Ml 69S to simulate the skin parasites present at the time of the 40hr treatments 
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employed in the RoNI protocols in this thesis. The larvae were then cultured for 24 
hours in M 169S containing 0-50µg/ml Rol 1-3128 (stock solutions were made in the 
organic solvent DMSO). Parasites were added at 50-70 parasites/well and percentage 
blebbing and death were assessed at 4 and 24 hours. Parasite viability was judged by 
their body shape, granularity and movement. 
As shown in Figure 4.1 . A, at 4 
hours, both irradiated and non-irradiated parasites started 
producing blebs at 0.625µg/ml and produced a high and comparable percentage of 
vesicular blebs at 1.25µg/m1-10.0µg/ml drug. Both the percentage parasites blebbing 
and the degree of blebbing were unaltered between 4 and 24 hours (Figure 4.1. B) for 
both irradiated and non-irradiated parasites. However, as can be seen from both Figures 
4.1 
.A and B parasites treated with 50µg/ml produced few blebs. 
Parasite mortality at 4 hours among non-irradiated parasites (Figure 4.1. C) reached 
100% among parasites treated with high drug concentrations from 2.5-50.0µg/ml. 
However, at 1.25µg/ml only 5% were dead. The irradiated parasites showed lower 
mortality in 2.5µg/ml but 100% mortality with higher drug concentrations. Low 
mortality occurred at low drug concentrations (0.039 -1.25µg/ml) among both irradiated 
and non-irradiated parasites. By 24 hours (Figure 4.1. D) all irradiated and non-irradiated 
parasites treated at 1.25µg/ml were dead but below this there was little effect. Control 
non-irradiated and irradiated parasites cultured in either M169S or DMSO alone were 
alive and healthy throughout the experiment. 
The observed effects of native drug on the schistosomula were comparable in irradiated 
and non-irradiated schistosomula and comparable to those seen with SDD in previous 
studies (Bickle et al., 1990) i. e., parasites produced thin-walled large vesicles which 
generally occurred first and most frequently at the anterior end of the larvae and with 
longer incubations at other points along the body. Many of the vesicles were compound, 
comprising/containing from one or two up to many smaller vesicles (multivesicular 
blebs). Some of the larvae exhibited both single and multivesicular blebs at any one 
time. Another type of exudates was produced from the posterior end of the larvae and 
was made up of small spherical, thick-walled structures, often 
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Figure 4.1. (A and B): Comparison of Rol 1-3128-induced 
blebbing by irradiated or non-irradiated schistosomula 
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Figure 4.1. A and B above, C and D below. Non-irradiated and 20krad-irradiated 
schistosomula cultured in M169S for 2 days were added at 50-70 parasites/well to 
Rol 1-3128 concentrations ranging from 0.039-50.0µg/ml. Controls consisted of 
parasites cultured in either M169S or M169S containing DMSO as 
in the wells 
containing drug. Cultures were incubated at 37°C and 5% 
CO2. Percentage blebbing 
was assessed at 4 hours (A) and 24 hours (B). Percentage 
death of Non-irradiated and 
Irradiated parasites was assessed at 4 hours (C) and 24 hours (D) (see following page). 
Results are representative of two separate experiments. Data is presented as the mean 
± SD for triplicate well observations. 
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Figure 4.1. (C and D): Comparison of Rol 1-3128-induced blebbing 
by irradiated or non-irradiated schistosomula 
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giving the appearance of a bunch of grapes. Constrictions occurred at one or more 
points along the body length, for both irradiated and non-irradiated parasites. A dose of 
1.25µg/m1 appeared to have comparable effects on morphology and viability to SDD 
(Smith et al., 1994) and so this dose was used in later studies (4.2.3.1). 
The fact that both non-irradiated and irradiated parasites behaved similarly indicated 
that the production of blebs per se is not the only requirement for the induction of 
optimal immunity by Rol 1-3128-terminated unirradiated infections and that the 
difference in protective potential of the irradiated and normal drug-treated parasites 
might relate to the antigenic composition of the material released or the length of 
survival of the parasites in RoNI and RoGI in vivo. 
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M159S DMSO 0.039 0.078 0.156 0.31 0.625 1.25 2.5 5.0 10.0 50.0 
M169S DMSO 0.039 0.078 0.156 0.31 0.625 1.25 2.5 5.0 10.0 50.0 
4.2.2 Vaccination with killed Rol1-3128-treated schistosomula 
One possible explanation for efficacy of Rol 1-3128 terminated infections relative to 
other drugs was that the drug caused damage to the parasites and that they were 
promoted to synthesize and/or release material including protective larval antigens. 
Although the above experiments showed that in vitro the drug-treated normal and 
irradiated schistosomula both produced similar amounts of blebs it is possible that the 
radiation-induced damage prevented the larvae synthesizing the same repertoire of new 
antigens compared with the unirradiated larvae. The following experiment was designed 
to simply test if injection of drug-treated parasites and their released products could 
induce protection. Three groups of 9 C57BL/6 mice were set up: Group A was 
vaccinated intradermally (i. d. ) with the drug-treated parasites; Group B were given 
RoNI and group C were control untreated mice. For the antigen preparation, 
transformed and purified schistosomula were cultured in M 169 for two days, washed 
and then cultured at 10,000 parasites/ml in 1.25 µg/ml Rol 1-3128 for two days. 
Figure 4.2 IFN--y response following vaccination with killed Rol 1-3128 treated 
schistosomula or RoNI 
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Figure 4.2 IFNy response by spleen cells of mice vaccinated by: i. d. injection of 
500 freeze/thawed, Rol 1-3128 treated schistosomula (Injected Ags); infection with 
500 cercariae followed by 200mg/kg Rol 1-3128 on day +2 (infection + Ro 11 
[RoNI]) or left untreated (Control). Day 21 spleen cells were cultured at a 
concentration of 5x 105/well and stimulated with Con A (2.5µg/ml), SCAP (10µg/ml) 
and DOC-SCAP (5µg/ml). Data for spleen cytokines were mean+SEM from 
separate cultures from 3 individual mice. 
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DOC SCA P Con A RPMI 
The whole culture was removed and frozen at -20°C. For the injection, the culture was 
thawed, diluted 1: 1 with sterile PBS and 100µl of carefully mixed suspension injected 
intradermally at two sites (i. e. 50µl/site) on the flank of the mice. 21 days post 
infection/injection three mice were sacrificed and spleen cell cultures set up. The results 
(Figure 4.2) showed that RoNI induced significant (P<0.01) IFN-'y production relative 
to the control mice, but although the mean level was also higher than the controls for the 
Antigen injected mice the difference was not significant. The mice were then bled 5 
weeks post vaccination and challenged two days later. The serum was tested for 
antibody against schistosomula antigens. The results in Figure 4.3 showed that there 
Figure 4.3: Antibody response to schistosomula antigens in serum of mice 
vaccinated with killed drug treated schistosomula or by RoNI. 
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Figure 4.3 : O. D. values from ELISA using serum from mice bled 35 
days post vaccination. Sera were tested at 1: 100 dilution. 
was a highly significant antibody response in the RoN1 group compared with the 
Controls (P<0.0001). The antigen injected mice also showed a statistically significant 
response (P<0.05) but this was low, and significantly 
lower than the RoNI response 
(P<0.001). 
At perfusion 3 weeks post challenge the worm recoveries were as shown 
in Figure 4.4. 
There was a highly significant (92.2%, P<0.0001) reduction 
in worm recovery from the 
RoNI relative to the Controls. The worm recoveries 
from the mice injected with killed 
schistosomula were very variable (1,10,13,47,53,63) with 
three mice showing low 
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SCAP DOC-SCAP 
and three higher counts. Overall, however, there was no statistically significant 
difference between this vaccinated group and the controls. 
Figure 4.4 : Worm recovery from mice vaccinated with killed drug-treated 
schistosomula or by RoNI 
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Figure 4.4 : Mean worm recovery (+SD) from vaccinated mice perfused 21 days 
post challenge of mice exposed to RoNI or vaccinated with killed schistosomula 5 
weeks before challenge. 
This simple in vivo experiment failed to demonstrate that the efficacy of Rol 1-3128 
treated parasites was simply due to production of increased protective antigens able to 
protect mice when injected intradermally. Later experiments in this Chapter were aimed 
at a more sensitive assay of antigen production, i. e., the ability of normal and drug- 
treated parasites to produce antigen in vitro which could induce a recall response in 
SLN cells from mice given RoNI. In these experiments it was planned that native drug 
was to be added to the cultures, and so it was necessary to be sure that the drug would 
not damage the SLN cells. So experiments were first planned to assess this using an 
established in vitro system. For this purpose the in vitro production of IFN-y by co- 
cultures of BCG and naive spleen cells were used (Bancroft, 1993). This system, which 
is known to promote a strong Th 1 response, was also of value to assess if Rol 1-3128, 
rather than being damaging to the immune cells, could act as an adjuvant for the 
generation of a ThI response such as develops after the RoNI (Chapter 3). 
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4.2.3 In vitro effects of Roll-3128 on BCG/spleen cell co-cultures. 
4.2.3.1 Rol 1-3128 dissolved in DMSO: 
Dimtheyl sulphoxide (DMSO) is a commonly used solvent for drugs in order to 
solubilize them for dilution in aqueous solutions, and had been found to be an effective 
solvent for Rol 1-3128 in the studies in section 4.2.1. So DMSO was used initially in 
these experiments. Naive spleen cells obtained from BALB/c mice were cultured with 
live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) (Glaxo-Wellcome- Glaxo 
strain, supplied by Evans Medical Ltd., Horsham, UK) and kindly provided by Dr D. 
Smith, LSHTM (at a Stock of 1x109/ml). Two BCG: spleen cells ratios were chosen, 
15x105 BCG: 3x105 spleen cells/well (BCG: cells 5: 1) and 30x105 BCG: 3xl05 spleen 
cells/well (BCG: cells 10: 1). Rol 1-3128 was added to cultures to give 10,5,2.5,1.25, 
0.625 and 0.31 µg/ml concentrations. This range of drug doses was chosen because it 
was based around the 1.25 µg/ml value which gave similar effects on the parasite in 
terms of blebbing and survival to those caused by serum from mice given the doses of 
Roll-3128 (200µg/ml) used to terminate infections in the RoNI system. So it was 
reasoned that this range of doses for in vitro use would include the concentration of 
drug which the immune cells of in vivo treated mice would be exposed to during the 
RoNI. In the first experiment described, the stock concentrations of Roll-3128 were 
dissolved in DMSO such that the final concentration of DMSO in the cell cultures was 
1: 1,000 (0.1%) (Figure 4.5). Culture plates were incubated at 37°C and 5%CO2. 
Supernatants were harvested at 48 hours for IL-4 detection and on day 5 for IFN-y 
detection. 
No IL-4 was produced in any of the cultures (data not shown). As for IFN-y, Figure 4.5 
showed that in the absence of the BCG stimulant no IFN-y was detected from cultures 
containing DMSO alone or Rol 1-3128. BCG did promote production of IFN-'y and 
there was a marked increase in IFN-y production with 10: 1 BCG: cells inducing twice 
the level of IFN-y compared with 5: 1. The presence of 0.1% DMSO appeared to 
markedly reduce the IFN-y production. However, the presence of 
Rol 1-3128 in the 
cultures appeared to overcome this DMSO effect 
in a dose dependent manner up to 
1.25µg/ml at which concentration the IFN-y production was comparable to the non- 
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DMSO treated cultures with both 5: 1 and 10: 1 BCG/cell ratios (NB the Rol 1-3128 
cultures all had 0.1 % DMSO in as well as drug). 
Figure 4.5 Observations on the immunomodulatory effect of Rol 1-3 12 8 dissolved 
in DMSO on cells in in vitro cultures as judo by IFN-y production 
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Figure 4.5 Naive BALB/c spleen cells were cultured with Mycobacterium bovis 
Bacillus Calmette-Guerin (BCG) in two BCG: cells ratio concentrations, 5: 1 and 10: 1 
(15x105 BCG: 3x 105 cells/well and 30x105 BCG: 3x 105 cells/well, respectively). Ro 11- 
3128 was added to cultures ranging from 0.31-10.0µg/ml. The final concentration of 
DMSO in the cultures was 0.1 %. Data were from pooled supernatants of duplicate 
wells. 
In view of this demonstration of an inhibitory effect of 0.1% DMSO this experiment 
was repeated using higher stock concentrations of Rol 1-3128 in DMSO so that the final 
concentration of DMSO was reduced to 1: 16000 (0.00625%) (Figure 4.6). As in the 
previous experiment BCG alone induced significant IFN-y production, but in this case 
the presence of 0.00625% DMSO had an enhancing effect although it did not induce 
IFN-y production from cells in the absence of BCG. Concentrations of 0.31-2.5µg/ml 
Rol 1-3128 did not significantly affect IFN-y production relative to the DMSO alone but 
concentrations of 5 and 10µg/ml had an inhibitory effect. 
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Figure 4.6 Observations on the immunomodulatory effect of Rol 1-3128 dissolved 
in DMSO on cells in in vitro cultures as judged by IFN--y production 
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Figure 4.6 Naive BALB/c spleen cells were cultured with Mycobacterium bovis 
Bacillus Calmette-Guerin (BCG) in two BCG: cells ratio concentrations, 5: 1 and 10: 1 
(15x105 BCG: 3x 105 cells/well and 30x105 BCG: 3x 105 cells/well, respectively). Ro ll- 
3128 was added to cultures ranging from 0.31-10.0µg/ml. The final concentration of 
DMSO in the cultures was 0.00625%. Data represent the mean+SD for triplicate wells. 
From these two experiments it is concluded that there is an interaction between the 
effects of DMSO and Rol 1-3128 on BCG-induced IFN-y production by spleen cells, 
which confuses the investigation of any direct immunomodulatory effect of Rol 1-3128. 
At a concentration of 0.1%, DMSO inhibits the IFN-y production and this can be 
overcome by increasing concentrations of Rol 1-3128 up to 1.25µg/ml but beyond this, 
Rol 1-3128 was itself inhibitory. In contrast DMSO at 0.00625% had a stimulatory 
effect on IFN-y production and Rol 1-3128 could not enhance this effect. 
It is concluded that the BCG/IFN-y in vitro system may be useful to investigate Ro 11- 
3128-induced effects but that alternatives to solubilising Rol 1-3128 in DMSO were 
needed. In the following experiment ethanol was tested. 
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4.2.3.2 Rol 1-3128 dissolved in Ethanol 
This was essentially a repeat of the above experiment but the mitogen Concanavalin A 
alone was used to stimulate some cultures non-specifically as a further control for any 
immunomodulatory effects of Rol 1-3128. Naive spleen cells obtained from BALB/c 
mice were cultured at 3xl 05 cells/well with either live Mycobacterium bovis Bacillus 
Calmette-Guerin (BCG) or with Concanavilin A (Con A) (Sigma, UK). BCG: Spleen 
cells were added/well at a ratio of 10: 1, and Con A was cultured at a concentration of 
5µg/ml/well. Rol 1-3128 was added to cultures to give 10,5,2.5,1.25,0.625 and 
0.31 µg/ml final concentrations in the culture wells. The stock concentrations of Ro 11- 
3128 were dissolved in absolute ethanol, such that the final concentration of ethanol per 
well was 0.0125% (1: 8000 dilution). This was based on the maximum concentration of 
drug that could be dissolved in ethanol. Culture plates were incubated at 37°C and 
5%CO2. Supernatants were harvested on day 5 for IFN-y detection. 
The results (Figure 4.7) showed that naive spleen cells were stimulated by both BCG 
10: 1 and Con A to produce high levels of IFN-y. In the absence of either stimulant no 
Figure 4.7 Observations on the immunomodulatory effect of Rol 1-3128 or 
Ethanol on cells in in vitro cultures as judged by IFN-y production. 
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Figure 4.7 Naive BALB/c spleen cells were cultured for 5 days with either 
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) at a BCG: cell ratio of 10: 1 
(3x 106BCG: 3x 105 cells/well) or Con A at a concentration of 5µg/ml. Rol 1-3128 
was added to cultures ranging from 0.31-10.0µg/ml. The final concentration of 
Ethanol in the cultures was 0.0125%. Data represents the mean ± SD for triplicate 
wells. 
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IFN-y was detected from cultures containing the different concentrations of Rol 1-3128. 
The presence of ethanol at 0.0125% did not induce IFN-y production. In BCG-treated 
spleen cells, IFN-y was produced at high levels in the presence of low drug 
concentrations (0.31µg/ml-2.5µg/ml), but this was only comparable to the levels 
induced by the control cultures containing BCG and BCG+ 0.0125% ethanol. At higher 
Rol 1-3128 concentrations, 5.0µg/ml and 10µg/ml, there was a significant reduction in 
IFN-y production. This pattern, however, was not observed with cultures stimulated 
with Con A in which Ro 11-3128 at high or low concentration had no effect, positive or 
negative, on levels of IFN-y. As can be seen from Figure 4.8. the presence of ethanol at 
this low concentration of 0.0125% did not cause the death of the cells in vitro. Spleen 
cell viability was also not affected by concentrations of Rol 1-3128 in the range 0.31 - 
5 µg/ml but there was evidence of reduced viability at 10µg/ml. 
Figure 4.8 Viability of spleen cells co-cultured in the presence of varying 
concentrations of Rol 1-3128. 
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Figure 4.8 See legend to Figure 4.7. Cell viability was assessed by removing cells 
at day 5 of co-culture and staining for viable cells by Trypan 
blue exclusion. 
It was concluded from these studies that although 
differing concentrations of DMSO 
had interesting effects on the BCG/spleen cell IFN-y production, overall there was no 
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evidence of an immunostimulatory effect of Rol 1-3128 on the spleen cell response to 
BCG. Specifically there was no evidence for immunostimulatory, inhibitory or cell 
viability effects of 0.31-2.5. tg/ml Roll-3128 delivered in 0.0125% ethanol but 
evidence of inhibitory effects at higher Rol 1-3128 concentrations. So for subsequent 
studies on the effects of Rol 1-3128 on antigen presentation by schistosomula in culture, 
Rol 1-3128 delivered in 0.0125% ethanol was employed. The experiments shown in 
Figure 4.1 were repeated using Roll-3128 dissolved in 0.0125% ethanol and similar 
levels of blebbing were seen as in Figure 4.1. 
4.2.4 Comparison of M169 and DMEM media. 
The above experiments on the effect of Rol 1-3128 on schistosomula were all carried 
out using M169 medium (Basch, 1981) which was specially developed for schistosome 
culture, but in order to study the effects of Rol 1-3128 on antigen presentation by treated 
schistosomula it was planned to co-culture the parasites with sensitized SLN cells and 
so the culture conditions needed to be suitable for both cells and parasites. Dulbecco's 
Modified Eagle's medium is one which has been used for culturing schistosomula 
(Coulson et al., 1998; James et al., 1998) and this is also recommended for mouse cell 
culture. A preliminary experiment was carried out to compare the viability and blebbing 
of schistosomula in these two media. The two concentrations of Rol 1-3128 that gave 
high percentage of blebbing for 24 hours (0.625µg/ml and 1.25µg/ml) were once more 
compared and followed over 48 hr. Levels of blebbing in M 169S were similar to 
previous studies (100% blebbing with 1.25µg/ml, 80% with 0.625µg/ml) but lower in 
the cDMEM medium (40% with 1.25µg/ml, 10% with 0.625µg/ml). However, in both 
media viability of drug treated parasites was somewhat better than in the experiments 
shown in Figure 4.1., with 100% and 50% of the schistosomula treated with 0.625µg/ml 
and 1.25µg/ml, respectively, still moving at 48hr post treatment. Schistosomula in 
control cultures without drug looked healthy over the 5 days they were observed with 
no mortality. 
Based on the various above studies, for the purposes of studying the Rol 1-3128 induced 
effects on antigen presentation by Rol 1-3128 treated schistosomula in vitro, Rol 1-3128 
was used at a final concentration of 1.25µg/ml (dissolved in 0.0125% ethanol) and co- 
cultures were set up using cDMEM. 
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4.2.5 How effective are living (normal or drug-treated) schistosomula in 
providing antigen for restimulation of sensitized T cells? 
These experiments were based on the earlier observation that Rol 1-3128 treated 
schistosomula seemed better than untreated schistosomula at presenting antigen to 
macrophages as judged by proliferation of lymph node cells from mice injected with 
crude larval antigen plus Complete Freund's Adjuvant (Smith et al., 1994). For the 
experiments described here, sensitized cells were derived from the SLN of mice 
exposed to RoNI. Initial experiments (not shown) had demonstrated that in contrast to 
soluble larval antigens (see Chapter 3) living drug-treated or normal schistosomula were 
poorly effective at inducing IFN-, y from total SLN cultures. Although the SLN 
preparation would have contained antigen presenting cells, it was decided to test the 
effects of addition of additional myeloid dendritic cells (DCs) produced by in vitro 
culture of bone marrow cells. Dendritic cells have been shown to be stimulated during 
the skin response to radiation attenuated cercariae (Hogg et al, 2003) and are likely to be 
involved in the recognition of drug-treated schistomula in the skin. Production of bm- 
DCs was also required for the studies in Chapter 5. 
4.2.5.1 Production and characterisation of in vitro generated bone marrow- 
derived dendritic cells. 
Initial experiments were set up to produce bone marrow derived-DCs (bm-DCs) and 
confirm their phenotype. The method of Lutz et al., (1999), which involved culture of 
bone-marrow leukocytes for 10 days in 10% GM-CSF (see section 2.9.3), centrifugation 
steps and changing of medium, was modified following 
discussion with Dr Jean 
Langhorne (NIMR, Mill Hill) in some of the initial experiments, where bone marrow 
leukocytes were cultured in cDMEM containing 1: 40 GM-CSF. On 
day 2,10 mis of 
fresh cDMEM containing 1: 40 GM-CSF was added to 10 ml cell cultures 
in their petri- 
dishes, and on day 4 half of the total volume of medium 
in the petri-dishes was replaced 
with fresh cDMEM/1: 40 GM-CSF by careful aspiration 
from the liquid surface as 
explained in section 2.9.3. The cultures were then 
left to develop for 6 days after which 
the non-adherent cells were collected and 
bm-DCs counted before being added to 96- 
well culture plates. 
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In vivo, immature DCs are highly efficient at capturing antigen after which they mature 
which includes upregulating various surface markers including MHC class II and they 
become efficient at antigen presentation. For use in antigen presentation experiments, it 
is important that the in vitro generated bm-DCs are immature. Because DCs can be 
readily activated even by physical manipulation (Gallucci and Matzinger, 2001) it is 
necessary to check that the majority of the cells used in subsequent experiments were 
immature bm-DCs. For this a FACScan analysis of day 6 cultures was carried out. 
Gating was carried out to include cells exhibiting CD 11 c+ and have low to moderate to 
high surface levels of MHC class II molecules which are characteristic of both 
immature and mature DC populations in such cultures (Lutz et al., 1999; Shortman & 
Liu, 2002; Ardavin et al., 2001). Visual inspection of the cultures showed the 
abundance of cells with typical DC morphology (Figure 4.9). 
Figure 4.9 Dendritic cells prepared from mouse bone-marrow cultures 
.4t: 
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Figure 4.9 Dendritic cells prepared from mouse bone-marrow cultures as 
described in Figure 4.9. were visualised under light microscopy at x400 
magnification. Note the typical irregular dendritic protrusions. 
Figure 4.10. A shows that among the day 6-old cells about 
45% of cells were CD 11 c 
high (regarded as DCs). Of these about 81 % were in the 
MHCIILow-to-medium range 
characteristic of immature DCs (Figure 4.10. 
B). 
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Figure 4.10. 
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Figure 4.10. A&B: Flow cytometric (FACScan) analysis of day 6 in vitro 
derived bone marrow-derived Dendritic cells from C57BL/6 mice. 
Bone marrow leukocytes were cultured for 6 days in cDMEM containing 1: 40 
GM-CSF. Cells were collected and stained with anti CD 1 lc-PE conjugated and 
anti -MHCII-FITC conjugated antibodies and analysed by FACS. Dot plot [A] 
shows the CD ll c+ve, MHC class Il+ve bm-DC population (shown gated). 
Histogram plot [B] shows the immature bm-DC population expressing low - 
medium MHC class II molecules (I--I ) and the mature MHC class II high 
population. About 80% of CD 1l c+ MHCII+ cells were MHC 11 
low-medium 
(Immature DCs) whereas 20% were MHC class 11 
high (Mature DCs). 
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4.2.5.2 Cytokine production from sensitized SLN cells during in vitro culture 
with living schistosomula ± Rol 1-3128 ± DCs 
C57BL/6 mice were infected and treated with 200mg/kg Rol 1-3128,40 hours post 
infection. At day 7 the Inguinal and Axillary lymph nodes of immunised and control 
(non-infected) animals were removed, and cells prepared for culturing. Loosely 
adherent day 6 immature bm-dendritic cells (bm-DCs), cultured in cDMEM/GM-CSF, 
were removed by gentle pipetting, washed once in cDMEM. Cells were cultured in 96- 
well flat-bottomed tissue culture plates by adding 2.5x 104 DCs plus 2.5x 105 lymph node 
cells per well (DC: LN 1: 10 cell ratio) (Semnani et al., 2001; Whelan et al., 2000). 
The parasites used had been transformed and then cultured for 4 days. The reason for 
choosing 4 day old parasites was that during the in vivo response to RoNI as used in 
Chapter 3, treatment was given at 2 days post infection. Treatment at earlier times (e. g. 
3hr or 24hr) led to less resistance (Bickle & Andrews, 1985) and this could be due to 
some maturation by the parasite. It was thought that any such changes would be more 
rapid in vivo than in vitro and this is why the 4 day in vitro culture was chosen. 
Parasites were divided into 2 groups, those that were cultured for 4 days in cDMEM 
containing mouse RBCs (+RBC), and those that were cultured in cDMEM only (-RBC). 
The use of RBC was again to try to mimic the in vivo situation by promoting maturation 
of the schistosomula and any associated important antigenic changes. Addition of RBC 
to cultures of schistosomula is known to be sufficient to promote development of skin 
stage schistosomula to the lung stages and beyond (Basch, 1981). Parasites that were 
cultured in RBC were washed 4 times in cDMEM to remove any adhering red blood 
cells before finally adding them to the cells in culture. Approximately 100 parasites 
from either group (P 100+RBC, P 100-RBC) were added in wells containing either 
Rol 1-3128 (1.25p g/ml) and bm-DCs (+Ro ll +DC), or in the absence of one of them (- 
Ro 11 +DCs, +Ro 11-DC) or in the absence of both (-Ro 11-DC). Those cultures without 
Rol 1-3128 contained DMSO instead, at 0.00625%. DOC-SCAP or Con A were added 
at 10µg/ml and 5µg/ml to control cultures, respectively (bm-DCs were not added to 
these). Supernatants were collected at 72 hours and IFN-y and IL-5 levels determined by 
ELISA to indicate the level of Thl or Th2 cytokine production. 
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As seen in Figure 4.11., the immune SLN cells showed a high level of IFN-y production 
following stimulation with Con A or DOC-SCAP whereas the control cells showed only 
a low level response to Con A. In contrast IL-5 production by the immune SLN cells 
was very low, lower than the naive cells. In the presence of living schistosomula 
variable levels of IFN-y was produced depending on the culture content. 
The results clearly showed that addition of bm-DCs to cultures containing 
schistosomula and sensitised LN cells strongly enhanced IFN-y production. In fact in 
this experiment no IFN-y was detected in cultures without bm-DCs whether there were 
schistosomula and/or drug present or not. Also there was no production of IFN-y from 
control cells showing that this was a recall response and not a primary effect of parasites 
on naive SLN cells (e. g. as was shown for the interaction of BCG and spleen cells in 
section 4.2.3). IFN-y production was however, dependent on the presence of 
schistosomula as no IFN-y was produced in control cultures lacking parasites. The IFN- 
y level in cultures containing drug-treated schistosomula, in the presence of bm-DCs, 
were comparable to the levels induced by Con A or DOC-SCAP. In the absence of 
Rol 1-3128 there was still enhanced cytokine production in the presence of DCs but this 
was lower than in cultures containing Rol 1-3128 (compare values with + or ++). A low 
level of IL-5 was also seen in cultures with Rol 1-3128 treated schistosomula and 
immune cells relative to control cells (Figure 4.11. ). There was evidence of slightly 
lower IFN-? production in cultures containing parasites previously cultured in the 
absence of RBCs than from those previously cultured in the presence of RBCs (Figure 
4.11. ). This was not seen with IL-5. 
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Figure 4.11.: Cytokine recall responses to living normal or Rol 1-3128 treated 
schistosomula in vitro. 
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Figure 4.11.: IFN-, y and IL-5 cytokine responses from lymph node cells co-cultured 
with additional Dendritic cells (DCs) and parasites. 
Day 7 inguinal and axillary LNs were pooled from 3 C57BL/6 mice in each group given 
RoNI or left untreated as controls. Cells were added at 2.5x 105 cells/well. Bm-DCs were 
added to some wells (±DC) at 2.5x104 DCs per well. 
±RBC: Parasites pre-cultured in cDMEM for 4 days with or without mouse red blood 
cells. ±Ro 11: in the absence or presence of Ro 11-3128 (1.25 µg/ml). 
P100: 100 mechanically transformed schistosomula per well ; PO :0 parasites per well. 
Control antigens used: Con A (5µg/ml), DOC-SCAP (10µg/m1). 
Data for IFN-y & IL-5 
were from pooled supernatants collected at 72 hours of culture. 
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4.2.5.3 Repeat of experiment 4.2.5.2 including, an attempt to define the source of 
stimulating schistosomula antigen. 
The above experiment indicated enhanced antigen presentation by living schistosomula 
in the presence of Rol 1-3128. The next experiment was set up to try to repeat these 
observations and to gain insight into the source of the antigens whose production was 
apparently enhanced by Rol 1-3128, i. e., (i) soluble released antigen or (ii) particulate 
antigen including membranous blebs. 
To investigate this, sensitized SLN cells were produced as above (7 days post RoNI). 
Mice were infected with 500 cercariae or left as controls and, were drug treated on day 
2 post-infection. Day 6 bm-DCs were cultured with LN cells at 2.5x104: 
2.5xl05cells/well, respectively. Cells were stimulated with DOC-SCAP (5µg/ml) and 
Con A (5µg/ml) in the absence or presence of bm-DCs. Parasites were cultured for 4 
days in cDMEM and mouse RBCs, washed 3x in cDMEM and added at 100 
parasites/well. In this experiment cultures were set up in triplicate in order to allow an 
estimate of the variation (standard deviation) to be calculated. 
In view of the evidence that Rol 1-3128 treated parasites gave better recall response 
than untreated larvae an attempt was made to test separate components of the drug 
treated parasites. To generate the soluble or particulate fractions, around 3000 of the day 
4 schistosomula were placed in a siliconized eppendorf tube containing 1.25µg/ml of 
Rol 1-3128 and left at 37°C and 5% CO2, for 5 hours. Small particulate material 
including membraneous blebs were separated from parasite bodies by vigorous 
pipetting, microscopic examination confirming that most blebs had 
become detached. 
The intact Rol 1-3128-treated schistosomula (RS) were then sedimented out leaving a 
supernatant containing soluble released antigen (SA) and shed particulate antigen 
including blebs (BB). This supernatant was carefully transferred into a separate tube. 
RS parasites were then resuspended in I ml of cDMEM and aliquoted 
in appropriate 
volume into culture wells (100 parasites/well). 
The SA and BB medium was centrifuged 
at 16,000 xg for 30 minutes at room temperature to 
form a pellet of BB. The SA- 
containing supernatant was carefully transferred 
into a third eppendorf tube, leaving 
behind a pellet of BB. BB pellet was resuspended in 1 ml of cDMEM and vortexed. 
The 
concentrations of SA and BB were adjusted such that material corresponding 
to culture 
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Figure 4.12. IFN-j and IL-4 production by sensitized lymph node cells co cultured 
with living schistosomula or antigens released from them by Rol 1-3128 
treatment. 
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Figure 4.12.: Day 7 inguinal and axillary lymph node cells were pooled from 3 
C57BL/6 mice and cultured at 2.5x105 cells per well, in the absence or presence of 
day 6 DCs at 2.5x104 DCs per well. Cells were stimulated with either Con A 
(5µg/ml); DOC-SCAP (5µg/ml); 4-day old living schistosomula cultured in cDMEM 
and mouse RBCs at 100 parasites/well with or without 1.25µg/ml Roll-3128 (in 
0.00625% DMSO) in culture; RS (residual parasites [after treatment with Rol 1-3128 
and removal of blebs]) (P 100/well), SA (soluble released antigens) or BB (released 
blebs). Data for IFN-? were from supernatants collected at 72 hours of culture. Data 
were mean+SD of triplicate wells. Data for IL-4 were from pooled supernatants 
collected at 24 hours of culture. (Immune = Infect+Ro 11; Control = Non- 
infect+Ro 11). 
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of 100 parasites was added to appropriate wells. Day 4 parasites which had not been 
treated were added to other wells with or without drug. All wells contained the same 
final volume. Supernatants for IL-4 and IFN-y were collected at 24 and 72hours, 
respectively, and the cytokine profile was determined by ELISA. 
The results are shown in Figure 4.12. Apart from ConA there was very little IL-4 
demonstrable with any of the antigens. In the positive control cultures the immune SLN 
cells produced high levels of IFN-y and low levels of IL-4 in response to ConA and this 
was not significantly affected by addition of bm-DC. High levels of IFN-, y were 
produced by immune cells in the presence of DOC-SCAP and addition of bm-DCs 
dramatically raised this to very high levels (P<0.001 with and without bm-DC). 
Regarding the stimulation by living schistosomula the data in Figure 4.12. is redrawn 
for clarity in Figure 4.13. This shows that living schistosomula were again shown to 
induce significant levels of IFN-y from immune cells in the presence of bm-DCs but not 
in their absence. However no statistically significant difference in IFN--y levels was seen 
between cultures with 100 schistosomula in the presence or absence of Rol 1-3128. This 
differs from the experiment in Figure 4.11. in which a marked difference was seen 
although in this case no statistical comparison was possible. 
Referring back to Figure 4.12., it is also clear that the levels of stimulation of IFN-y 
with the living schistosomula (P 100 ± Rol 1 +DC) was comparable to that seen by 
addition of RS (RS+DC), i. e., parasites that had been exposed to Rol 1-3128 and then 
washed free of any blebbing or soluble released materials. In vitro these parasites did 
not continue to produce blebs, and remained alive up to 24 hours and so this suggests 
that the particulate material including blebs released by drug treated parasites is not the 
prime stimulus for the recall response produced by 
drug treated parasites. However, 
stimulatory activity was not demonstrated using either soluble antigen 
(SA) or blebs 
(BB) removed from the drug treated parasites. 
The two experiments (Figures 4.11., 4.12. and 4.13. 
) both showed the dramatic 
difference by adding bm-DCs to the cultures, but they were not consistent regarding the 
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effects of Rol 1-3128 on SLN cell re-stimulation. So a third experiment was carried out 
to try to confirm this point. 
Figure 4.13: Selected data from Figure 5.12 redrawn to focus on the stimulation 
with living schistosomula. 
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Figure 4.13: Selected redrawn data from Figure 4.12. See 
legend to Figure 4.12. 
4.2.5.4 Further investigation of the effects of re-stimulation using living 
schistosomula with or without Rol 1-3128. 
Through experience of trying slightly modified ways of producing DCs a method was 
settled on which produced a relatively high percentage of 
immature DCs which would 
be required for antigen processing. Mature DCs in the co-culture experiments would not 
be efficient antigen processors but could influence the co-cultures 
by secreting 
cytokines. In this experiment bm-DCs were prepared 
in this way based on the 10 day 
protocol developed by Lutz et al., (1999), using 
10%GM-CSF/cDMEM and using 
minimal physical disturbance to the cells. 
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The experiment was set up as for 4.11. and 4.12. except that the schistosomula used 
were cultured for 24hr in cDMEM in the absence of mouse red blood cells since there 
was little evidence from experiment 4.11. that the RBC affected the immunogenicity. 
The other difference was that this experiment used Rol 1-3128 in 0.0125% ethanol as 
the experiment in Figure 4.7 demonstrated no significant effect of this concentration of 
ethanol on the BCG/splenocyte production of IFN-y. The results are shown in Figure 
4.14. 
Figure 4.14.: IFN-y recall responses to living normal or Rol 1-3128 treated 
schistosomula in vitro. 
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Figure 4.14: Day 7 inguinal and axillary lymph node cells were pooled from 3 
C57BL/6 mice and cultured at 2.5x 10' cells per well, in the absence or presence 
of day 10 DCs at 2.5x 104 DCs per well. Cells were stimulated with either 
Con A 
(5µg/ml); DOC-SCAP (5µg/ml); living schistosomula previously cultured in 
cDMEM for 24hr and used at 100 parasites/well with 
(P 100+Ro 11) or without 
(P100) 1.25µg/ml Rol 1-3128 (in 0.0125% ethanol) in culture. Data are from 
supernatants collected at 72 hours of culture. 
Data were mean+SD of triplicate 
wells. (Immune =lymph node cells 
from Infect+Ro 11; Control = Non- 
infect+Rol 1). Note: the bottom graph shows the same data as the top one but with the 
Con A data removed to highlight the comparison of antigen specific responses. 
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In agreement with both Figures 4.11. and 4.12., high levels of IFN-y were induced by 
Con A and DOC-SCAP was seen. Unlike experiment 4.12. there was no marked and 
significantly raised response to DOC-SCAP in the presence of DCs. The reason for this 
is not apparent as the same batch of antigen was used in both experiments. Regarding 
stimulation by schistosomula, only schistosomula in the presence of DCs and Ro 11- 
3128 treatment stimulated any response. The lack of any response in the absence of DCs 
was the same as in the other two experiments. The lack of any response with non-drug 
treated schistosomula is a similar pattern to Figure 4.11. in which the response with 
Rol 1-3128 treatment was higher with Rol 1-3128 than without. Figure 4.12. did not 
show any such difference. 
Apart from Con A no other stimulus induced significantly elevated IL-4 responses (data 
not shown). 
4.2.6 Is IL-12 crucial for the DC mediated enhancement of IFN-y production to 
living schistosomula in vitro? 
The experiments described in Figures 4.11. -4.14. show that addition of bm-DCs to 
sensitized SLN cells markedly enhanced the response induced by soluble larval antigen 
and enabled antigen from living schistosomula to stimulate IFN-y production. This 
could be due to enhanced capture and presentation of schistosomula antigen or to 
increased production of Th 1 promoting cytokines. IL-12 is such a cytokine and has been 
shown to be upregulated in the lungs during the challenge of mice vaccinated with 
irradiated cercariae (Wynn et al., 1994) i. e., during the recall response which is 
simulated in vitro in these experiments. To investigate if this DC mediated IFN-y 
production involved IL-12, neutralising antibody to IL-12 was added to the cultures. 
The experiment was carried out as for the above experiments (Figures 4.11. and 4.12. ) 
except that purified rat anti-mouse IL-12p70 mAb (C17.8 cell line, produced as 
described in section 2.13) was added to some wells (final concentration 10µg/ml). This 
concentration of anti-IL-12p70 mAb was selected from the results of a preliminary 
experiment in which production of IFN-y by spleen cells activated by in vitro incubation 
with Burkholderia pseudomellii was abolished (carried out in collaboration with Dr 
Ganjana Lertmemongkolchai, LSHTM [Data not shown]) (Lertmemongkolchai et al., 
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2001). As controls other wells had purified Rat IgG (Sigma, UK) added (at 10µg/m1) or 
were untreated. 
There was no effect of neutralising IL-12 on the very low level of IL-4 production in 
this experiment (data not shown). Again the DC dependence of the IFN-, y production 
was clear. The mean level of IFN-, y produced was slightly lower in the wells with rat 
IgG compared with untreated wells but the difference was not significant (Figure 4.15). 
With anti-IL-12p70 the mean levels were lower again, less than half the values in the 
untreated controls and also lower than in the wells with rat IgG but in both cases the 
differences were not significant. So although this indicated that IL- 12 may play a role in 
the DC mediated effects it was not totally dependent on its presence. 
Figure 4.15 Effect of neutralising IL-12 on DC function in vitro 
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Figure 4.15 IFN-y production from cultures containing day 7 inguinal and axillary 
LN cells cultured at 2.5x 105 cells/well, 100 parasites/well (P 100), 
Roll-3128 (at 
1.25µg/ml), in the absence or presence of DCs (2.4x104 cells/well), and either rat 
monoclonal anti-IL-12 immunoglobulin, rat IgG or no antibody. 
Supernatants were 
collected at 72 hours of culture and the data 
is the mean + SD of triplicate wells. 
(Immune = Infect+Ro 11 [RoNI]; Control = Non-infect+Ro 
11 [RoCC]). 
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4.3 Discussion 
Exposure of mice to Rol 1-3128 treated infection results in high levels of immunity and 
is known to arrest the vast majority of the larvae at the skin stage (Bickle & Andrews, 
1985; Mastin et al., 1985a; Mountford et al., 1989). The fact that similar treatment with 
other drugs or exposure to highly irradiated cercariae which also arrest larvae in the skin 
induce relatively poor levels of protection (Bickle & Andrews, 1985: Bickle et al., 
1990) led to investigations to try to explain why Rol 1-3128 seems to be so effective at 
inducing this immunity. Possibilities considered were (i) Production of (protective) 
membraneous material (blebs) by the drug, (ii) Non-specific adjuvant effects of Rol 1- 
3128, promoting protective Thl immune responses, (iii) Increased production/release of 
other protective antigens including soluble antigens, (iv) Sensitization of the lung due to 
migration of a proportion of the lethally damaged larvae there, and (v) Persistent antigen 
release due to protracted survival of drug damaged larvae in the skin. The work in this 
Chapter specifically addresses the first three of these possibilities. 
Production of protective membraneous material. 
It has been suggested that the efficacy of infections terminated at the skin stage with 
Rol 1-3128 on 1 or 2 days post-infection in inducing immunity may be related to the 
way in which the drug affects antigen presentation by schistosomula of this age. In vitro 
studies had shown the production of large and multiple membranous vesicles (blebs) at 
the parasite's surface, and the release of smaller vesicles and particulate matter (Bickle 
et al., 1990). More recently, by injecting schistosomula into skin pouches (Daly et al., 
1999) of drug treated mice and recovering the larvae, Dr Yaobi Zhang (personal 
communication) has shown that this blebbing also occurs in vivo. The antigenic 
composition of these blebs has been shown to be qualitatively different from that of the 
rest of the larval surface. For example, the membrane glycoprotein Sm 16, a vaccine 
candidate antigen (Bickle et al., 1986) is present in the blebs (Bickle et al., 1990) but 
Sm38 is not. Sm16 is associated with the preformed membraneous bodies (Bickle & 
Oldridge, 1999) which give rise to the schistosomular membrane (Hockley & McLaren, 
1973) suggesting that Rol 1-3128-induced blebs may originate from this membrane 
reservoir. The production of membraneous material may explain why 
Rol 1-3128- 
abbreviated infections stimulate strong antibody responses to 
larval surface antigens 
(Bickle, Sacko & Vignali, 1990). 
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Smith et al. (1994) found that in vitro Roll-3128 treatment of schistosomula co- 
cultured with macrophages led to increased cell proliferation when these macrophages 
were subsequently cultured with cells sensitized by injection of larval antigen with 
Complete Freund's adjuvant. It was further shown that this enhanced response was 
associated with the particulate matter released from the drug-treated parasites. So it was 
suggested that the membraneous blebs might be responsible. However, drug-treated 
irradiated infections (RoGI) are poorly protective (Bickle & Andrews, 1985; Mountford 
et al., 1989; Chapter 3 section 3.2.1) and so if the simple production of blebs was 
responsible alone for the optimal immunity induced by RoNI, it is necessary to suggest 
that either fewer blebs are produced by the irradiated parasites and/or that they are 
antigenically different. To test the first of these possibilities, irradiated and normal 
schistosomula were cultured with increasing concentrations of native drug. Another 
purpose of these studies was to establish the dose of native drug that induced optimal 
blebbing. Native drug was tested rather than use of 50% heat inactivated serum from 
mice treated with curative doses of Rol 1-3128 (serum-derived drug, SDD, as used by 
Smith et al., 1994) because SDD was inconvenient to produce in bulk and not suitable 
for the planned co-culture of sensitised mouse lymphocytes with schistosomula for 
assessment of released cytokines. 
There was a clear bell-shaped dose response with doses of 0.625-10µg/ml inducing 
blebbing in a high proportion of parasites but both lower and higher doses producing 
little blebbing probably because of rapid killing of the larvae at the higher 
concentrations (50µg/ml). 1.25µg/ml was selected as the best dose for use in treating 
schistosomula in vitro for co-culture experiments because it produced the maximum 
level of blebbing, similar to that reported for 50% SDD (Smith et al., 1994; Bickle et al., 
1990) but more protracted survival than higher doses. No differences were observed 
between normal and irradiated schistosomula regarding the survival or percentage of 
parasites with drug-induced morphological changes, notably production of 
blebs. So it 
appears that, assuming the drug interactions seen in vitro reflect what 
happens in vivo, 
simply inducing blebs is not adequate to induce optimal 
levels of immunity. This did 
not necessarily rule out the possible involvement of the membraneous 
blebs in RoNI 
immunity, as it was possible that there are subtle differences 
in the antigenic 
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composition of the particulate material produced/released in irradiated and normal 
infections and/or differences in the release of soluble antigens. It nevertheless remains a 
possibility that the unique Roll-3128-induced production of membraneous material 
and/or associated release of soluble antigens accounts for the high levels of antigen 
specific IFN-y production by SLN cells at day 21 post infection (Figure 3.3 and 3.4, 
Chapter 3). Further work on this possibility could compare such skin and SLN 
responses following Ro 11-3128 terminated infections and those terminated with Ro 15- 
5458 which seems to be ineffective in inducing resistance (Bickle et al., 1990). 
Further comparisons of antigen production between the normal and irradiated drug- 
treated schistosomula, e. g., by Western blotting or metabolic labelling and co- 
precipitation were not carried out here but the possibility that Roll-3128 promoted 
production/release of protective antigen from normal schistosomula was directly tested 
by a simple immunization experiment. This involved the intradermal injection of the 
equivalent of 500 schistosomula plus attached blebs and any soluble released antigens, 
and this compared with the RoNI protocol which uses 500 percutaneously applied 
larvae drug treated in vivo. It is clear that the RoNI induced marked IFN--y production 
by the spleen cells whereas the killed vaccine was largely ineffective at inducing IFN-y 
although there was some production of antibody albeit much less than with RoNI. At 
challenge there was little evidence of protection. Low worm counts in the three mice, 
given the killed vaccine did not correlate with higher antibody or IFN-, y levels and the 
reason for the low counts is unknown. In spite of this, it is clear that any short term 
induction of increased antigen release/production induced by Rol 1-3128 such as occurs 
in vitro is not sufficient to induce optimal protection, confirming the idea that the RoNI 
requires the protracted survival of the drug-treated schistosomula. 
There has been limited success in immunizing with crude dead antigens in 
schistosomiasis (Dean, 1983). The most successful series of experiments were also 
based on attempts to induce IFN-y responses following studies of the 
irradiated vaccine 
(James et al., 1984) discovered that significant protection 
(35-70% protection) could be 
induced by freeze/thawed schistosomula injected i. d. together with BCG. In addition to 
the requirement for this vaccine to be given with 
BCG it also involved injection of 
10,000 schistosomula. Any enhanced production/release of protective antigens 
by the in 
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vitro Rol 1-3128-treated 500 schistosomula which was the number used per mouse in 
the present study was obviously not sufficient to compensate for the vastly greater 
numbers of parasites or the adjuvant activity of the BCG used in the James et al. (1984) 
studies. However, one possibility which was considered was that, in vivo, Rol 1-3128 
itself may be able to act as an adjuvant for Thl mediated immune responses. 
Are there non-specific adjuvant effects of Rol 1-3128 which promote protective Th 1 
immune responses? 
A number of drugs against infectious agents are known to have immunostimulatory 
effects and for some of these, notably the intracellular organisms like Leishmania the 
therapeutic action is based on this immune activation (Croft and Coombes, 2003). The 
possibility that Rol 1-3128 might have immunostimulatory effects was investigated in 
vitro by its effects on the interaction of macrophages with BCG. This is a system that is 
known to induce a strong Thl response (Bancroft, 1993). Naive mouse spleen cells 
cultured with live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) results in 
induction of IFN-y by NK cells stimulated, in culture, by the pro-inflammatory 
cytokines (IL-12, IL-18 and TNF-a) produced from infected macrophages, early in the 
response. By 5 days the action of this IFN-y promotes IFN-, y production from antigen- 
sensitised Thl cells. So this is an assay for both the innate IFN-y response and the 
primary antigen-specific response. 
This in vitro system also provided an ideal way to test if Rol 1-3128 and/or solvents 
used in the preparation of the Rol 1-3128 stock solution, DMSO or ethanol, would have 
a damaging effect on lymphocytes in culture. This was important to determine as 
experiments had been planned to extend the work of Smith et al. (1994) by co-culture of 
living drug-treated parasites directly with sensitized cells which it was hoped would 
provide a more sensitive way of looking at Ro 11-3128 effects on antigen presentation. 
Three experiments were conducted testing the effects of a range of concentrations of 
Rol 1-3128. The stock drug had initially been dissolved in DMSO, and in the first 
experiment the final concentration of DMSO was 1: 1000 
but in the second experiment 
the concentration was lowered to 1: 16000. In both experiments the 
dominant cytokine 
produced from the BCG-stimulated cells was IFN-y. 
No IL-4 was detected in any of the 
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cultures. In both experiments, cell cultures containing BCG showed the expected 
increase in IFN-y production. The presence of 1: 1000 DMSO markedly reduced the 
IFN-y production, but the presence of Roll-3128 appeared to overcome this DMSO 
effect in a dose-dependent manner up to 1.25. ig/ml at which concentration the IFN-y 
production was comparable to the non-DMSO treated cultures. The negative effect of 
1: 1000 DMSO was overcome by reducing the concentration to 1: 16000 in a subsequent 
experiment. In fact this concentration had an enhancing effect on IFN-y production with 
higher levels of IFN-y production in cultures containing BCG/DMSO/cells than in 
cultures containing BCG/cells only. At this DMSO concentration, Rol 1-3128 had no 
significant enhancing or inhibitory effect at 0.31 -2.5 µg/ml but at 5-10µg/ml the IFN-y 
production was significantly reduced. 
From these results, two conclusions were reached: (i) within the range of concentrations 
of Rol 1-3128 from 0.31-10µg/ml there was no evidence of a stimulatory effect of 
Rol 1-3128 but at 5-10µg/ml there was an inhibitory effect. (ii) for the purposes of using 
drug-treated schistosomula as antigen sources, the use of Rol 1-3128 at 1.25 µg/ml and 
final concentrations of DMSO of 0.00625% was the optimum, producing good 
production of blebs, reasonable parasite viability but not inhibiting the splenocyte 
production of IFN-y by BCG. Because DMSO itself had either inhibitory or stimulatory 
effects on the BCG/splenocyte system depending on the concentration, ethanol was also 
used as the solvent for Rol 1-3128. A concentration of 0.0 125% had no effect on IFN-y 
production in the BCG/splenocyte cultures and using this it was also shown that 
concentrations of Rol 1-3128 from 0.31-2.5µg/ml there was no evidence of a 
stimulatory effect of Rol 1-3128 but at 5-10µg/ml there was an 
inhibitory effect. 
Interestingly non-specific stimulation with Con A was not affected by any of the drug 
concentrations, suggesting that high concentrations of 
Rol 1-3128 were having an effect 
at a different point in the pathway to induction of 
IFN-y rather than simply being 
cytotoxic to lymphocytes. 
In conclusion to these BCG/macrophage studies there was no evidence 
that Rol 1-3128 
either caused spontaneous production of 
IFN-'y in culture or promoted the generation of 
the Thl response following prolonged BCG co-culture with spleen cells. 
So there was 
no evidence that the drug has an adjuvant effect at 
least using this in Otro system. It 
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would be possible to test if the drug affected in vivo immune responses by looking at the 
response to a defined antigen or to a live antigen such as BCG but this was not followed 
up in the present studies. 
Does Rol 1-3128 promote antigen presentation to sensitized cells? 
To assess if Rol 1-3128 induces enhanced production/release of antigenic material 
(possibly including protective antigens) which is relevant to the in vivo RoNI 
immunization, a system was set up to culture living schistosomula with SLN cells from 
RoNI immunized mice and to look at the effects of addition of Rol 1-3128 on cytokine 
production. This was based on the work of Smith et al., (1994) who cultured 
schistosomula with macrophages and then used these as antigen presenting cells (APCs) 
with lymph node cells from mice given crude antigen plus Complete Freunds adjuvant. 
They reported that Rol 1-3128 enhanced proliferative responses in this system. The 
system used here was considered an improvement since RoNI sensitised LN cells were 
used directly in cultures with living schistosomula (± Rol 1-3128) together with bm- 
DCs (as APCs) and the effect of drug-treatment was assessed by production of IFN-y 
which has been implicated in protection in Chapter 3. 
Quite a lot of effort went into developing the conditions for preparation and culture of 
the schistosomula. Initially use was made of M169 (Basch, 1981) a complex medium 
capable of supporting the in vitro development of a high proportion of larvae into adult 
worms but not suitable for culture of murine cells. For co-culture of parasites with 
mouse SLN cells, however, use of DMEM throughout proved to 
be the best 
compromise; the schistosomula proved to be less healthy 
if they were initially set up in 
M169 but then transferred to DMEM when the SLN cell co-cultures were set up. In 
terms of parasite viability DMEM was superior to RPMI-1640 although 
both fine for 
mouse cells. Various methods were tested 
for production and purification of 
mechanically transformed schistosomula 
by vortex shearing (Ramalho-Pinto et al., 
1974) or needle passage (James & Taylor, 1976) of cercariae 
for breaking the cercarial 
heads from their tails; repeated orbital shaking in Petri-dishes (Basch, 1981) or 
sedimentation, or density centrifugation on 
Percoll gradients (Lazdins et al., 1982) for 
separation of larval heads and tails. Needle passage and gradient 
centrifugation proved 
the best methods in terms of purity and viability of the 
larvae and production of sterile 
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preparations. Schistosomula produced in this way, followed by 5 washes in E/LAC 
containing 300U/ml Penicillin, 300µg/ml Streptomycin and 160µg/ml gentamicin (see 
section 2.4) did not get contaminated with bacteria or fungi. In the co-culture 
experiments described, aliquots of the schistosomula were cultured alone for 1-2 weeks 
to ensure that there was no bacterial or other growth among the parasites, which might 
have been hidden in the co-cultures due to phagocytosis/ attachment by macrophages or 
bm-DCs. 
Use of such living schistosomula as sources of antigen in in vitro recall experiments has 
not been reported previously. These co-culture experiments are aimed at mimicking the 
interactions that might occur between drug treated schistosomula and DCs as antigen 
presenting cells in skin/SLN in vivo. In the Rol 1-3128 model it is supposed that the 
skin Langerhans cells (LC) would be required for antigen transfer from the skin to the 
draining lymph nodes and for the priming of the primary T-cell response at that site. 
Any Rol 1-3128 attenuated schistosomula reaching the SLNs would be expected to 
make intimate contact with SLN DCs and would boost the response primed by LC 
carrying antigen from the skin. 
Released antigen and the dying/blebbing parasites themselves would be expected to 
make contact with epidermal LC (Wang et al., 1999; Jakob et al., 2001). LCs express a 
range of myeloid markers, including Cub, stains low for CD8 and has high surface 
levels of DEC-205 (Shortman & Liu, 2002). After contact with antigen in the skin the 
LCs move to the SLNs where they express high levels of langerin a characteristic 
marker of epidermal LCs, and these are believed to be the mature 
form of the LC 
(Henri et al., 2001). One cell surface molecule that is decreased on LN LC compared to 
epidermal LC is E-cadherin (Borkowski et al., 1994) ; Schwarzenberger 
& Udey, 1995) 
which has led to the speculation that decreased E-cadherin expression may 
be one 
mechanism permitting LC to depart the epidermis. 
Upon reaching the LNs , 
LC have 
typically differentiated into cells that express higher levels of MHC II and costimulatory 
molecules like CD80, CD86 (Larsen et al., 1994; 
Kawamura & Furue, 1995), rendering 
them more effective at stimulating the proliferation of naive 
Ag-reactive T cells they 
encounter in the LN. 
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Studies on myeloid DCs are difficult because they are rare in the body tissues and 
therefore isolation procedures are time consuming and cell yields are low (Williams et 
al., 1994). In mice about 6x1 04 LCs can be isolated from the epidermis of one ear 
(Ortner et al., 1996) and about 1-10x 105 DC from one spleen or thymus (Vremec et al., 
1992; Inaba et al., 1998). However, 1-3x108 bm-DCs per mouse can be produced after 
10-12 days using mouse bone marrow cells and GM-CSF (Lutz et al., 1999). Such DC 
are now commonly used and were the ones used in these studies. 
In the co-culture experiments (Figs 4.11-4.14) the first point of interest is that addition 
of 500 parasites/ml (±Ro l 1-3128) to naive SLNs ± bm-DC did not stimulate detectable 
levels of IFN-y at least within the 3 days of culture. In similar kinds of experimental set 
up certain other organisms notably the intracellular organisms such as Trypanosoma 
cruzi (Aliberti et al., 1996) or Burkholderia pseudomallei (Lertmemongkolchai et al., 
2001) can be shown to induce IL-12 and/or IL-18 from macrophages which then 
induces IFN-y production by naive spleen cells. Thus although irradiated or drug-treated 
schistosomula clearly induce a biased Thl response characterised in the irradiated 
infection by IFN-y production within days of presentation in vivo (Hogg et al, 2003; 
Hogg et al., 2003b) it was not possible to demonstrate interactions with naive cells of 
the innate immune system leading to IFN-y production in the in vitro system studied. 
The work in Chapter 5 looks in more detail at activation markers in DC/schistosomula 
interactions. 
In the presence of immune cells, added as a sensitive readout of altered antigen 
presentation, soluble larval antigen (DOC-SCAP) could induce IFN-y production 
by the 
sensitised SLN cells alone (as in Chapter 3) although this was enhanced 
by the addition 
of bm-DCs. In contrast, the living schistosomula were unable to 
induce IFN-y 
production by SLN cells alone but the addition of 
bm-DCs did induce IFN-y production 
in some circumstances in the three experiments 
(Figures 4.11. -4.14. ). Comparing 
normal and Ro 11-3128-treated schistosomula, non-drug-treated schistosomula 
induced 
IFN-y production in the presence of bm-DCs in the 
first experiment but this was 
somewhat less than in the presence of the 
drug. In the second experiment both normal 
and drug treated schistosomula worked equally well whereas 
in a third experiment the 
drug treated parasites induced significant IFN-y production whereas the normal 
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schistosomula did not. So in two of the three experiments there was evidence that Ro 11- 
3128 treated schistosomula are better able to present antigen to DCs than non-treated 
schistosomula. 
In the experiments of Smith et al. (1994) using fixed macrophages as APCs, T cell 
activation (measured by the production of IL-3/GM-CSF i. e., stimulatory activity of T 
cells) was demonstrated using material recovered from drug-treated schistosomula and 
this effect was removed by filtration suggesting that it was the particulate material that 
was the stimulus. In the present experiments no effect on IFN-y production from RoNI 
sensitised cells using material recovered from schistosomula treated with native drug 
was observed. The most obvious difference between these experiments was the use of 
fixed macrophages in one situation and bm-DCs in the other. Banchereau et al., (2000) 
stated that DCs have the unique ability of presenting antigens to naive T cells, whereas 
macrophages and B cells can only activate primed T cells. In this regard it could be 
argued that macrophages are a more suitable cell for use in recall responses, but the 
experiments here were aimed at looking at altered antigen release by Rol 1-3128 which 
might explain enhanced priming of the immune response during RoNI, and the use of 
sensitized cells was as a read out of any altered antigen release. Other differences were 
the use of SDD by Smith et al., (1994) which may have altered the antigen production 
and the use of crude larval antigen in CFA to produce sensitized cells which is likely to 
have primed responses against many different antigens from RoNI. 
It is probable that the enhanced IFN-y production in the presence of bm-DCs is due to 
increased antigen presentation by the bm-DCs to supplement the resident APCs from 
the SLN preparations, but in theory they could also be providing stimulatory cytokines 
to presentation by other cells in the culture. IL- 12 positive DCs have been demonstrated 
in the skin of mice vaccinated with GI (Hogg et al., 2003). In a preliminary experiment 
addition of anti-IL-12p70 mAb to the cultures reduced the level of IFN-y produced but 
not to a significant extent. 
In vivo the schistosomula in the skin are presented with a much more complex set of 
cell types and immunological components. Apart 
from direct effects of the drug on the 
nature and amount of antigen released from the parasites and presented to antigen 
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specific T cells, it is possible that drug treatment could alter interactions between the 
parasite and cells of the innate immune system. Previous studies showed that the 
infective cercarial stages of S. mansoni had the capacity to produce a wide range of 
eicosanoids, including the arachidonic metabolite PGE2 (Fusco et al., 1985; Salafsky & 
Fusco, 1987). In addition, Ramaswamy et al., (2000) reported that cercariae produced 
significant quantities of PGE2 following incubation with linoleic, a free fatty acid found 
on the surface of the skin. The parasites also induced PGE2 and IL- 10 from human and 
mouse keratinocytes. The skin stage schistosomula was also reported to have same 
effect on keratinocytes, as was observed in the analysis of mouse skin. In the skin of IL- 
10-deficient mice a prominent cellular reaction occurred around the parasite, and there 
was considerable delay of the parasitic migration through the skin (Hogg et al., 2003b). 
Irradiation inhibits this induction resulting in lower IL-10 production. It is possible that 
drug treatment inhibits the anti-inflammatory strategies developed by the schistosomula. 
This might explain the strong induction of IFN-y responses in the SLN of mice exposed 
to GI and particularly to Rol 1-3128 abbreviated infections, but would not explain the 
fact that comparable responses that were induced in the SLN of both RoNI and RoGI do 
not result in comparable levels of protection (Chapter 3). 
The nature of the antigens released by the living schistosomula which stimulate the 
IFN-y production seen in vitro is not known. A number of antigens are known to be 
released from normal schistosomula both in vitro and in vivo. Membrane proteins 
labelled with iodine have been shown to be lost in vivo much more rapidly than during 
in vitro culture (Pearce et al., 1986). Antigens are also lost from the larval surface 
during in vitro culture. Some surface antigens have been shown to be 
glycosylphosphatidylinositol (GPI)-anchored to the membrane (Sauma et al., 1991). 
Molecules released from schistosomula in vitro have been shown to include antigens 
recognized by IgE from immune rats (Auriault et al., 1984), 
including a 26,000 MW 
antigen. In addition to the release from the schistosomula surface of membrane-attached 
antigens, certain enzymes with a normally cytosolic 
location have been reported to 
occur at the larval surface and have been implicated 
in protection e. g. Glutatione-S- 
transferase (GST) (Taylor et al., 1988), triose phosphate isomerase (TPI) (Ham et al., 
1992) and glyceraldehyde-3-phosphate dehydrogenase 
(Goudot-Crozel et al., 1989). 
Their apparent lack of membrane-attachment structures and, 
in the case of GST and 
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TPI, their transient appearance at the larval surface, suggests that such antigens would 
be released during in vitro culture. It is likely that a large number of antigens released 
by living schistosomula are able to stimulate IFN-y production by RoNI SLN cells, but 
as candidate vaccine larval antigens are identified by proteomic or genomic approaches 
and become available by recombinant DNA techniques their ability to induce strong 
IFN-y production by such cells would give strong support to their possible protective 
potential and use in a vaccine to mimic the attenuated larval vaccines (James et al., 1986 
Coulson, 1997; Chapter 3). 
In conclusion, the results in this Chapter show that the normal and 20krad 
schistosomula have comparable levels of production of membraneous blebs in response 
to Rol 1-3128 in vitro indicating that this altered antigen presentation itself is not solely 
responsible for inducing high levels of immunity. This was further demonstrated by the 
failure to induce protection by i. d. injection of drug treated freeze/thawed parasites. The 
conclusion reached in Chapter 3 was that the particular efficacy of RoNI compared with 
RoGI relates to greater persistence of the antigenic stimulus possibly due to greater 
longevity of the non-irradiated parasites. It would be very interesting if this could be 
confirmed and also the morphological state of the parasites e. g. do the drug treated 
schistosomula reported in the SLN show persistent production of membraneous blebs? 
Addition of Rol 1-3128 to an in vitro culture system in which BCG activates spleen cell 
cultures and which involves macrophage, NK cell and Th 1 cell activation leading to 
IFN-, y production failed to show enhancement of these effects which did not support the 
idea that adjuvant activity accounts for the high levels of Thl cell stimulation in the 
SLN of both RoNI and RoGI. However, there are many other points in generation of an 
immune response that were not represented in this culture system and direct testing in 
vivo, for example the response to BCG could be of interest. The 
development of the co- 
culture protocol for use with immune cells, DC and live schistosomula showed the 
enhancing effects of adding bm-DCs to the culture and this prompted studies 
into 
effects of schistosomula on bm-DC maturation (Chapter 
5). Schistosomula, with or 
without Rol 1-3128 did not induce production of IFN-y 
from cultures of naive SLN cells 
with or without bm-DC, unlike certain other organisms which 
induce Thl responses, 
which fails to demonstrate a Thl priming signal 
from the living larvae. However. using 
recall responses by RoNI-sensitized SLN cells there was evidence 
that the drug 
154 
treatment can enhance antigen presentation and this could contribute to the high levels 
of Thl responsiveness seen in the SLNs of both RoNI and RoGI mice. To further 
investigate this possibility further comparisons could be made of the SLN responses to 
infections terminated with Rol 1-3128 or Rol 5-5458 which kills larvae in the skin but 
does not induce the obvious morphological changes to the membrane and does not 
induce immunity. 
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CHAPTER 5 
IN VITRO INTERACTIONS OF S. MANSONI SCHISTOSOMULA 
WITH BONE-MARROW DERIVED DENDRITIC CELLS 
5.1. Introduction: 
The studies in Chapter 3 had shown that a Thl biased response (IFN-y » IL-4) was 
induced in mice following exposure to large numbers of larvae whether or not they 
were attenuated (y-irradiation or the drug, Roll-3128) although the attenuated 
infections induced markedly higher IFN--y responses in the SLN and spleen. This is 
consistent with the earlier demonstration of a Thl cytokine response during the 
prepatent period of S. mansoni infection even with low numbers of larvae (Pearce et 
al., 1991) and the demonstration of a skewed Thl response in the SLNs 18-23 days 
following irradiated infections (Pemberton et al, 1991). 
In Chaper 4 the idea that enhanced antigen production/release caused by the effects of 
Rol 1-3128 on the larvae might underlie the high efficacy of the drug in inducing 
immunity led to in vitro studies in which normal or drug-treated schistosomula were 
used to re-stimulate cytokine responses from sensitized T cells. These studies showed 
that when SLN cells from mice exposed to RoNI were co-cultured with schistosomula, 
IFN-, y production could only be detected when bm-DC were added to the cultures. It is 
believed that the antigen release caused by Rol 1-3128 may facilitate antigen loading 
of DC, and/or stimulate their functional differentiation in a manner which facilitates 
protective immunity. No previous experiments have been reported on the effects of 
schistosomula on DC function but, using in vivo-activated peritoneal adherent cells as 
APC Smith et al. (1994) previously showed that treatment of schistosomula in vitro 
with Rol 1-3128 results in enhanced antigen presentation 
during co-culture of the fixed 
cells with T cells from S. mansoni antigen sensitized mice. 
Furthermore, in these 
experiments the blebs and other antigens released by Rol 
1-3128-treatment could be 
separated from the otherwise intact schistosomula and also caused enhanced 
APC 
induced IL-3/GM-CSF production from sensitized T cells. Most of this APC activity 
was induced by the particulate fraction as shown 
by its removal by filtration. In this 
paper nothing was reported on studies about 
if and how the macrophages were 
activated. 
156 
The studies in this Chapter were initiated to extend these observations using DC, 
which are now known to play the central role in antigen presentation (Kelsall et al., 
2002). Encounter of immature myeloid-derived DC with microbial antigens in 
peripheral tissues is believed to have two main consequences. The engagement of 
`pattern recognition' receptors (PPR) on DCs initiates the process of maturation which 
include alteration in cell surface phenotype (e. g., CD80, CD86, CD40 expression) and 
of sub-cellular MHC class II trafficking. The latter facilitates interaction with 
microbial antigens, and stabilises newly formed MHC-peptide complexes at the 
plasma-membrane for subsequent presentation (Pierre et al., 1997; Cella et al., 1997). 
In addition, maturation is accompanied (and may be facilitated) by DC migration to the 
T-cell zones of secondary lymphoid organs (Pierre et al., 1997; Randolph et al., 1998). 
Here they encounter naive T cells and are responsible for primary T cell activation 
(Ingulli et al., 1997). DCs are also responsible for directing Th cell development along 
the Th 1 and Th2 pathways. There has been increasing evidence that the local 
conditions of DC maturation, such as prostaglandin E2 may downregulate the capacity 
to produce IL-12, so biasing towards Th2 development (De Smedt et al., 1997; Vieira 
et al., 1998). Identification of microbial characteristics which may modulate DC into 
cells capable of biasing such differentiation of T cells is critical to understanding the 
host's immunity. 
Two major DC subsets that differ in both CD8 expression and localization in different 
regions of the lymphoid organs have been reported to have different functions in the 
induction of T cell responses (Vremec et al., 1992; Pulendran et al., 1997). CD8a+ DC 
have been suggested to be specialized for promoting Th1 responses and CD8a- for Th2 
responses (Maldonado-Lopez et al., 1999; Pulendran et al., 1999), however, 
subsequent studies have shown that distinct DC subsets are able to promote either type 
of response depending upon pathogen-derived signals and host-derived cytokines 
present in the microenvironment (Vieria et al., 2000; De Smedt et al., 2001; 
MacDonald et al., 2001: Maldonado-Lopez et al., 2001). 
In vivo studies of the GI model have indicated that IL-12 
is an important cytokine in 
induction of the IFN-y mediated immunity (Wynn et al., 1996; Anderson et al., 
1998). 
Hogg et al. (2003) have reported finding CD 11 c+ve DC within the 
inflammatory site 
induced in the skin post infection and shown persistent IL-12 production 
in the skin 
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following GI as compared with unattenuated infections. They suggest that the majority 
of the IL-12+ve cells trafficking from cultured isolated skin sections following GI are 
myeloid DCs perhaps migrating Langerhans cells although macrophages were also 
represented. In the RoNI model, immuno-histochemical analysis, in collaboration with 
Dr Chris Engwerda, showed that IL-12+ve cells with DC morphology can be found in 
the SLNs 6 days following infection. In Figure 5.1. such cells are seen in close 
juxtaposition to a drug-treated larva within the draining lymph node. 
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Figure 5.1 Photomicrograph showing IL-12p40+ve, putative dendritic cells (DCs) 
adjacent to a schistosomulum (S) in the draining popliteal lymph node 6 days 
following RoNI (Courtesy of Chris Engwerda and Quentin Bickle). 
The studies in this Chapter were initiated to investigate the interaction of bm-DCs, 
which are of myeloid origin, with living normal, drug-treated and/or irradiated 
schistosomula in vitro to see if such DCs can be activated towards a typical Thl- 
promoting phenotype. 
5.2. Results: 
Activation of DCs is associated with upregulation of a number of surface markers 
including MHCII and the costimulatory molecules CD86 and CD40 (Banchereau et al., 
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2000) and these were used to assess activation in these studies. Figure 5.2 shows the 
population of cultured bone marrow cells gated for the FACS staining. The CD 11 c+ve 
cells in this population were deemed bm-DCs and gated on for analysis of MHCII and 
CD86/40 expression. The negative staining using the isotype controls is also shown. 
Examples of positive staining FACS for MHCII and CD86 are shown later in Figure 
5.12. 
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Figure 5.2: Flow cytometry settings gated on the population of bm-DCs. The above 
settings were used to gate on day 10 bone-marrow derived DCs. A shows the R1 
population which according to SSC (size of the cells) vs FSC (granularity of the cells) 
indicates a population where the majority of the cells are bm-DCs. B shows a dot plot of 
the isotype controls for MHCII and CD86. C shows that 51% of the R1 gated population 
in A were CDI Ic+ i. e., bm-DCs (gated as R2). Combining the gates R1+R2 represents 
the cells that according to size, granularity and CD 11 c expression are considered bm- 
DCs. 
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5.2.1 Effect of soluble antigens released from the skin stage larvae on the 
maturation of bone-marrow derived DCs: 
The work in Chapter 4 had shown that bm-DC could enhance stimulation of sensitized 
cells by the soluble crude antigens SCAP and DOC-SCAP. So initial experiments in 
this Chapter were set up to see if soluble larval preparations would induce maturation 
in bm-DCs. The first type of antigen used was a soluble preparation of whole cercariae 
(SCA) similar to the SCAP used in other parts of this thesis (see section 2.5). The 
second antigen was a preparation of molecules released by the parasite at the onset of 
infection, called cercarial transformation fluid (CTF) which consists of the material in 
which cercariae are mechanically transformed to schistosomula and then cultured for 3 
hrs. So this contains penetration cercarial enzymes, remnants of the cercarial 
glycocalyx and other antigens. Both of these were kind gifts from Prof. Mike Doenhoff 
(Bangor University). 
5.2.1.1 Effect of CTF antigens on bm-DCs. 
CTF was filter sterilized and added at 1,5,25 and 125µg/ml (stock = lmg/ml) to a 
final volume of 1 ml/well containing 5x l 05 DCs, in 24-well culture plates. These were 
incubated for 22 hours at 37°C and 5% CO2, after which bm-DCs were carefully 
collected from the wells and stained for CDIIc, MHCII and CD86 surface markers. 
Cells which were CD I1c +ve, CD86 and Class II high (see Figure 5.3. ) are referred to 
as "Mature" in this Chapter. LPS was included as a positive control. 
The naive bm-DCs showed 36% mature DCs and this was unaffected 
by the addition 
of 1µg/ml CTF but with higher concentrations there was a 
dose-dependent increase in 
mature cells with 73% becoming activated 
by the highest concentration of CTF 
(125µg/ml). LPS (1µg/ml) induced the highest % maturation among DCs of 91%. 
160 
Figure 5.3 
100 
90 
80 
r 70 
a, 
60 
V 
50 
40 
C, 30 
= 20 
10 
Co 0 
pg/ml CTF 
Figure 5.3 Cercarial Transformation fluid (CTF) was added at 1,5,25, and 125µg/ml 
to 5x105 immature day 10 bm-DCs. For positive control, bm-DC cultures were 
stimulated with 1µg/ml LPS. Cultures were left incubating for 22 hours. Cells were 
stained for CD 11 c, MHCII and CD86. Data represents the percentage of CD 1l c+ cells 
that were CD86, MHCII high. Data were from single well observations. 
5.2.1.2 Comparison of the activation of bm-DCs by whole cercarial antigen (SCA) and 
secreted antigens (CTF). 
The effect of whole cercarial antigen, SCA, was then tested and compared to CTF. 
SCA was added at the same protein concentrations as the CTF in the first experiment 
i. e. 1,25,125µg/ml (stock =4.9mg/ml). These cultures were incubated for 20 hours at 
37°C and 5% CO2, and the cells were then carefully removed and stained as above. 
The results are shown in Figure 5.4. A high percentage (56%) of the immature bm- 
DCs were activated in the medium control and the LPS made little difference to this 
but the highest percentage maturation was among bm-DCs stimulated with both SCA 
and CTF at 125µg/ml (76% and 79%, respectively). 
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Figure 5.4 Soluble cercarial antigen (SCA) and Cercarial Transformation Fluid 
(CTF) were added at 1,25 and 125µg/ml to 5x105 immature day 10 bm-DCs. For 
positive control cultures bm-DCs were stimulated with LPS (1µg/ml). Cultures were 
left incubating for 20 hours after which the cells were carefully removed and stained 
for CD 11 c, MHCII and CD86. Data represents the percentage of CD 11 c+ cells that 
were CD86, MHCII high. Data were from single well observations. 
This suggested that the cercariae contain/release antigens that are taken up by bm-DCs 
and induce their maturation, but the possibility that the preparations might be 
contaminated with endotoxin derived from contamination of the preparations with 
bacteria from the snail water into which the cercariae were shed was considered and an 
experiment was set up to test this. 
5.2.1.3 Do parasites and parasite-specific antigens (CTF, SCA) stimulate DCs in the 
absence of TLR-4 signalling? 
C3H/OuJ mice possess the gene for LPS responsiveness whereas C3H/HeJ mice have 
a null mutation in the gene encoding for the Toll-like receptor 4 (TLR-4), which is 
involved in recognition of, and signal transduction from, the LPS receptor complex. 
This means these mice do not develop rapid inflammatory responses to LPS (Hopkins 
et al., 1996). 
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In this experiment, bone marrow leukocytes from female C3H/HeJ and C3H/OuJ mice 
were cultured in the usual way and then cultured with 50,100 or 1000 
schistosomula/well or with CTF and SCA at 1,5,25 and 5,15 and 50 µg/ml 
respectively. Cultures were incubated for about 20 hours at 37°C and 5% CO2. after 
which the cells and parasites were separated and all cells were stained for CD I1c. 
MHCII and CD86. The results are shown in Figure 5.5. 
For reasons that are not apparent the naive cells in this experiment showed a very low 
level of spontaneous maturation. However, compared to medium alone SCA induced a 
clear dose response in bm-DC maturation of normal LPS responder cells (C3H/OuJ 
mice). A similar response was seen with C3H/HeJ cells but this was much lower in 
terms of percentage maturation (14% compared with 58% for the responder cells). 
CTF antigen, on the other hand, induced some maturation of the C3H/OuJ (Normal 
LPS-responder) cells but no maturation of the non-responder cells. As for 
schistosomula, these did not induce any significant bm-DC maturation of either -ve or 
+ve LPS responder cells. These results suggested that there was endotoxin 
contamination in the CTF and SCA preparations. Independent testing of these 
(European endotoxin testing service, Biowhittaker, Inc) showed that the CTF and the 
SCA had respectively 11.4 and 5.3 EU/ml of endotoxin (IEU=100pg) and it is 
probable that this contributed significantly to the activation seen. (NB. This 
experiment was carried out using a different preparation of SCAP from the one used in 
the rest of the thesis which was prepared at LSHTM. This was also tested and found to 
have 0.05 EU/ml a value considered acceptable for the restimulation studies). 
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Figure 5.5 
Figure 5.5 
(A) Stimulation of C3H/OuJ (Normal LPS-responders) bm-DCs. 
(B) Stimulation of C3H/HeJ (LPS-non-responders) bm-DCs. 
Live and transformed schistosomula (50,100,1000P/ml) and the antigens CTF and SCA 
were added to 5x 105 immature day 10 bm-DCs/well. For positive control, bm-DC 
cultures were stimulated with 1 µg/ml LPS. Cultures were left incubating for 20 hours, 
after which cells were collected and stained for CD 11 c, MHCII and CD86. Data 
represents the percentage of CD 11 c+ cells that were CD86, MHCII high. Observations 
were from single wells. [N. D. =Not Done]. 
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The main value of these studies on CTF and SCA was that they allowed experience 
with the FACS techniques but also this experiment was also the first one with living 
schistosomula and DCs and the failure to demonstrate DC activation in either the 
responder or non-responder cells showed that LPS contamination in these live parasite 
preparations was not a problem. Further work on CTF and SCA was not continued as 
interest was focussed on the use of living schistosomula because this allowed the 
effects of Rol 1-3128 to be assessed. Although this first experiment showed little signs 
of DC maturation by living schistosomula this needed confirmation and further 
investigation. 
5.2.2 Studies on the ability of Drug-treated and/or Irradiated parasites to affect 
bm-DC maturation as judged by upregulation of surface markers. 
From the results shown in Chapter 4 (Figures 4.1 A&B), it was clear that Rol 1-1328 
induced comparable blebbing from both irradiated and non-irradiated schistosomula, 
and there was no difference in the overall viability of the parasites. Also the results in 
Chapter 3 indicate that there is a strong induction of Th 1 responsiveness in both RoGI 
and RoNI at least in the short term post-vaccination indicating that early events such as 
activation of skin DCs are unlikely to explain the difference between the two models. 
However, these results were not available at the start of the studies described here. So 
in the experiment described below both normal and irradiated parasites were cultured 
with bm-DCs with or without Ro 11-3128. 
5.2.2.1 Co-culture of bm-DCs with 50,100 or 1000 schistosomula/ml. 
Cercariae were irradiated, as described in section 2.3, at an optimum 
dose of 20krad. 
Then both irradiated and non-irradiated cercariae were transformed and schistosomula 
were added at 50,100 and 1000P/ml/well. Bm-DCs were cultured at 
5x105cells/well 
together with either non-irradiated parasites + Rol 1-3128, or 
irradiated parasites+ 
Rol 1-3128. Control cultures received either no stimulation + Rol 1-3128 or were 
stimulated with LPS at 1µg/ml. After 22 
hours bm-DCs were separated from parasites 
and stained for CD 11 c, MHCII and CD86. 
Photomicrographs showing the appearance 
of the types of cultures used throughout this 
Chapter are shown in Figure 5.6. The 
experiment shown is one in which 10,000 parasites/well were used. 
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Figure 5.6. Photomicrographs of culture of MS and bmDC. The well shown is of a 
culture containing 10,000 MS treated with Rol 1-3128. 
The top picture shows the 
clustering of the parasites at the centre of the flat 
bottomed well of the 24 well plate. 
Blebbing parasites (S) and DCs can be seen in the 
bottom picture. 
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The results of the DC surface marker expression are shown in Figure 5.7. 
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Figure. 5.7 Irradiated and non-irradiated schistosomula (50,100,1000P/ml) were added to 
5x l O5/well immature day 10 bm-DCs from C57BL/6 mice. Rol 1-3128, dissolved in 
0.0125% ethanol, was added to the appropriate wells at 1.25µg/ml/well. Cultures were left 
for 22 hours, after which cells were collected and stained for CD 11 c, MHCII and CD86. 
Data represents the percentage of CD 11 c+ cells that were CD86, MHCII high. Observations 
were from duplicate wells. (Total events [i. e. No. of cells counted by FACScalibur 
=25,000]). P=non-irradiated schistosomula, Irr. P=Irradiated schistosomula. [N. D. =Not Done]. 
The naive DC population showed around 35-38% activation but increasing numbers 
(50-1000P/ml) of normal or irradiated parasites did not induce noticeably enhanced 
DC maturation as assessed by upregulation of MHCII and CD86 (compared to 
controls with LPS, maturation was 78%). Neither did drug treatment lead to 
upregulation. 
5.2.3 Can priming of DCs with LPS or TNF-a reveal a secondary maturation 
signal from co-cultured MS as judged by upregulation of surface markers? 
It was observed from the above results that up to 1000 parasites/ml (whether normal, 
irradiated or drug-treated) had no effect on activating bm-DCs. Possibilities considered 
were: that the schistosomula might simply not have the ability to 
directly activate DCs; 
that they secrete products (e. g., enzymes, etc. ) that inhibit DC maturation; or that a 
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secondary signal may be required for activation e. g., host derived cytokines produced 
by other cells of the innate immune system. The possibility that schistosomula may be 
able to further activate DCs which are already primed by an additional signal was 
tested below. Various studies on the activation potential of infectious organisms have 
used LPS to provide partial activation of DCs (e. g., Van Overtvelt et al, 1999; Urban et 
al., 1999). 
5.2.3.1 Effect of co-culture with 400 schistosomula on bm-DC also activated with 
TNF-a or LPS. 
In this experiment two priming signals were used: one, an activating cytokine TNF- a 
and the other, a microbial ligand, LPS. Four concentrations of recombinant murine 
TNF-a (rMu-TNF-a) were tested, 0.5,5,50 and 500U/ml, and LPS was also added at 
three different concentrations, 0.01,0.1 and 1 µg/ml. Cultures were incubated for 16 
hours at 37°C and 5% CO2, after which bm-DCs were collected and stained for 
CD 11 c/MHCII/CD86. The results are shown in Figure 5.8. 
Bm-DCs showed increasing percentage maturation with increasing concentration of 
TNF-a (0.5,5,50,500U/ml). Adding parasites to such cultures neither reduced nor 
enhanced the levels of DC activation. The same pattern was observed when parasites 
were cultured with increasing concentrations of LPS (0.01,0.1 and 
1µg/ml, ). So there 
was no evidence that 400 schistosomula/ml could (i) provide an activation signal to 
primed DCs or (ii) inhibit LPS or TNF-a induced DC maturation. 
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Figure 5.8. (A & B). Live schistosomula (400/ml) were added to 5x105 cells/well of 
day 10 immature bm-DCs from C57BL/6 mice. (A) LPS was added to these cultures at 
0.01,0.1 and 1µg/ml and (B) TNF-a added at 0.5,5,50 and 500U/ml. Cultures were 
left incubating for 16 hours, after which they were collected and stained for CD 11 c 
MHCII and CD86. Open bars are DC alone and shaded bars DC plus 400 MS/ml. 
Observations were from single wells. 
5.2.3.2 Effect of increasing parasite numbers to 1000/ml on the maturation of TNF-a- 
stimulated bm-DCs as judged by MHCII/CD86/CD40 upregulation. 
In the last experiment 400 schistosomula/ml did not affect TNF-u- nor LPS-stimulated 
bm-DC maturation. Therefore, in this experiment parasite numbers were increased to 
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0 0.5 5 50 500 
I 000/ml, to try and see if this would increase bm-DC maturation in the presence of 
TNF-a stimulant. TNF-a was added to cells and parasites at 0.5, or 5, or 50 U/ml. 
After 20 hours of incubation at 37°C and 5% CO2 bm-DCs were stained for CDl lc, 
MHCII, CD86, and another costimulatory surface molecule CD40. The results are 
shown in Figure 5.9. 
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Figure 5.9. Schistosomula (1000 P/ml) were added to 5x105cells/well of day 10 immature 
bm-DCs from C57BL/6 mice. TNF-a was added at 0.5,5,50 U/ml. Cultures were left 
incubating for 20 hours, after which bm-DCs were collected and stained for (A) CD 11 c, 
MHCII and CD86, or (B) CD 11 c, MHCII and CD40. Observations were from single 
wells. Final volume/well was I ml. 
As judged by CD86/MHCII upregulation the pattern was like that seen before (Figure 
5.8. B) i. e., there was a dose response in activation by TNF-a 
but addition of the 
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parasites did not increase this although there was some indication of enhanced 
expression with schistosomula in the medium alone. However there was no evidence 
of activation by the parasites alone as judged by CD40 expression (Figure 5.9. B). As 
with CD86, expression of CD40 showed a dose response with increasing TNF-a. 
Addition of parasites did not enhance this expression and there was some indication at 
lower TNF-a concentrations that the parasites inhibited the expression, although at 
high TNF-a concentrations there was no evidence of inhibition. 
5.2.3.3 Does increasing the numbers of parasites to 2500/ml and/or adding Rol 1-3128 
affect bm-DCs maturation with or without TNF-a priming 
Since no response was seen with 1000 live schistosomula experiments were set up to 
add even more parasites to the cultures and to see if Rol 1-3128-induced blebbing/ 
killing was able to increase the DC maturation in the presence or absence of TNF-a- 
stimulation. This time the final volume of medium in the wells was reduced to 
400µ1/well in order to increase the contact between the cells and parasites. Immature 
day 10 bm-DCs were cultured at 5x105 cells/well with either 500P/ml or 2500P/ml in 
the presence or absence of TNF-a at 0.5,5,50 U/ml. Rol 1-3128 was added to the 
wells to make a final conc. of 1.25µg/ml. For an additional positive control LPS was 
added to cells at 1µg/ml. The results are shown in Figure 5.10. Parasites alone at either 
low (500P/ml) or high (2500P/ml) numbers did not induce upregulation of MHCII and 
CD86 markers. Even drug-treated, blebbing parasites did not enhance this 
upregulation. Dose dependent upregulation, however, took place 
in the presence of 
TNF-a. The presence of parasites (500 P/ml or 2500P/ml) alone or drug-treated 
in such 
cultures neither increased nor inhibited the 
TNF-a-induced upregulation of 
CD86/MHCII markers. It was considered that this large number of schistosomula 
would have been enough to show any physiologically relevant effects on 
DC surface 
maturation but in final experiments on this theme the concentration was 
increased to 
10,000/ml/well. 
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Figure 5.10. 
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Figure 5.10. Schistosomula were added at (A) 500P/ml or (B) 2500P/ml to 5x105 
cells/well of day 10 immature bm-DCs from C57BL/6 mice. TNF-a was added at 0.5,5, 
50 U/ml. Rol 1-3128 was added to the appropriate cultures at 1.25µg/ml. For positive 
control LPS was added to cells at 1µg/ml. Cultures were left incubating for 22 hours, 
after which bm-DCs were collected and stained for CD I1c, MHCII and CD86. Final 
volume in wells was 400µl/well (Total events = 45,000-50,000). 
5.2.3.4 Can bm-DC maturation with or without LPS stimulation be affected by adding 
very high numbers of schistosomula (10,000/ml) with or without Rol 1-3128? 
The experiment was set up as above but instead of TNF-u, LPS was used as a priming 
signal. The results are shown in Figure 5.11. 
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Figure 5.11 Day 10 bm-DCs, were cultured at 5.0x105/well and stimulated with 10,000 
parasites (P) in the absence or presence of Ro 11-3128 (1.25µg/ml). The final 
volume/well was 500µl/well. LPS was added at 1µg/ml. Bm-DC maturation was 
assessed by gating on MHCII and CD86 high CD 11 c+ DCs after 19 hours of incubation. 
Data represents Mean values + Standard Deviation of triplicate culture wells. 
From Figure 5.11. there was no evidence of increased CD86 and MHCII upregulation 
of bm-DC surface markers following culture with 10,000 schistosomula/ml. Adding 
Rol 1-3128 to these cultures did not significantly affect this baseline expression 
compared with medium alone. LPS induced the expected significant increase 
(P<0.001) in expression but the presence of 10,000 schistosomula/ml did not enhance 
this expression in fact it was slightly reduced but not significantly (P= 0.32, as 
compared to LPS+DC). Addition of Ro 11-3128 to the schistosomula and LPS cultures 
did not enhance surface marker expression. 
This experiment was essentially repeated and the data shown as FACS plots is shown 
in Figure 5.12. The three left hand plots show the three control cultures to demonstrate 
the reproducibility of the system (i. e. 39.4,40.7 and 40.0% activated DCs). DC+LPS 
alone showed 70.9% activation, with 10,000 schistosomula added this was 70.7 and 
with parasites plus Rol 1-3128,63.7%. 
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Figure 5.12. Upregulation of MHCII and CD86 in the presence or absence of 
10,000 S. mansoni schistosomula. 5x 105 Bm-DCs were cultured for 19 hours + 
10,000parasites ± LPS (1 µg/ml) + Ro 11-3128 (1.251tg/ml). The cells were then stained 
with CD 11 c-PE, MHCII-FITC and CD86-QR, and analysed by three colour flow 
cytometry. Results were gated on 50,000 CD 11 c+ cells. Numbers within quadrants 
represent % of cells expressing either immature bm-DCs MHCIIb°" and CD86b0 v 
(bottom left quadrants) or activated bm-DCs MHCIIhigh CD86high markers (top right 
quadrants). Dotted lines represent isotype controls for MHCII and CD86 (see Fig. 5.2. B). 
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The above experiments failed to show upregulation of surface activation markers by 
DC in the presence of 50-10,000 schistosomula. This was not affected by addition of 
Rol 1-3128 or partial activation by LPS or TNF-a. DC maturation can also be 
characterised by increased expression of a variety of cytokines so the next series of 
experiments cytokines were assayed. 
5.2.4 Effects of schistosomula on cytokine production by bm-DC 
As in the above experiments LPS was also added both as a positive control and to see 
if schistosomula could provide a signal to bm-DCs already primed with LPS. The 
cytokines chosen (IL-6, IL-12p70 and IL-10) are associated with induction or 
regulation of Thl responses and were all shown to be upregulated in the skin of mice 
given RoNI (Yaobi Zhang- personal communication) and mice given GI (Hogg et al., 
2003). They have been measured in numerous DC studies e. g. Van Overtvelt et al., 
1999: Brodskyn et al., 2002; Seixas et al., 2001). . 
5.2.4.1. Effect of 2500-5,000 parasites/ml on cytokine production (IL-6 and IL-12p70) 
by naive or LPS primed bm-DCs. 
Culture supernatants collected at 18 hours of incubation were analysed for the levels of 
IL-6 and IL-12p70 secreted from bm-DCs using enzyme-linked immunosorbent assays 
(ELISA) (as explained in section 2.11). The results are shown in Figure 5.13. 
Considering IL-6, the results (Figure 5.13. A) indicate that the presence of 2500-5,000 
parasites/ml, whether drug-treated or not, enhanced the production of IL-6 as 
compared with cells in medium alone (36 and 38% increase in IL-6, respectively with 
normal or drug treated schistosomula). Addition of LPS induced a 51 % increase in IL- 
6 production, and this LPS-induced level remained elevated in the presence of 2500 or 
5000P/ml but was not increased whether the added parasites were normal or drug 
treated. So this result indicated that living schistosomula may increase the level of IL-6 
production compared with medium alone but that they were not able to enhance the 
level of activation induced by LPS. 
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From Figure 5.13. B, neither the presence of 2500 nor 5000 P/ml induced the 
production of IL-12p70 from bm-DCs. However, IL-12p70 was produced at an 
Figure 5.13. 
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Figure 5.13. Day 10 bm-DCs, were cultured at 5.0x 105 /well and stimulated with 
2500 or 5000 schistosomula/ml in the absence or presence of Rol 1-3128 
(1.25µg/ml) and the presence or absence of LPS at 1µg/ml. Supernatants were 
recovered 18 hr later and IL-6 (Top graph) or IL-12p70 (bottom graph) assayed 
by ELISA. Data represents single well observations. 
elevated level from LPS-stimulated bm-DCs and interestingly, this IL-12p70 level 
was much lower from LPS-stimulated bm-DCs in the presence of either 
2500 or 5000 
parasites/ml (reduced 85% and 77% respectively, as compared to 
LPS+DC cultures). 
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This effect was independent of the presence of Rol 1-3128. Further investigations of 
this negative effect on IL-12p70 production were carried out. 
5.2.4.2 Effect of 10,000 parasites/ml on cytokine production (IL-6 and IL 12p70) by 
naive or LPS primed bm-DCs 
A 
B 
Supernatants had been kept from Experiment 5.2.3.4. using 10,000 parasites which had 
had no effect on baseline or LPS-induced percentage upregulation of MHCII and 
CD86 expression. The cytokine expression levels are shown in Figure 5.14. 
Figure 5.14. 
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Figure 5.14. Day 10 bm-DCs, were cultured at 5.0x 105 /well and stimulated with 
10,000 parasites (P) in the absence or presence of Rol 1-3128 (1.25 µg/ml). The 
final volume/well was 500µl/well. LPS was added at 1µg/ml. Supernatants were 
recovered after 19 hours of incubation and assayed for cytokines by ELISA. Data 
represents Mean values from pooled supernatants. 
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Figure 5.14. A shows that adding 10,000P/ml produced the same IL-12p70 pattern seen 
in Fig. 5.13. B. There was no evidence of production of IL-12p70 from cultures 
containing the parasites only, either in the presence or absence of Roll-3128. 
However, such large numbers of parasites had markedly reduced the levels of LPS- 
induced IL-12p70 (501pg/ml) production by 85% as compared to the positive control 
cultures with LPS alone (3,453pg/ml). 
From Figure 5.14. B, 10,000P/ml in culture induced a 14% increase in IL-6 production 
from bm-DCs as compared to bm-DCs only. IL-6 levels were highest in LPS- 
stimulated bm-DCs cultures (2,253pg/ml) which accounted for an increase of 37% 
from the basal IL-6 levels produced by naive bm-DCs. The addition of 10,000 P/ml to 
these LPS-stimulated bm-DCs did not inhibit nor increase this elevated IL-6 level 
produced (2,259pg/ml). Addition of Rol 1-3128 did not affect any of these parasite- 
induced effects. The apparent effect on DCs in culture alone is regarded as unreliable 
as this had not been observed in other similar experiments. 
These last two experiments seemed to show that schistosomula were unable to induce 
IL-12p70 production in DCs but rather had an inhibitory effect on LPS induced IL- 
12p70 upregulation. In contrast IL-6 seemed not to be affected. However, it was 
realised that the values for the IL-6 ELISA from the culture wells were at the top of the 
standard curve of the cytokine ELISAs which meant that the IL-6 values were not 
reliable. The culture supernatants had been tested neat so in future experiments 
attention was paid to diluting the supernatants to ensure the values fell on the standard 
curve. 
5.2.4.3 Effect of 1,250-10,000 schistosomula on cytokine production (IL-6, IL-12p70, 
and IL-10) by naive or LPS primed bm-DCs. 
This experiment was set up as above. The results are shown in Figure 5.15. 
IL-6 
Following preliminary testing the supernatants were eventually tested at 1: 500 
dilution. As seen from Figure 5.15. A, when this was done the levels of IL-6 detected 
were vastly increased compared with the above experiments 
in which the supernatants 
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Figure 5.15. 
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Figure 5.15. Day 10 bm-DCs, were cultured at 5.0x 10'/well and stimulated with 1250- 
10,000 parasites (P) in the absence or presence of Rol 1-3128 (1.25 µg/ml) and/or LPS at 
1 µg/m1. The final volume/well was 500µl/well. Supernatants were recovered after 19 
hours of incubation and assayed for cytokines by ELISA. Data represents Mean values + 
Standard Deviation of triplicate culture wells. 
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were tested neat. Co-culture with 1250-10,000 schistosomula/ml did not increase IL-6 
production from bm-DCs. In fact adding increasing numbers of schistosomula led to a 
progressive decline in the level of background IL-6 production (P< 0.01 for 2,500- 
10,000 parasites). Addition of LPS led to a ten fold increase in IL-6 production. 
Adding of schistosomula to such LPS-stimulated bm-DCs reduced the level of IL-6 
production (by 17 % with 1250P/ml [P=0.009], by 15% with 2500P/ml [P=0.006], by 
26% in cultures with 5000P/ml [P=0.0011] and by 16% in cultures with 10,000P/ml 
[P=0.031]) which did not show a clear dose response. Adding Roll-3128 to LPS- 
stimulated bm-DC cultures containing 1250 and 2500 P/ml did not show any 
significant difference in IL-6 levels from their non-drug-treated equivalents (P=0.47 
and 0.21, respectively). However, with larger number of parasites, drug-treatment 
produced a greater inhibition of IL-6 production. This was significantly lower (P<0.02) 
for 5000P/ml, although it was not significant for 10,000 parasites (P=0.085). 
The ten fold higher IL-6 values recorded in this experiment compared with the 
experiments in Figures 5.13. A and 5.14. B indicate that the cytokine concentrations in 
these last two experiments were underestimated due to the OD values being beyond 
the top ELISA standard and so the conclusion that the IL-6 levels were not affected by 
schistosomula was unreliable. 
IL-12p70 
As was also observed in Figure 5.13. B, 1250-10,000 schistosomula alone reduced the 
baseline levels of IL-12p70 production by bm-DCs as compared with medium alone. 
Although the pattern was not entirely consistent, the levels generally dropped as the 
number of schistosomula increased like with IL-6. Addition of LPS led to the expected 
increase in IL-12p70 production. Adding 1250-10,000 P/ml to LPS-stimulated bm-DC 
led to a generally progressive drop in IL-12p70 production (by 38%, 71%, 57% and 
88% with 1250,2500,5000 and 10,000 schistosomula respectively as compared to 
positive control LPS-stimulated bm-DCs, P<0.01,0.001,0.001 and 
0.001, 
respectively). As before, addition of Rol 1-3128 to the cultures 
did not consistently 
affect the suppression caused. 
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IL-10 
Low baseline levels of IL-10 were produced in medium alone and the presence of 
1250-10,000 schistosomula/ml bm-DCs led to progressive but slight increases (Figure 
5.15. C) although these were not statistically significant. LPS induced increased 
secretion of IL-10 by around 15 fold. Adding 1250,2500,5000, and 10,000 
schistosomula/ml to LPS-stimulated bm-DCs led to increases of IL-10 production 
(45%, 25%, 39% and 35% [P<0.01, P=0.095,0.011,0.0126, respectively]). Adding 
Rol 1-3128 to these cultures with parasites did not change IL-10 production from that 
seen in equivalent non-drug treated cultures. 
This experiment showed that co-culture of bm-DCs with schistosomula reduced both 
baseline and LPS-induced levels of IL-6 and IL-12p70 but increased corresponding IL- 
10 levels. In view of the apparent different effects of schistosomula on the LPS 
induction of different cytokines this experiment was repeated and measurement of 
TNF-a included. Culture with 625-2500 P/ml was used to try to determine the lower 
range of parasites for inducing these effects. 
5.2.4.4 Effect of 625-2500 schistosomula on cytokine production (IL-6, IL-12p70, IL- 
10 and TNF-a) by LPS primed bm-DCs. 
The experiment was set up like the previous ones. The results are shown in Figure 
5.16. 
IL-6 
LPS induced approximately 15 fold increase in IL-6 production (Figure 5.16. A, 
P<0.00001). This LPS-induced high level of IL-6 was reduced in the presence of 
parasites by 24%, 27%, and 35% in the presence of 625,1250 and 2500 schistosomula 
respectively (P=0.011,0.0045,0.0019, respectively). Cultures containing 
drug-treated 
parasites produced similar amounts of IL-6 as their equivalents with non-drug treated 
parasites. 
IL-12p70 
Stimulation of bm-DCs with LPS induced approximately 40 
fold increase in IL- l 2p70 
production (Figure 5.16. B). On addition of 
increasing numbers of parasites, there was 
a parasite dose-dependent suppression of 
IL-12p70 production from LPS-activated 
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bm-DCs (625,1250,2500 schistosomula respectively resulting in 18%, 23% and 72% 
[P=0.30,0.14 & 0.00025, respectively]) reduction in IL-12p70 produced as compared 
to control LPS-stimulated bm-DCs). Drug-treated 625P/ml induced a reduction of only 
8% in IL-12p70 production from LPS-stimulated bm-DCs, but 1250 and 2500 drug 
treated parasites induced higher reductions than equivalent non-drug treated cultures 
(64% and 86% respectively for 1250 and 2500 P/ml as compared to DC+LPS) 
although the difference was only statistically significant for the 2500 parasites (P< 
0.001). 
Figure 5.16. 
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Figure 5.16. A and B above, C and D below. Day 10 bm-DCs, were cultured at 
5.0x105/well and stimulated with 625-2,500 parasites (P) in the absence or 
presence of Rol 1-3128 (1.25µg/ml) and/or LPS at 1µg/ml. The final volume/well 
was 500µ1/well. Supernatants were recovered after 19 hours of incubation and 
assayed for cytokines by ELISA. Data represents Mean values + Standard 
Deviation of triplicate culture wells. fN. D. = Not Donel. 
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TNF-a 
As seen in Figure 5.16. C LPS induced approximately 7 fold increase in TNF-a 
production from bm-DCs. The lower parasite numbers, 625 and 1250 P/ml did not 
suppress this level of LPS-induced TNF-a production (P=0.069 and P=0.122, 
respectively). However, 2500P/ml did reduce TNF-ct production by 28% as compared 
to DC+LPS (P<0.001). Addition of Rol 1-3128 had no significant effect on these 
values. 
IL-10 
Unfortunately the values obtained for IL-10 were very low and not consistent with 
other experiments (Figure 5.16. D). This seems to have been due to a general failure of 
the ELISA because in addition to the low values the variation was very high. Due to 
lack of remaining supernatant it was not possible to repeat the ELISA. 
Figure 5.16. (continued) 
C 
D 
10000 
9000 
8000 
7000 
6000 
5000 
Q DC 
DC+Ro11-3128 
4000 
Z 3000 
2000 
1000 N. D. 
0 
Medium 625 1250 2500 LPS 
P/ml+LPS P/mI+LPS P/ml+LPS 
500 
450 
400 
E 350 
Q 300 Q DC 
Q 250 
®DC+Ro11 3128 
200 
150 
100 
50 N. D. 
0 
Medium 625 1250 2500 LPS 
P/mI+LPS P/mI+LPS P/mI+LPS 
183 
Because of the very high variation little can be learned from this data although the 
general pattern of the mean values was like that in 5.15. C. i. e., LPS values were higher 
than medium alone, in the cultures with parasites the values were higher than LPS 
alone and presence of drug did not induce marked differences. 
IL-4 
IL-4 was assayed also but none was found (data not shown). 
5.2.5 Are the differential effects on cytokines detected in culture due to parasite- 
induced cell damage combined with different kinetics of cyokine 
production? 
The above experminents show that there were differential effects of co-culture of 
mechanically-transformed schistosomula (MS) and DCs on the LPS-induced secretion 
of the different cytokines (IL-12p70>IL-6>TNF-a) and IL- 10 seemed to be unaffected. 
Possiblities considered to explain this were that (a) schistosomula products selectively 
and specifically signal DCs to inhibit different cytokine pathways. (b) Schistosomula 
products (e. g. enzymes) could directly degrade secreted cytokines and have different 
effects on different cytokines. (c) Parasites simply damage/kill DCs and, to explain 
the apparent differential effects on cytokines, it may be that the various cytokines are 
produced with different kinetics following LPS stimulation e. g. IL-10 may be 
produced early in the response (before cell damage had occurred) whereas TNF-a, IL- 
6 and IL-12p70 may be produced later and so are progressively more affected by any 
damage to the cells. 
This last possibility was investigated by putting parasites and cells together and either 
adding LPS at the start or 18hr later. It was hypothesised that if cell damage was 
responsible for the observations then co-culture for 18hr before LPS activation would 
produce less of all of the cytokines and would reduce levels of IL-10, 
for example, 
compared with LPS activation at time 0. 
5.2.5.1 Does preculturing of DC with schistosomula for 24hr increase the effects on 
LPS induced ctokine production? 
In the following experiments there were essentially two treatments: 
Group (A) DC + MS +LPS all added at the same time. This is the standard protocol 
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Group (B) DC + MS added as in (A) but LPS added 24hr later. The schistosomula 
used were 3hr old. Supernatants were sampled at both +6hr and +24hr post LPS- 
treatment in order to test if the different cytokines were produced with different 
kinetics (e. g. IL-l0 predominantly early and IL-12p70, IL-6 and TNF-alpha 
predominantly later). The results are shown in Figures 5.17. A to D. Control values in 
medium alone are not shown but were low, in the usual range. 
IL-6 
It can be seen from Figure 5.17. A that in the standard protocol (treatment group A) 
LPS induced about 220 ng/ml IL-6 by 24hr, exactly comparable to Figure 5.16. A. 
Addition of the parasites to the cultures (2500(3h)+LPS(Oh)-24h) caused a mean level 
of IL-6 at 24hr which was 24% lower than with LPS in the absence of parasites 
[P=0.003] (i. e., similar to the reduction seen in Figure 5.16. A). However, the levels of 
IL-6 produced by bm-DCs cultured overnight with MS (treatment group B), was 
exactly comparable to that induced in the absence of MS at both 6hr and 24hr post 
LPS treatment. This indicated that the DCs were perfectly able to respond to LPS by 
producing IL-6 after 24hr with the parasites and so there was no evidence that the cells 
were killed or damaged by the ON culture with parasites. It is interesting to note that 
the DCs which has been cultured overnight in the 24well plates produced similar levels 
of IL-6 by just 6 hrs post LPS (176 ± 8ng/ml) as compared with the 24hr cultures set 
up at the start of the experiment (222.479 ± 3.234 ng/ml). But by 24hr these cells 
produced much higher levels of IL-6 (338± 3ng/ml, P=0.003) indicating that the 
harvesting and plating of the DCs primed them for LPS activation. A similar apparent 
priming of cytokine production was also seen for IL-12p70 (see below). 
IL-12p70 
As in previous studies addition of parasites and LPS to cultures at time Oh (treatment 
group A) induced 63% reduction in IL-12p70 measured in the cultures (P=0.0002). 
When DCs and parasites were co-cultured for 24hr and then LPS added the level of 
parasite induced reduction in IL-12p70 was 31% at 6hr 
(P=0.015) and only 38% by 
24hr(P=0.0365). 
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Figure 5.17. A and B 
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Figure 5.17. A and B. Day 10 bm-DCs, were cultured at 5.0x 105/well with or 
without 2,500 3hr old parasites (2500 [3h]) P)/ml and LPS at 1µg/ml. LPS was either 
added at time 0 [LPS (0h)]or at 24h [LPS (Day 1)]. Supernatants were recovered after 
6h or 24h after LPS stimulation and assayed for cytokines by ELISA. Data represents 
Mean values ± Standard Deviation of triplicate culture wells. 
TNF-a 
The pattern of TNF-a production (Figure 5.17. C) was similar to IL-12p70 (Figure 
5.17. B) but the parasite inhibition was less pronounced. Addition of parasites and LPS 
to cultures at time 0 resulted in 34% reduction in TNF-a levels compared without 
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parasites (P=0.002). A similar pattern of parasites reducing the cytokine levels was 
observed at both 6 hours and 24 hours post LPS addition at 24 hr (13% [P=0.003] and 
36% [P=0.005] reductions, respectively) compared with LPS alone. As with IL-6 and 
IL-12p70 the DCs cultured in the 24well plates for 24 hr produced higher cytokine 
levels compared with the freshly plated cells. 
Figure 5.17. C and D 
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Figure 5.17. C and D (See Figure 5.17. A and B). 
IL-10 
Levels of IL-10 (Figure 5.17. D) showed a quite different pattern. 
As in the previous 
studies, co-culture of freshly plated DCs with schistosomula 
[2500(3h)+LPS (0h)-24h] 
did not affect LPS induced IL-l0 production at 
24hr relative to LPS-activated DCs 
alone [LPS (0h)-24h]. In marked contrast to IL-6, 
IL-12p70, and TNF-a, DCs cultured 
ýr 
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overnight in 24 well plates (in the absence of parasites) produced much less IL- 10 
following LPS activation compared with activation of freshly plated cells. Even so the 
lowish level of IL-10 production following adding LPS at 24hr was increased rather 
than decreased in the cultures containing parasites (252±53 pg/ml as compared to 
169±16 pg/ml, a 33% increase at 24 hr after LPS activation [P=0.062]). 
These results showed that DCs precultured with 3hr old MS for 24hr responded 
similarly in respect of LPS induced cytokine production compared with cultures in 
which the LPS was added at the start of the cultures. It is considered that these data do 
not support the idea that the 3hr schistosomula simply damage the cells resulting in a 
general reduction in LPS inducible cytokine production. 
5.2.5.2 Do large numbers of parasites cause cell death? 
In this experiment viability was simply assessed by trypan blue staining to distinguish 
live from dead DCs. Cultures were set up using 2500 and 5000 schistosomula with or 
without LPS and IL-6 measured after 18hr when DC viability was also assessed. The 
results are shown in Figure 5.18. 
As above adding 2500P/ml and 5000P/ml did not induce IL-6 production by DCs but 
did significantly reduce LPS-induced IL-6 production (49% [P=0.006] and 53% 
[P=0.002], respectively) rather more than in most other experiments. There was no 
enhanced or inhibitory effect of drug-treatment. Cell viability counts showed 80-90% 
viable cells and little difference between any of the treatments. The data for cultures 
with Rol 1-3128 is not shown but was very similar. 
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Figure 5.18 
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Figure 5.18. Day 10 bm-DCs, were cultured at 5.0x 105/well and stimulated with 2,500 - 
5,000 parasites (P) in the absence or presence of Ro 11-3128 (1.25µg/ml) and/or LPS at 
1µg/ml. The final volume/well was 500µl/well. Supernatants were recovered after 18 
hours of incubation and assayed for cytokines by ELISA. DC viability was assessed by 
Trypan blue staining, after 18 hours of incubation. Cells not stained blue with the dye 
were classified as viable, whereas those stained blue were classified as dead. Data 
represents Mean values ± Standard Deviation of triplicate culture wells. 
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5.2.5.3 Annexin V and propidium iodide staining method for apoptotic cells and cell 
death 
Another method for measuring cell viability is staining by Annexin V and Propidium 
Iodide as described in Section 2.12.2500 schistosomula/ml were cultured with bm- 
DCs for 24hr and the cells were then stained with Annexin V and Propidium Iodide. 
Those cells +ve for Annexin V were considered +ve for early stages of apoptosis, 
those that were +ve for Propidium Iodide were considered dead (Necrotic). Those that 
were +ve for both Annexin V and PI were considered either at the end stage of 
apoptosis or undergoing necrosis (App+Nec). Percentage of apoptotic, necrotic and 
App+Nec bm-DCs were measured by FACS analysis. The results are shown in Figure 
5.19. 
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Figure 5.19. Day 10 bm-DCs, were cultured at 5. Ox 105/well and stimulated 
with 2,500 parasites. The final volume/well was 500µ1/well. Cells were 
recovered at 18hr, stained using Annexin V and propidium iodide as 
described in section 2.12. 
Although there was some difference in the different categories, the results show a 
comparable level of necrotic and apoptotic cells with or without the schistosomula 
(25% and 30% respectively for apoptotic and necrotic cells together) which 
indicates 
that 2500 schistsomula did not induce singificantly greater cell 
damage compared to 
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medium alone. A similar result was obtained using 10,000 schistosomula (data not 
shown). 
The above studies had used schistosomula just 3hr after mechanical transformation. 
Because drug treatment in the RoNI is not given until day 2 post infection it was of 
interest to see if older schistosomula would also induce these effects on DCs. To 
investigate this, experiments were carried out with schistosomula cultured for 24hr. 
5.2.6 Comparison of the effects of 3hr and 24hr schistosomula on LPS induced 
cytokine production. 
5.2.6.1 Experiment 1 
Cultures were set up as in earlier experiments. In this experiment 3hr schistosomula 
were set up with day 10 bm DCs on one day and the remaining schistosomula kept for 
24hr and then set up with day 11 bm-DCs from the same preparation the following 
day. The results are shown in Figure 5.20. The control, medium alone, values were 
low and in the expected range. 
IL-6 
Addition of either 2500 3hr or 24hr schistosomula alone to bm-DCs did not induce IL- 
6 production after 24 hours of culture (see Figure 5.20. A. ). LPS induced the expected 
high levels of IL-6. The 3hr schistosomula reduced this level by 24% [P=0.003] but 
24hr schistosomula had no effect compared with LPS alone. 
IL-12p70 
As seen in Figure 5.20. B adding LPS (1µg/ml) stimulated 
day 10 bm-DCs to produce 
3,109±134 pg/ml of IL-12p70 by LPS, a level that was significantly reduced 
by 63% in 
the presence of the 3hr schistosomula [P=0.00021]. 
The LPS-stimulated day 11 bm- 
DCs produced lower IL-12p70 (1,907± 150 pg/ml) than the 
day 10 bm-DCs but 
interestingly, 24hr schistosomula did not significantly suppress this. 
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Figure 5.20. 
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Figure 5.20. A and B. Day 10 bm-DCs, were cultured at 5.0x 105/well with or without 
2,500 3hr old parasites (2500 [3h])/ml. The following day 24hr old parasites (2500 
[24h])/ml were added to day 11 bm-DCs. LPS was added at 1 µg/ml to some of the 
cultures. Supernatants were recovered 24h after LPS stimulation and assayed for 
cytokines by ELISA. Data represents Mean values + Standard Deviation of triplicate 
culture wells. 
TNF-a 
Neither 3hr nor 24hr schistosomula stimulated any TNF-a production from bm-DCs 
(Figure 5.20. C). The LPS activation produced comparable TNF-a production from the 
day 10 and day 11 cultures. Adding 3hr parasites to LPS-stimulated day 10 bm-DCs 
suppressed the level of TNF-a by 34% compared to LPS control cultures [P=0.002] 
and adding the 24hr parasites also suppressed production (by 17%. P=0.01). 
192 
Figure 5.20. (contd. ) 
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Figure 5.20. C and D. See legend to Figure 5.20. A and B. 
IL- 10 production 
The 3hr parasites alone did not stimulate IL-10 (Figure 5.20. D). The 24hr parasites did 
seem to have stimulated IL- 10 production at 6hr following co-culture (data not shown) 
but none was detected at 24hr. Adding LPS to cultures containing freshly prepared 
parasites induced the production of high levels of IL-10, as with IL-6. Neither 3hr nor 
24hr schistosomula significantly reduced or enhanced this level. 
These results confirm earlier ones showing that 3hr schistosomula can reduce LPS 
induced cytokine levels in bm-DC culture (IL-12>TNF-a & IL-6) but IL-10 is 
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unaffected. The 24hr schistosomula, however, did not significantly affect the levels of 
any of these cytokines. 
A 
B 
5.2.6.2 Repeat comparison of 3hr and 24hr parasites 
This was similar to the previous experiment but this time the 24hr schistosomula were 
prepared on one day and the 3hr schistosomula the following day. These were then 
added to the same batch and age of bm-DCs. The results are shown in Figure 5.21. 
Figure 5.21. 
Figure 5.21. A and B. Day 10 bm-DCs, were cultured at 5.0x 105/well with or without 
2,500 3hr old or 24hr old parasites [2500 (3h)/ml] or [2500 (24h)/ml]. LPS was added 
at 1 µg/ml to some of the cultures. Supernatants were recovered 
24h after LPS 
stimulation and assayed for cytokines by ELISA. Data represents 
Mean values + 
Standard Deviation of triplicate culture wells. 
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As was observed in previous experiments neither 3hr or 24hr schistosomula induced 
elevated levels of IL-6 or IL-12p70 production by DCs on their own. Also as in earlier 
experiments 3hr schistosomula reduced the level of IL-6 (38%, P=0.00012) and IL- 
12p70 production (90%, P<0.0001). But 24 hr cultured schistosomula had no effect on 
the IL-6 production by DC and caused a slight reduction in IL-12p70 (31%, 
P=0.00048) although the levels remained significantly higher than with 3hr 
schistosomula (P=0.0008). 
These two experiments comparing 3hr and 24hr cultured schistosomula both show (i) 
that neither types of schistosomula induce cytokine production from bm-DCs but (ii) 
that the 3hr parasites have a more marked effect on LPS-induced cytokine production. 
Discussion 
The studies in this Chapter were initiated to try to get a better understanding of how 
RoNI is able to induce such effective immunity in vivo. RoNI results in a protracted 
Thl response in the SLN and the interpretation of the data in Chapter 3 was that 
protracted antigenic stimulation of the skin/SLN by the drug treated schistosomula 
results in strong priming of Th 1 responses leading to specific systemic responses 
demonstrated by high antigen specific IFN-7 responses persisting at day 21 in the 
spleen. However, even non-attenuated schistosomula produce a Thl biased response 
in the SLN (Pemberton et al., 1991) and this was clearly seen by day 7 post-infection 
in Chapter 3. A key question is when and how this is induced. The production of IL- 12 
has been shown to be a crucial cytokine for production of the GI induced Th 1 response 
and for protection (Anderson et al, 1998; Wynn et al. 1996) and in the studies by Hogg 
et al., (2003) IL-12 p70 was produced in the skin infection site within 24-48hr of GI 
and NI. Also the majority of MHCII, IL-12p40 positive cells emerging from skin 
explants taken at day 4 post vaccination were myeloid DCs or macrophages. Other 
studies have shown that certain Thl promoting infectious organisms can activate DCs 
directly in vitro (Gorak et al, 1998; Marriott et al., 1999; Seixas et al., 2001) and so the 
experiments in this chapter focussed on finding out if schistosomula could similarly 
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activate DCs and whether this could be enhanced by Rol 1-3128 treatment. No 
previously published data on this was available. It was hoped that by studying the 
interaction of DCs, which are so important in influencing the nature of the response to 
a new antigenic stimulus, with normal or drug treated schistosomula in vitro some clue 
would be found about how this Th 1 biased response is generated. 
Technically these experiments worked well. The `naive' bm-DC preparations prepared 
on different occasions showed varying proportions with the mature phenotype which 
was defined as MHCII and CD86 high. This was especially so in the early 
experiments. Bm-DC activation was low among immature DCs (-P33%) and the 
separation of the DCs from the schistosomula by filtration, which was very effective, 
did not further activate the cells. LPS or TNF-a stimulation normally increased this 
surface expression more than two fold. The schistosomula preparations using the 
percoll separation technique produced pure preparations of schistosomula 
uncontaminated with cercarial tails. The percoll separation combined with the 
extensive washing in antibiotics produced preparations that did not develop bacterial 
contamination. Samples of each preparation were kept for at least 10 days and bacterial 
or fungal contamination was monitored and was a very rare event. Experiments in 
which this was seen in these controls even if not seen in the parasite DC cultures were 
abandoned. As it turned out the lack of bacterial/endotoxin contamination in the 
parasite preparations was clear from the uniform lack of DC activation seen. 
Experiments focused on use of living schistosomula but initial studies showed that 
soluble antigens derived from the penetrating parasites such as CTF (cercarial 
transformation fluid) and SCA (soluble cercarial antigen) upregulated the expression 
of MHCII and CD86 in a dose-dependent manner. However, it was 
found that both 
CTF and the cercarial antigen preparation used in this experiment 
had measurable 
levels of endotoxin and when the experiment was repeated in C3H/HeJ mice which are 
LPS non-responders (Hopkins et al., 1996) there was no upregulation 
in the case of 
CTF and a markedly lower response for SCA. It was concluded that there was no 
reliable evidence of parasite induced DC activation 
by these soluble antigens. Since a 
focus of the work was to look at the effects of Rol 
1-3128 treatment of schistosomula 
on DC activation this work on soluble products was not continued. 
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In numerous experiments, of which 6 separate experiments using 50-10,000 
schistosomula/ml are presented in this Chapter there was no evidence of upregulation 
of surface markers (MHCII, CD86, CD40). In these cultures the parasites showed good 
viability throughout the duration of the experiment. Addition of Rol 1-3128 to the 
cultures caused the expected effects on the schistosomula surface but had no 
significant effects on the surface marker expression and neither did exposure to 
irradiation. In an attempt to prime the DCs by partial activation with LPS or TNF-a no 
extra surface marker expression was seen. Overall therefore the data indicates that 
bm-DC do not respond to molecules released by living schistosomula at least in the 
time frame of the experiments carried out here, 24hr culture. Seixas et al. (2001), using 
the same type of bm-DC with Plasmodium c. chabaudi schizonts have found 
upregulation of these markers at 20hr of co-culture. 
In five separate experiments schistosomula (650-10,000/ml) also failed to induce 
significant effects on DCs as judged by levels of cytokine production (IL-12p70, TNF- 
a, IL-10 or IL-6). These effects were also independent of the presence of Ro 11-3128. 
However, co-culture of DC with schistosomula reduced the levels of LPS-induced 
cytokine production by bm-DCs in a dose-dependent manner and had differential 
effects on production of the different cytokines. A marked reduction occurred with 
high numbers of larvae (2500-10,000/ml), while this inhibition was less with lower 
numbers 625-1250/ml. IL-12p70 production was most affected (mean reduction of 
80%) followed by IL-6 (mean reduction of 34%) and TNF-a (mean reduction of 32%). 
IL-10 was relatively unaffected, and IL-4 levels were undetectable. As with the CD86 
and MHCII expression, the negative effects of schistosomula on cytokine expression 
was unaffected by the addition of Rol 1-3128 to the cultures. 
To explain the lack of upregulation of surface markers and of cytokine production 
during schistosomula/DC co-culture and the differential effects on LPS-induced 
secretion of the different cytokines various possibilities were considered: (a) 
schistosomula products (pathogen-associated molecular patterns, PAMPs) fail to signal 
activation of DCs but rather selectively and specifically signal DCs to inhibit different 
cytokine pathways (b) schistosomula simply damage/kill DCs and, to explain the 
apparent differential effects on cytokines, it may be that the various cytokines are 
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produced with different kinetics following LPS stimulation e. g. IL-10 may be 
produced early in the response (before cell damage had occurred) whereas TNF-a, IL- 
6 and IL-12p70 may be produced later and so are progressively more affected by any 
damage to the cells. Differential rates of production during co-culture of bm-DCs with 
P. c. chabaudi have been reported (Seixas et al., 2001) although in this study TNF-a 
peaked at l hr whereas both IL-6 and IL-12p70 increased to peak at 20hr, (c) 
schistosomula products may promote cytokine production but other larval products 
(e. g. enzymes) could selectively degrade secreted cytokines (IL-12p70»IL-10). 
The explanation that progressive loss of cell viability combined with different rates of 
cytokine production was investigated by setting up the co-cultures and adding LPS 
either at the start or after 24hr. The same patterns of effect on cytokine production with 
the schistosomula were seen for each cytokine for LPS addition at time 0 or 24hr and 
in fact were less pronounced at the 24hr time point compared with time 0 (36% 
reduction at 24h compared with 34% reduction at Oh in TNF-a levels, and 38% 
reduction at 24h compared with 63% at Oh in IL-12p70 levels). For IL-10 there was an 
enhancement of 33% in the presence of the schistosomula compared with no effect at 
time zero. This supports the idea that the schistosomula have specific and differential 
effects on the production of the different cytokines rather than having cytotoxic effects 
and this is also indicated by the lack of evidence for general loss of cell viability or for 
apoptosis by methylene blue staining and the Annexin V and propidium iodide 
staining. However, further experiments would be needed to extend and confirm this. 
The possibility that parasite products may degrade cytokines can be investigated by 
adding known cytokine concentrations to the cultures and then assessing their levels at 
intervals during culture. Since the 24hr cultured parasites did not have the same effect 
as the 3hr cultured parasites it would be useful to compare these in such an experiment. 
It would also be important to establish if the effects on cytokine production can be 
seen at the mRNA level by RNAse protection or RT-PCR methods. Inclusion of 
house-keeping genes in the assays would control for the general effects on cell 
viability. If differential effects could be seen at the mRNA level 
it would indicate some 
specific signalling by parasite factors. In addition other DC 
functions could be 
measured such as the ability to process and present other antigens and 
for this the use 
of ovalbumin and the ovalbumin specific transgenic 
T cells would be suitable (Hsieh et 
al., 1993). 
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Angeli et al. (2001) looked at activation of skin Langerhans cells (LC) in situ 
following infection of mice with S. mansoni cercariae. They reported that LC showed 
upregulation of MHCII and CD86 from 1-120hr post infection as judged by 
immunohistochemistry and were also positive for the DC activation marker DEC-205. 
It was also reported that the most intensely stained LC were surrounding the parasites. 
In collaboration with Dr Stephen Jolles (National Institute for Medical Research, Mill 
Hill) experiments were carried out co-culturing schistosomula with cells extracted 
from mouse epidermal sheets using trypsin (Tokura et al., 1994) and staining for 
MHCII and CD86. Unfortunately, the process of extraction and manipulation of these 
cells, which contain around 5% LC amongst keratinocytes, resulted in 100% of the 
cells upregulating these markers even in control cultures and the mean fluorescence 
intensities were also comparable with or without parasites. The work of Angeli et al. 
(2001) demonstrates a rapid activation of LC after infection and a close association 
between the parasite and the activated cell but it does not show that parasite products 
induce the activation directly. Keratinocytes, the most abundant cell type in the skin 
are known to be activated by microbial stimuli to produce a range of cytokines (Tokura 
et al 1994) and it is possible that the activation of LC seen by Angeli et al. (2001) is 
secondary to these effects and not caused directly by LC/schistosomula molecular 
interactions. 
The observed upregulation of MHCII and CD86 (Angli et al, 2001) is typical of the 
response of DCs to Thl activating signals such as heat-killed Propionebacterium 
acnes (MacDonald et al., 2001), and indicates a Thl priming signal in the skin soon 
after infection. In contrast, the Th2 priming signal, S. mansoni egg antigen, did not up- 
regulate the expression of DC costimulatory molecules in vitro: CD40, CD54, CD80, 
CD86 or OX40L and produced no detectable IL-4, IL-10, or IL-12, displaying only a 
minor increase in MHC class II expression, yet were able to prime a strong Th2 
response when injected into naive recipient animals (MacDonald et al., (2002b). A ThI 
response can be demonstrated in cultured skin from isolated pinnae soon after 
infection 
of mice with either normal (NI) or irradiated (GI) cercariae 
but is more pronounced in 
the GI (Hogg et al., 2003). These authors did not look before 24hr post infection but at 
that time the Thl promoting cytokines IL-12p70 and IL-18 were elevated in both NI 
and GI at 24hr, and the majority of MHCII, 
IL-12p40 positive cells emerging from 
skin explants taken at day 4 post GI vaccination were myeloid 
DCs or macrophages. 
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However, the response at this early time is not exclusively Thl dominated, both 
antigen specific IL-4 and IFN-, y were demonstrated to be produced in SLN at day 4 
post infection (Hogg et al., 2003b). It was only subsequent to this that production of 
both of these cytokines declined in the NI but IFN--y persisted until day 14. So on 
balance it is uncertain precisely what feature of the attenuated infections favours the 
Thl dominance and where and when it is induced but the results of the studies in this 
chapter suggest that schistosomula do not release factors that can activate DCs but 
rather that they are inhibited. 
The balance of effects observed, reduced IL-12p70 and TNF-a but no effect on IL-10 
are likely to be anti-inflammatory as IL-12 is a proinflammatory cytokine governing 
the development of IFN--y producing T cells (Trinchieri, 1998) and IL-10 is a strong 
inhibitor of IL-12 transcription (Aste-Amezaga et al., 1998) and inhibits IL-12 
production by DC (De Smedt et al. 1997). Various in vitro studies have shown that IL- 
12 is produced by dendritic cells following stimulation with microbial products (Reis e 
Sousa et al., 1999) and that such DC are then able to transfer development of 
protective Th-1 cell responses to mice in such infections as Leishmania and 
tuberculosis (Ahuja et al 1999; Tascon et al., 2000). Also IL-12 production by DC has 
been shown in mice early after injection of microbial antigens (Reis e Sousa et al., 
1997). In contrast IL-10 is an immunosuppressive cytokine which DC also produce 
and which can down regulate IL-12 production and so reduce Th 1 development 
(Moore et al., 2001). Addition of IL-10 to DC can reduce their expression of IL-12 and 
also their ability to induce IFN-y producing T cells in vivo (De Smedt et al., 1997). 
Conversely, endogenous inhibition of IL-10 expression in DC can boost Th1 immunity 
to Chalmydia infection (Igietseme et al 2000). Both IL-12 and IL-10 are produced in 
the skin of mice infected with normal or irradiated cercariae of S. mansoni (Hogg et 
al. 2003) and reciprocal regulatory effects of these two cytokines were recently 
demonstrated using irradiated infections (Hogg et al., 2003b). IL-12-/- mice 
vaccinated with GI failed to develop IFN-y in the 
SLN but notably showed a marked 
increase in IL-10 production in the skin and SLN. This resulted in reduced skin 
inflammation. Conversely in GI vaccinated IL-10-/- there was a marked increase in IL- 
1P and IL-12p40 in the skin and in IL-12p40 and 
IFN-y in the SLN. Such mice showed 
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a marked increase in skin inflammation. This shows that IL-10 production in the skin 
during GI has an anti-inflammatory role preventing excessive dermal inflammation. 
Earlier, Ramaswamy et al., (2000) had reported that S. mansoni schistosomula are able 
to produce significant amounts of prostaglandin E2 (PGE2) following incubation with 
linoleic acid, a free fatty acid found on the surface of the skin and that they were also 
able to induce PGE2 production by mouse keratinocytes. This PGE2 led to IL-10 
production by keratinocytes as PGE2 is a potent inducer of IL- 10 production which in 
turn leads to reduced IL-12 production (van der Pouw Kraan et al, 1995; Harizi et al., 
2002). This PGE2/IL-10-inducing effect was associated with a fraction <30 kDa 
molecular size in the parasite secretions, and addition of this fraction or of parasite- 
stimulated keratinocyte culture supernatant to Con A-stimulated spleen cells caused 
the suppression of cell proliferation. It was proposed that this PGE2 -dependent, IL-10- 
mediated effect would inhibit skin inflammatory responses which would help parasite 
survival. With regard to the present observations it is interesting that IL-12 production 
can be inhibited in DC by agents that increase cyclic AMP, which include PGE2 
(Kalinski et al., 1997). Kalinski et al., (2001), showed that PGE2 could enhance IL- 
12p40 mRNA expression and protein secretion in human TNF-a-stimulated immature 
DCs. However, this effect was not accompanied by the induction of IL-12p35 
expression and thus not by the secretion of the bioactive IL-12p70 heterodimer. When 
the DCs were stimulated with LPS, as in the present studies, PGE2 inhibited the 
production of both IL-12p70 and IL-12p40. PGE2 was also reported to inhibit TNF-a 
mRNA, protein level and release from bm-derived DCs stimulated with LPS 
(Vassiliou et al., 2003). So it is possible that the observed reduction in LPS-induced 
IL-12p70 in the DC/schistosomula co-cultures is mediated at least in part by PGE2 
released by the co-cultured schistosomula. 
Angeli et al. (2001) found that LC, although activated by infection, did not migrate 
from the skin and that this was due to PGD2 which is produced 
by the parasite and 
may be produced in the skin by the release by the penetrating 
larvae of large amounts 
of PGD2 synthase. They did not detect DC accumulation 
in the SLN up to day 10 post 
infection and it was suggested that the reduced emigration of 
LC and accumulation of 
DCs in the SLN may play a key role in control of cutaneous 
immune responses and 
again facilitate parasite survival. 
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Ramaswamy et al. (2000) also reported that y-irradiation attenuation of parasites 
significantly abrogated their ability to induce PGE2 or IL-10 from skin cells and it was 
suggested that this could account for the enhanced skin inflammation and protection 
seen with GI. Hogg et al., (2003b) also described lower IL-10 in the skin of mice 
given GI compared with NI at day 4 post infection but since the levels of IL- 10 in the 
skin in GI were substantial they did not consider that this difference accounted for the 
difference in inflammation. The idea that attenuated parasites may be less effective in 
producing immunosuppressive molecules like PGE2 and PGD2 and so allow more 
effective immune responses to develop could also apply to the RoNI model and it 
would be interesting to see if the RoNI treatment prevented such PGE2 and PGD2 
production. 
In the present studies, the inhibitory effect on cytokine and in particular IL-12p70 was 
much less marked when schistosomula were cultured for 24hr rather than when they 
were used at 3hr. So what might the 3hr schistosomulum produce that is not present 
after 24hr culture? The cercarial stage has pre- and post-acetabular glands which 
contain a number of different products which may be released during penetration. One 
of these is a serine proteinase with elastase activity (Mckerrow et al., 1985) and this is 
reported to be the only protease present in the acetabular gland secretions (Salter et al., 
2000). However, this protease is rapidly released during mechanical transformation 
and Dalton et al. (1997) found that 3 hr cultured schistosomula no longer contained 
any of this enzyme. Dalton et al. (1997) did however, describe the presence of the 
cysteine protease, cathepsin L in the postacetabular glands of cercariae and this could 
be detected at a low level in extracts of 3hr schistosomulum. However, it is not known 
if this enzyme is released from the glands or if the protease found in the extracts of 3hr 
schistosomula is present in remnants of the glands or in the body of the larvae where it 
is also found in the adult. 
Faveeuw et al, (2003) have recently shown that the post-acetabular glands of freshly 
transformed schistosomula contain glycoproteins with core a3-fucose and core ß2- 
xylose specificities which were also found in abundance in egg antigens. Egg derived 
glycoconjugates containing a3-fucose e. g the Lewis x trisaccharide (LeX) have been 
shown to promote Th2 responses when injected in vivo (Okano et al, 2001) and are 
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also able to promote Th2 responses when mixed with DC which are then injected into 
mice (Faveeuw et al, 2003). Several species of organism interact with DCs Via CHO 
structures on the organism and C-type lectins on the DC. Amongst these is the DC 
specific lectin DC-specific ICAM (intercellular adhesion molecule)-3-grabbing non- 
integrin (DC-SIGN) and this has recently been shown to bind to Lex specificities and 
to Lex -rich S. mansoni antigen (Appelmelk et al., 2003). Unlike the Toll-like receptors 
(TLR) which recognize specific pathogen components such as LPS and then induce 
intracellular signalling resulting in upregulation of cytokine production and 
costimulatory molecules (Underhill et al., 2002), the C-type lectins seem to be 
involved in internalization of the organisms for antigen processing rather than signal 
transduction (Figdor et al., 2002) but engagement of DC-SIGN by zymosan can lead to 
the production of IL-10 (Cambi et al., 2003). Recently, Thomas et al. (2003) have 
reported that Lex presented on lacto-N-fucopentaose III can signal through TLR4 
which has previously only been associated with Thl-driving molecules. Interestingly 
the stimulated DCs failed to upregulate surface marker expression as reported by 
MacDonald et al. (2001) and similarly drove a Th2 response in vitro. It is suggested 
that opposing effects on TLR4 engagement by Thl- promoting (e. g. LPS) or Th2 - 
promoting (e. g. Lex) may be controlled by the intensity of the TLR4 engagement with 
accessory molecules playing a role. Van der Kleij et al. (2002) showed that lipid 
derived from schistosomal eggs or adult worms e. g., schistosome-specific di-acylated 
phosphatidylserine activated TLR2 also directing DCs into a Th2 promoting DC 
phenotype, while the presence of mono-acylated lyso-phospatidylserine (lyso-PS) 
induced maturation into a DC phenotype that promotes development of T regulatory 
cells that inhibit proliferation of bystander T cells through IL-10. These interesting 
pro-Th2 effects of Lex - containing schistosome molecules have been 
focussed on egg 
products which is known to induce strong Th2 responses, but the presence of this 
structure in the larval stages might also be involved in immuno-regulatory processes 
associated with this stage of the life cycle including perhaps the observed effects on 
DC responses reported here. However, it is not yet known 
if such glycosylated 
molecules are even secreted from the schistosomula glands in vivo or whether they are 
transiently expressed. Apart from the possible involvement of the remnants of 
molecules in the penetration, transformation 
is associated with rapid changes to the 
membrane with loss of the carbohydrate rich glycocalyx 
but with the appearance of 
new antigens (Bickle et al, 1986). Persistence of components of 
the glycocalyx or 
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transiently expressed surface associated molecules could also be responsible for the 
effects of 3hr schistosomula. 
Regarding how schistosomula products might induce differential effects on different 
cytokine expression following LPS activation, it is known that the DC surface has a 
complex array of surface receptors including the C-type lectin receptors, the Toll-like 
receptors (which include 10 different family members and also non-Toll-like pattern 
recognition receptors (Kelsall et al., 2002). Other infectious organisms and their 
products are also known to modulate DC functions and in some situations differential 
effects on DC cytokine production has been shown. Urban et al. (1999) reported that 
prior incubation of human DC with Plasmodium falciparum - infected red blood cells 
inhibited subsequent LPS -induced upregulation of surface activation markers 
including HLA-DR, CD80, CD86 and CD40. Cholera toxin, a potent mucosal vaccine 
adjuvant inhibited the production of IL-12p70 and TNF-a but not IL-10, IL-6, TGF-ß 
or prostaglandin E2 by LPS-activated blood monocyte-derived DCs (Gagliardi et al., 
2000) and these were able to prime naive T cells in vitro, skewing polarization to a 
Th2 response. However, unlike in the present studies, the cholera toxin-treated DCs 
up-regulated the expression of HLA-DR molecules, B7.1 and B7.2 co-stimulatory 
molecules. More similar to the studies in this Chapter, Van Overtvelt et al. (1999) 
showed that infection of human monocyte-derived DCs with T cruzi significantly 
reduced the LPS-induced secretion of IL-12, TNF-a and IL-6, as well as the up- 
regulation of HLA-DR and CD40 molecules. The same effects were induced by T 
cruzi-conditioned medium, indicating that these inhibitory effects were mediated by 
released soluble factors and a small family of type 1 Glycoinositolphospholipids 
(GIPLs) found on the cell-surface of the epimastigote and metacyclic forms of T. cruzi 
have been shown to have similar effects (Brodskyn et al. 2002). GIPLs had differential 
effects on LPS-induced cytokine production. There was a significant 
decrease in 
secretion of TNF-a, IL-10 and IL-12 but not IL-8 
from both LPS-stimulated human 
macrophages and DCs. So in contrast to the present studies, 
both IL- 12 and IL- 10 were 
affected. However, Weigt et al. (2003) reported that mycoplasma-derived 
lipopeptide 2 
induced differential IL-10/IL-12 responses in DCs upregulating IL-10 only and 
resulting in unpolarized immune responses. 
Recently, Semnani et al. (2003) reported 
that human DCs exposed to live Brugia malayi microfilariae (MF) up-regulate 
both the 
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cell surface and gene expression of CD54 (ICAM-1), and result in a 3-fold increase in 
DC death compared with MF-unexposed DCs, primarily due to apoptosis. They 
demonstrated, using microarray and real-time RT-PCR, that live MF up-regulate the 
expression of mRNA of proinflammatory molecules such as IL-8, RANTES, IL-lß 
and TNF-a in DCs, the presence of which is also detected at the protein level, while 
inhibiting the production of IL-12 (p40 and p70) and IL-10. Soluble excretory- 
secretory products from live MF diminished IL-12 and IL-10 production and induced 
DC death, although to a lesser degree. 
Although co-cultured schistosomula failed to activate DC as judged by surface marker 
and cytokine expression, the studies in Chapter 4 showed that DCs had a marked effect 
on the level of schistosomula mediated IFN-, y produced in recall experiments using 
RoNI sensitized SLNs. This may be explained by the fact that DC use different 
receptors for antigen uptake e. g. the C-type lectin receptors like CD205 than for 
cellular activation e. g. the Toll-like and non-Toll-like pattern recognition receptors 
(Kelsall et al., 2002). So in the recall experiments the DCs may simply enhance 
antigen presentation to the population of SLN cells amongst which Thl cells 
predominate. 
In conclusion, the experimental studies in this Chapter were initiated to see if the Th 1 
biased response that develops following S. mansoni infection of mice and which is 
markedly enhanced following in vivo termination of the infection with the drug Ro 11- 
3128 might be influenced by direct schistosomula/DC interactions leading to pro-Thl 
activation of the DCs and whether Rol 1-3128 treatment of the larvae would enhance 
any such activation. The results showed that incubation with a large range of 
concentrations of larvae failed to induce upregulation of MHCII or the co-stimulatory 
molecule, CD86 and CD40 in bm-DCs and this was not affected either 
by irradiation 
of the larvae or by Rol 1-3128 treatment. LPS induced the expected upregulation of 
these molecules but co-cultures with the schistosomula neither 
increased or decreased 
this expression. Similarly, schistosome/bm-DCs co-cultures 
failed to induce cytokine 
production but rather reduced LPS induced expression 
in a dose dependent way and 
with differential effects on different cytokines, 
IL-12 being most affected and IL-10 
not affected. These effects could not be attributed to toxic effects of 
the larvae on the 
cells but further work to confirm the specificity of 
the response is needed. If these 
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direct effects are confirmed they may represent another way in which schistosomula 
products modulate skin inflammation. 
The failure to demonstrate an effect of Rol 1-3128 treatment of schistosomula on DC 
activation suggests that other features of the Rol 1-3 128 terminated infections promote 
the high Thl responses. The tissue damage caused by the death of larvae in the skin 
may induce production of pro-inflammatory factors from keratinocytes and other cells 
recruited to the skin (as in the case of the GI model, Riengrojpitak et al., 1998), and 
activation of Langerhans cells, the skin DCs, may occur secondarily to this. The 
inflammatory response induced by the drug-terminated infections is persistent and in 
fact does not peak in the skin until day 7 post infection as judged by IL-1 ß mRNA 
production (Zhang et al. - manuscript in preparation). Furthermore, antigen-specific 
IFN-y continues to rise in the SLN until at least day 21 suggesting persistent antigen 
stimulation probably by persistence of drug-treated schistosomula in the nodes. So it is 
suggested that these persistent inflammatory responses in the skin and SLN are 
responsible for the generation of a strong protective Th 1 response rather than simply 
direct effects of Rol 1-3128 treated schistosomula on DC activation. 
206 
CHAPTER 6 
GENERAL DISCUSSION 
To design an anti-schistosome vaccine that will effectively and significantly reduce the 
incidence of severe disease, it is vital to understand the mechanisms of immunity 
induced in schistosomiasis. In experimental animals the previously most effective and 
extensively studied immunization regimens were based on y-irradiated cercarial 
infections (GI). In order to stimulate optimal levels of immunity (60-70%) the 
immunizing irradiated larvae need to survive through to the lung stage. Based on earlier 
observations, work in this thesis showed that even higher levels of protection (>90%) 
could be induced in C57BL/6 mice by percutaneously applied Schistosoma mansoni 
infections which were treated with 200 mg/kg of the drug Rol 1-3128, on day 2 post- 
infection (RoNI) when the larvae were in the skin. However, combining both types of 
attenuations (irradiation and drug-treatment) to the schistosomula (RoGI) induced poor 
levels of resistance (-' 30%). 
All of these attenuated infections as well as normal unattenuated infections (NI) resulted 
in a Thl biased cytokine recall by skin draining lymph node (SLN) cells (IFN-'y > IL-4). 
At day 7 post-infection the IFN-y response was highest in the RoGI and GI, whereas the 
RoNI response was lower and more comparable to that of the NI in one experiment and 
higher than NI in another. However, the drug-treatments (RoNI and RoGI) induced 
enhanced and more prolonged antigen-specific IFN-y cytokine responses in the SLN 
compared with the NI and GI at day 21 post-infection. This can be explained by the fact 
that the vast majority of the NI and GI larvae would have left the skin and migrated to 
the lungs before day 21 (Mangold and Dean, 1983) whereas the drug-treated 
schistosomula either by their death or persistence in the skin/SLN 
(Mountford et al., 
1988; Mountford et al., 1989) provides stronger local stimulation. The pattern of higher 
IFN-y production by SLN cells in the RoGI than in RoNI at 
day 7 and the reversal at 
day 21 is consistent with the idea that the larvae in RoGI 
die more rapidly after 
infection in the skin rather than in SLN (Mountford et al., 1988; Mountford et al., 
1989) 
compared to RoNI leading to higher initial antigen production and cytokine responses 
but less persistent responses. The major difference 
between RoNI and RoGI was the 
higher IFN-y responses in the spleen in RoNI at day 21. More prolonged stimulation of 
the SLN by RoNI could explain this stronger systemic spread of antigen specific 
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effector/memory Thl cells. It would be interesting to extend the time of observation of 
the immunological and immuno-histological responses to the persistent schistosomula 
in the SLNs beyond the 21 days followed in the present studies 
There is strong evidence that the RoNI unlike the GI does not rely on the arming of the 
lungs by death of attenuated larvae, since extensive histology of the lung failed to find 
either parasites or reactions at day 14 or 21 post-RoNI treatment (in this model using 
200mg/kg) in contrast to a parallel study using GI (Quentin Bickle-personal 
communication). Also extensive cytokine and chemokine mRNA studies showed no 
evidence of inflammatory responses in the lungs at any time following RoNI, as judged 
by production or presence of antigen-specific or non-specific IFN--y producing cells in 
the lung tissue or in broncho-alveolar lavage during the time schistosomula are expected 
to reach and die in the lungs i. e., up to 21 days post infection (Yaobi Zhang-personal 
communication). Furthermore, double treatment with Rol 1-3128 (on days +2 and +4) 
which would be expected to cause even more restriction on the survival of the RoNI, 
and again histology failed to demonstrate any parasites or parasite reactions in the lung 
at day 14 post-infection, in contrast to GI (Quentin Bickle-personal communication). 
However, this regimen induced comparable levels of protection to the single treatment. 
Further work could focus on comparison of the survival/migration in skin/SLN 
following the RoNI single and double treatments and the RoGI protocols, in addition to 
measuring and comparing IFN-y responses in the SLN and spleen. Monitoring 
cytokines associated with induction of Thl responses in the skin/SLN would be 
interesting e. g., IL-12, IL-23, IL-27. 
Looking at the serum antibody responses on day 21 post vaccination 
from mice given 
the four treatments (NI, GI, RoGI and RoNI) the levels were comparable and 
significantly raised among the 3 attenuated infections 
(GI, RoNI and RoGI), whereas it 
was raised but to a lesser extent with NI. So this measure 
did not distinguish responses 
between the protective and non-protective regimes. 
Antigen specific IL-10 production also occurred and tended 
to correlate with IFN-, y 
levels. This suggested that IL-10 rises along with 
IFN-7 until it is able to terminate the 
IFN-y response (Wynn et al., 1994). The antigen-specific 
IL-10 production by SLN 
cells from RoGI was higher than 
in the RoNI at day 7 post-infection, but by day, 21 
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post-vaccination when the levels of IL-10 had dropped there was no significant 
difference between RoNI and RoGI IL-10 levels. This higher IL-10 at day 7 did not 
cause lower IFN-y responses but rather correlated with higher levels. It is not known 
whether this higher level of IL- 10 during the early part of RoGI results in more rapid 
attenuation in IFN-y response or could inhibit later macrophage mediated inflammatory 
responses to challenge larvae, as was shown in P strain mice which develop poor 
protection when given irradiated cercariae. Thus specific antigen stimulation of spleen 
cells from P strain mice produced levels of IFN-7 comparable to the highly protected 
C57BL/6 mice, but made 3x more IL-10 and >2x IL-4 than the C57BL/6 mice (Oswald 
et al., 1998). This observation together with the demonstration that IL-10 KO mice 
develop higher levels of protection than wild-type controls (Hoffmann et al., 1999) led 
to the suggestion that effective schistosome vaccines focussed on induction of Th 1 
protective responses should not induce high IL-10 levels. The present results are 
consistent with this notion as the protective RoNI regimen produced comparable IL-10 
to the GI in the early after vaccination in C57BL/6 mice but this did not prevent the 
subsequent development of high IFN-'y levels. However, the RoNI model shows that it 
is possible to get very high levels of protection (comparable to those in IL- 10 KO mice) 
even if some IL- 10 is produced early during the vaccination procedure. 
The above in vitro studies suggested that IFN-7 was important in the RoNI-induced 
immunity, and to confirm this in vivo studies were carried out in gene knock-out (KO) 
and anti-cytokine treated mice. Vignali et al., (1989a) had previously shown that 
immunity in GI and RoNI can be ablated or reduced following treatment during 
challenge infection with anti-CD4 antibody but not with anti-CD8 antibody. So this 
suggested that the elimination of challenge parasites was due to the CD4-T cell 
component of CMI responses. In this study the immunological specificity of the RoNI 
protocol was shown by the complete lack of protection in B6. RAG-1-/- mice which are 
deficient in T and B cells. Vaccination of IFN-y -/- mice showed a 53-54% reduction in 
protection, but depletion of IFN-y with neutralizing monoclonal antibody during the 
challenge phase led to a loss of protection. µ-MT mice showed almost comparable 
protection to wild-type controls (82% compared with 
94% in controls) showing that B 
cells and antibody are not significantly involved 
in this protection. It is concluded that 
the protection following RoNI is mediated almost entirely 
by IFN-y mediated 
mechanisms and antibody is not involved. It 
is also suggested that the high efficacy of 
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the RoNI is related to the induction of very strong and protracted Thl responses in the 
skin which, unlike the RoGI, disseminate systemically giving rise to memory in other 
lymphoid tissues (as seen by elevated but persistent IFN-y responses in the spleen). but 
which does not seem to require parasite induced inflammation in the lungs as is needed 
for high levels of immunity in the GI. Although the µMT mice, which make no 
antibody, were fully protected the lack of a protective role for antibodies in the single 
RoNI could be confirmed by passive transfer experiments and it would be of particular 
interest to investigate the role of antibody in mice given repeated RoNI as, in the case of 
repeated GI, antibody comes to play the key protective role (Kelly and Colley, 1988; 
Mangold and Dean, 1986). 
Parallel approaches to investigate why RoNI is so effective in inducing immunity were 
concerned with the direct effects the drug has on antigen presentation to the host by 
inducing membraneous blebs at the larval surface. In vitro studies showed that Ro ll- 
3128 in its native form, at doses of 1.25-2.5µg/ml, caused damage to schistosomula 
resulting in the production of membraneous blebs at their surface. The antigenic 
composition of these blebs has been shown to be different from that of the surface of the 
penetrating larvae e. g., in expressing the membrane glycoprotein Sm16, a vaccine 
candidate antigen (Bickle et al., 1986). Other studies by Smith et al., (1994) showed that 
the particulate matter released from the drug-treated parasites was responsible for 
increased stimulatory activity as measured by production of IL-3/GM-CSF from antigen 
sensitized T cells. In the present study it was shown that drug-treated 20 krad y- 
irradiated schistosomula (the poorly protective RoGI) also produced blebs in in vitro 
cultures, indicating that production of membraneous blebs per se did not account for the 
superior immunity induced by unirradiated drug-treated infections. No differences were 
observed between RoGI and RoNI parasites regarding survival or percentage of 
parasites with drug-induced morphological changes (production of blebs). However, the 
antigenic composition of the membraneous blebs and soluble antigens 
produced/released from RoGI parasites was never tested. It would, therefore, be 
interesting to know if they are antigenically different from RoNI parasites by using 
Western blotting techniques or metabolic labelling and co-precipitation. It would also 
be interesting to compare skin/SLN cellular responses following RoNI and infections 
terminated by Ro15-5458 another drug which is effective against the skin stage 
schistosomula but which induce low levels of 
immunity and which does not induce the 
210 
production of membraneous blebs at the surface (Bickle et al., 1990). The 
demonstration by Smith et al (1994) of enhanced antigen presentation by Rol 1-3128- 
treated schistosomula was further investigated by culturing parasites and cells from the 
inguinal and axillary lymph nodes of either immunized or non-immunized animals and 
cytokine production measured. No IFN-y production could be detected with RoN1- 
sensitized SLN cells and schistosomula alone, but addition of in vitro bone-marrow- 
derived dendritic cells (bm-DCs) induced IFN-y production. In this situation there was 
evidence in some experiments that Rol 1-3128 increased the recall response indicating 
that the altered antigen production by the parasites by the direct effects of the drug may 
also be involved in inducing the high levels of response seen in the skin during drug- 
terminated infections. However, the soluble and membraneous material contained in 
supernatants of drug-treated schistosomula did not induce IFN-y production by RoNI- 
sensitized SLN cells contrary to what was shown by Smith et al., (1994). To directly 
assess if altered antigen presentation itself was solely responsible for inducing high 
levels of immunity, mice were immunized with 500 F/T drug-treated parasites and any 
soluble released material intradermally. This did not induce marked IFN-y production 
by the spleen cells (at day 21) compared with the RoNI model and did not significantly 
reduce worm burdens. This work supports the notion that optimal protection due to 
RoNI requires protracted survival of the drug-treated schistosomula rather than any 
specific effect of the drug on the parasite surface. From the viewpoint of vaccine design 
this emphasizes the value of protracted stimulation of the SLN. 
The possibility that Rol 1-3128 might have a direct immunomodulatory effect on host 
cells was investigated using spleen cells cultured with Mycobacterium bovis Bacillus 
Calmette-Guerin (BCG) in the presence of a range of Rol 1-3128 concentrations. 
Production of IFN--y in this system involves interactions of activated macrophages, 
natural killer cells and T cells allowing for assessment of the 
drug on induction of 
immune responsiveness. No enhancement of IFN-y production was seen at any 
concentration but at high drug concentrations (5-10µg/ml) 
inhibition was seen. So there 
was no evidence of an adjuvant effect of Rol 
1-3128 per se although it might be of 
value to confirm this by looking at drug effects on 
in vivo immune responses to a 
defined antigen or to a live antigen such as BCG. 
In Chapter 5 studies were carried out to investigate if the 
Th 1-skewed response induced 
by exposure to larval schistosomes in vivo was 
due to direct effects of larval parasites 
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on dendritic cells and if this was influenced by drug treatment. Addition of varying 
numbers of living schistosomula (50-10,000/ml) to bm-DCs did not significantly affect 
(up- or down- regulate) MHCII and CD86 expression on the surface of DCs. When bm- 
DCs were partially activated by addition to the cultures of a range of concentrations of 
TNF-a or LPS the parasites were still not able to enhance expression of MHCII, CD86 
and CD40. Addition of Roll-3128 to the cultures did not affect the 
response. Schistosomula also failed to induce significant levels of cytokine production 
(IL-12p70, TNF-a, IL-10 or IL-6). These effects were also independent of the presence 
of Roll-3128 in the cultures. However, in the presence of LPS co-culture with 
schistosomula did, in fact, reduce the levels of cytokine production by bm-DCs in a 
dose dependent manner. A marked reduction occurred with high numbers of larvae 
(2,500-10,000 P/ml), while this inhibition was less with lower numbers 625-1,250/ml. 
There were differential effects on the different cytokines, IL-12p70 being most affected 
(mean reduction of 80%), followed by IL-6 and TNF-a (mean reduction of 34% and 
32%, respectively). IL-10 was relatively unaffected. The lack of effect of schistosomula 
on CD86 and MHC class II expression and the negative effects on cytokine expression 
were unaffected by the addition of Rol 1-3128 to the cultures. 
A possible explanation for this was that either the schistosomula products failed to 
signal DC activation and therefore inhibit different cytokine pathways, or that 
schistosomula products (enzymes, etc., ) selectively degrade secreted cytokines (IL- 
12p70 » IL-10) from bm-DCs, or that they damage/kill DCs resulting in this 
differential effect on cytokine production. However, regarding the last possibility the 
same differential effects on cytokines was obtained when parasites and bm-DCs were 
cultured together for 24h prior to stimulation with LPS. Furthermore, bm-DCs cultured 
with freshly transformed schistosomula were 70-90% viable as measured by Trypan 
blue staining and AnnexinV and Propidium Iodide staining. The other possibilities 
could be investigated by (i) directly testing whether cytokines are degraded in the 
presence of schistosomula, and (ii) looking at the mRNA expression of the different 
cytokine genes in relation to housekeeping genes. The possible role of PGE2 released 
by the parasites or induced by keratinocytes in mediating these effects could be studied 
by addition of indomethacin to the cultures. It would be interesting to study whether the 
schistosomula-treated bm-DCs showed inhibition of other functions such as the ability 
212 
to process and present antigens, using ovalbumin and ovalbumin specific transgenic T 
cells (Hsieh et al., 1993). 
The inhibitory effect on cytokine production induced by 3hr schistosomula was much 
less pronounced with schistosomula pre-cultured for 24hr in medium alone before use. 
Factors which might explain this are the release of oligosaccharides which interact with 
receptors on the DC surface. For example, the Lewis x (Le') oligosaccharide has been 
reported to interact with DC-SIGN (Appelmelk et al., 2003) and Lewis x has been 
shown to be present in the cercarial glycocalyx (Ham et al., 1987; Ko et al., 1990), 
remnants of which would survive at the surface of the newly transformed schistosomula 
but subsequently be lost as the new heptalaminate membrane fully forms. In addition, 
Faveeuw et al., (2003) showed that core a3-fucose and core ß2-xylose determinants 
(which contain Lewis x) are expressed in the excretory-secretory systems of 
schistosomula and certain of these would be released during culture. 
This demonstration of inhibitory effects of living schistosomula on DCs is consistent 
with a recent report by Trottein et al., (2004) who compared the transcription of genes 
induced in immature mouse DCs (called D1, a DC line) by S. mansoni eggs and skin 
stage schistosomula, and found that schistosomula-treated DCs did not secrete TNFa, 
IL-2, IL-1 a, IL-6, IL-12p40 nor IL-12p70. The authors also mentioned (data not shown) 
that the general effects described exerted by the live schistosomula on DC were not 
mimicked by their corresponding antigen extracts and suggested that physical contact, 
rather than soluble factors, are involved in these phenomena. By looking at mRNA 
expression they found other inhibitory effects on DCs. The schistosomula, unlike the 
eggs, did not up-regulate H-2M, which plays a crucial role in the peptide loading of 
MHCII molecules, the costimulatory molecules CD40 and ICAM-1 or chemokines and 
the Cathepsins D and L, which are believed to remove invariant chain from its complex 
with MHCII molecules, were down-regulated by schistosomula suggesting a reduction 
in the antigen processing capacity exerted by the larval stage on DC. So this work 
together with the studies in this thesis show inhibition of DC functions suggesting 
additional ways to those already described (Angeli et al., 
2001; Ramaswamy et al., 
2000; Trottein et al., 2004) in which schistosomula may inhibit inflammatory processes 
in the skin. Although this can be considered an advantage to survival of the parasite 
it 
fails to give any insight into how the Thl response which ultimately 
does develop is 
induced. 
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Finally, what has been learnt from the RoNI model which may have relevance for 
vaccine development? There was no evidence that specific drug-induced antigen 
presentation or adjuvant effects were involved. Rather the data suggests that the drug- 
treated infections promote strong Thl responses in the SLNs. However, high antigen 
specific Thl responses in the SLN are not sufficient to ensure high levels of immunity 
as the poorly protective RoGI induced comparable protracted IFN-y responses to the 
highly protective RoNI in the SLN at both 7 and 21 days post-infection which were both 
significantly higher than that induced by the GI infection by day 21 p. i.. The 20krad GI 
is characterised by the irradiated larvae migrating to the lungs and there is strong 
evidence that this phase is essential to recruit/boost cellular responses primed in the skin 
(e. g., Coulson and Wilson, 1997). However, the RoNI does not appear to transit to the 
lungs and induce inflammation there but rather the RoNI is distinguished from the RoGI 
by evidence of more prolonged stimulation of the SLN response leading to higher 
antigen specific systemic IFN-y responses in the spleen. It is proposed that the 
protracted survival of the RoNI parasites results in local stimulation of a strong local 
response which can lead to systemic spread of memory cells to the lung lymph 
nodes/lungs where they can respond rapidly to larvae of a challenge infection as seen by 
a rapid rise in IFN-y and chemokine levels in the lungs post-challenge (Dr Yoabi 
Zhang- personal communication), i. e., a systemic Thl mediated protection, and so 
provides a paradigm for development of vaccine strategies that mimic this. In this 
regard several studies demonstrated the efficacy of prime-boost vaccination strategies in 
generating cellular immunity to a variety of pathogens (Woodland, 2004). This strategy 
is based on T cell priming with DNA vaccines or recombinant virus followed by 
boosting with a heterologous recombinant virus expressing the same antigen gene. 
Examples of such studies include, M tuberculosis (Tanghe et al., 2001), HIV (Amara et 
al., 2001), malaria (Bruna-Romero et al, 2001; Gilbert et al., 
2002), herpes simplex virus 
(Meseda et al., 2002), leishmania (Gonzalo et al., 2002), Ebola virus (Sullivan et al., 
2000), Listeria monocytogenes (Fensterle et al., 1999), hepatitis C virus (Matsui et al., 
2003), hepatitis B virus (Pancholi et al., 2001). The studies in the RoNI indicate that 
such prime-boost vaccination could be administered 
in the same site e. g., the skin, 
provided protracted responses were induced. 
On the other hand, to mimic the GI it 
would be necessary to prime in the skin and then 
boost in the lungs. Such an approach 
may well be possible long term as successful vaccination with recombinant viruses via 
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the intranasal route has been reported (Goonetilleke et al., 2003) for Mycobacterium 
tuberculosis infections in mice. It should be emphasized however, that following 
repeated vaccination with GI, protective antibody responses are induced (Mangold and 
Dean, 1986; Wynn et al., 1996), and the need for recruitment of sensitized cells to the 
lungs to arm the lungs is no longer needed as depletion of CD4-T cells is without effect 
(Kelly and Colley, 1988). Nevertheless, the mechanisms of immunity which might be 
effective in human is unknown and so development of vaccine strategies that stimulate a 
range of immune responses should be investigated. From the perspective of the Th 1 
axis, the main challenge now is to identify the likely vaccine candidate antigens to 
express in vectors for use in the prime-boost strategies. 
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APPENDIX 
A. 1 E/LAC Medium: 
The main constituents of Earle's medium were Earle's Balanced Salt and Lactalbumin 
Enzymatic Hydrolysate, hence the abbreviation E/LAC. E/LAC is made up of: 8.64g 
Earle's Balanced salts [EBSS] (Sigma, UK), 0.85g sodium bicarbonate [NaHCO3] 
(Sigma, UK), 5.00g Lactalbumin Enzymatic Hydrolysate (Sigma, UK) / Litre MilliQ 
water (pH 7.4). This medium was then filtered sterilized and stored at 4°C. 
A. 2 M169 Medium: 
Table A. 2. Schistosome culture medium M169. 
Component Stock Conc. Add stock Working conc. 
BME (Basal Medium[Eagle]) 
Lactalbumin Hydrolysate * 
Glucose * 
Hypoxanthine * 
Serotonin * 
10"3 M4 
1 0-3 M4 
Insulin, crystalline 
Hydrocortisone * 
Triiodothyronine 
MEM vitamins 
Schneider's medium 
HEPES 
NaOH 
NaHCO3 
MilliQ water 
8 mg/ml ý 
10-3Mg 
2x10-4Mg 
100x 4 
lx 
5N 
Adapted from Basch P. (1981). 
*= Products obtained from Sigma, UK. 
Products obtained from Gibco, UK. 
1 Litre 
lg 
lg 
0.5 ml 
l ml 
I ml 
l ml 
l ml 
5 ml 
50 ml 
2.4 g 
2.2 g 
1 Litre 
1 g/Litre 
11.1 mm 
5x10-'M 
10-6 M 
8 µg/m 
10-6 M 
2x 10-'M 
0.5x 
5% 
10mM 
pH 7.4 
26 mM 
4= stocks frozen at -20°C. Working concentration 
is based upon a theoretical total volume of I litre. 
M169 Medium was filter sterilized and stored at 
4°C. 
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A. 3 FACS-EDTA buffer: 
1% Horse serum (Sigma, UK), Ix PBS (Sigma, UK), 0.1% sodium azide [NaN3], 0.05 
M EDTA (Ethylenediaminetetracetic Acid). 
A. 4 Gey's Solution: 
Stock Components Weight (g) Made up to 
STOCK A NH4C1 35.00 g 
KC1 1.85 g 
Na2HPO4.2H2O 7.50 g 
KH2PO4 0.12 g 
D-glucose 5.00 g 
Phenol Red (Optional) 0.05 g 
MilliQ water (Triple Red Lab. 1000 ml 1000 ml 
Technology, UK) 
Stock Components Weight (g) Made up to 
STOCK B MgC12.6H2O 0.42 g 
(Magnesium Chloride Hexahydrate) 
MgS04.7H2O 0.14 g 
(Magnesium Sulphate Heptahydrate) 
CaC12 0.34 g 
MilliQ water (Triple Red Lab. 100 ml 100m1 
Technology, UK) 
Stock Components Weight (g) Made up to 
STOCK C NaHCO3 2.25 g 
MilliQ water (Triple Red Lab. 100 ml 100ml 
Technology, UK) 
1x Gey's Solution was made of 20 parts STOCK A+ 5 parts STOCK B+5 parts 
STOCK C + 70 parts double distilled water. It was then 
filter sterilized and stored at 
4°C, until use. 
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A. 5 lOx PBS Buffer (Phosphate buffered solution) : 
This is used for ELISA's and any non-sterile technique. 
I 
80. Og NaCl, 2. Og KC1,11.6g Na2HPO4,2. Og KH2PO4, and made up to I litre with 
distilled water (pH 7.2). 
A. 6 Reagents provided in Annexin V-FITC staining Kit I: 
a- FITC-conjugated Annexin V: 
Buffered in 50mM Tris, pH 8.0,80 mM NaCl, 1mM EDTA, 0.09 % (w/v) sodium 
azide. Stored at 4°C. Used at 5µl per test (1x105 cells). 
b- Propidium Iodide Staining Solution (PI): 
50µg/ml stock solution of PI in Ix PBS buffer, pH 7.4. Stored at 4°C. 
c- IOx Binding Buffer: 
0.1 M HEPES/NaOH, pH 7.4; 1.4M NaCl, 25mM CaC12. Sterilized with 0.2µm filter. 
Diluted to lx prior to use. Stored at 4°C. 
BML 
22186 t O"DI U41. 
